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SOMMARIO 
 
L’identificazione di nuovi biomarcatori rilevanti dal punto di vista clinico risulta 
cruciale per la diagnosi precoce e miglioramanto terapeutico di diverse malattie con 
conseguentemente riduzione del tasso di mortalità. I fluidi biologici costituiscono 
circa il 60% della massa corporea e rappresentano una fonte significativa di 
biomarcatori. Sfortunatamente, molti biomarcatori sono difficilmente rilevabili nei 
fluidi biologici tramite spettrometria di massa o saggi immunologici a causa della loro 
ridotta concentrazione, della loro tendenza a degradarsi facilmente e della presenza 
di proteine molto abbondanti come albumina e immunoglobuline. Per superare tali 
barriere biologiche abbiamo sviluppato nanoparticelle composte da poly(N-
isopropilacrilamide) (NIPAm) e funzionalizzate con “esche chimiche” in grado di 
catturare, concentrare e preservare i biomarcatori presenti in un fluido biologico 
(urina, sangue, sudore, fluido cerebrospinale) rapidamente attraverso pochi semplici 
passaggi. In questa tesi verranno descritte la composizione, la sintesi e 
l’applicazione delle nanoparticelle di idrogel (Nanotrap). La novità di questa 
tecnologia risiede nel fatto che mentre in passato le nanoparticelle di idrogel 
venivano studiate solo come mezzo di rilascio di molecole farmacologicamente 
attive, la loro applicazione nel nostro studio si focalizza invece sulle loro abilita’ di 
riconoscere e catturare analiti in soluzione a scopi diagnostici. Le nanoparticelle 
vengono incubate con un fluido biologico e catturano i biomarcatori tramite ligandi 
ad alta affinità immobilizzati covalentemente al loro interno, allo stesso tempo 
escludendo proteine molto abbondanti come in cromatografia di esclusione 
molecolare. Una volta catturati, i biomarcatori potenzialmente significativi sono 
concentrati in volumi molto piccoli e poi analizzati con tecnologie di biologia 
molecolare. Il fattore di concentrazione (fino a 10000 volte a seconda del volume del 
campione di partenza) permette di migliorare l’effettiva sensibilità della spettrometria 
di massa e di saggi immunologici e identificare proteine precedentemente invisibili, 
quindi favorendo la scoperta di nuovi biomarcatori e lo sviluppo di nuovi test 
diagnostici.  
La tesi si focalizza principalmente sullo sviluppo di un test antigenico in urina per la 
diagnosi della malattia di Lyme. Esiste una necessità clinica di migliorare la 
specificità di test diagnostici 1) per la diagnosi precoce della malattia di Lyme nel 
periodo precedente lo sviluppo di una robusta risposta sierologica e 2) per 
sorvegliare la terapia antibiotica. Borrelia burgdorferi è l’agente eziologico della 
malattia di Lyme. Grazie all’utilizzo delle Nanotraps abbiamo studiato la presenza 
della proteina di Borrelia Outer surface protein A (OspA) e nello specifico della sua 
regione C-terminale in pazienti nel primo stadio della malattia prima e dopo il 
trattamento antibiotico, e in pazienti nello stadio tardivo e disseminato dell’infezione. 
La cattura e concentrazione dell’OspA tramite Nanotraps unita all’utilizzo di un 
anticorpo monoclonale specifico contro il peptide C-terminale dell’OspA, ci ha 
consentito di ottenere un test ad alta sensibilita’(1.7pg/mL, limite di rilevazione 
analitico) e specificita’.  
La regione C-terminale OspA236-239, riconosciuta dall’anticorpo, risulta conservata 
nelle specie infettive di Borrelia, e manca di omologia con proteine umane e cross-
reattività con proteine di virus comuni e batteri non appartenenti al genus di Borrelia. 
IV 
 
268 campioni di urina provenienti da pazienti in vari stadi della malattia sono stati 
raccolti  in un’area endemica per la Borreliosi di Lyme (Virginia, Stati Uniti). I risultati 
di questo studio clinico indicano che, in assenza di terapia, 24 su 24 campioni 
appena diagnosticati con erythema migrans (EM) sono risultati positivi alla presenza 
di OspA in urina mentre nessun paziente asintomatico (0/117) e’ risultato falsamente 
positivo (p<10-6). 10 pazienti su 10 che hanno mostrato la persistenza di sintomi (EM 
rash) durante il corso della terapia antibiotica sono risultati positivi per la presenza 
di OspA in urina. 8 su 8 pazienti sono passati da un segnale positivo per l’OspA ad 
assenza di segnale dopo la risoluzione dei sintomi in seguito a trattamento. 40 su 
40 campioni che mostravano sintomi clinici sono risultati positivi per l’OspA. La 
specificita’ del nostro test antigenico in comparazione con il risultato serologico e’ 
risultata essere del 87.5% (21 positivi per l’OspA in urina/24 positivi per serologia, 
p=4.072e-15). 41 su 100 pazienti con sospetto di Borreliosi di Lyme in una zona 
endemica sono risultati positivi per l’OspA in urina. Il rilascio di OspA in urina è 
correlato con la presenza attiva di sintomi (EM rash e artrite), mentre la risoluzione 
di tali sintomi in seguito a terapia e’ correlata alla conversione di OspA da positivo a 
negativo. La rilevazione dell’OspA e’ stata inizialmente ottenuta tramite western blot, 
tuttavia maper ottenere risultati quantificabili, è stato successivamente sviluppato un 
saggio ELISA. Risultati preliminari hanno mostrato un limite di rilevazione analitico 
di 0.5 pg/mL3 pazienti su 3 con sintomatologia positiva che sono risultati positivi per 
il western blot sono risultati positivi anche in ELISA. Un altro formato promettente, 
attualmente in fase di sviluppo, consiste in un saggio che utilizza la spettrometria di 
massa (Multiple Reaction Monitoring) per l’identificazione di proteine di Borrelia 
nell’urina dopo processamento con Nanotraps. Di fondamentale importanza, infatti, 
e’ la possibilità di misurare diversi antigeni in aggiunta a OspA, come OppA, e DbpA, 
cosi’ da poter raccogliere informazioni più accurate sullo stadio della malattia e di 
raggiungere una migliore sensibilita’ clinica.  Risultati preliminari hanno mostrato una 
sensibilità di 5pg/ml e un’ottima riproducibilità utilizzando soluzioni modello di urina 
proveniente da individui sani e contenente quantità note di proteine di Borrelia. Per 
ultimo, abbiamo sviluppato una nuova generazione di nanoparticelle parzialmente 
degradabili che sono state utilizzate per produrre un prototipo di saggio 
immunologico a flusso. Questo saggio si basa sulla proprietà delle nanoparticelle di 
esporre l’antigene catturato al loro interno per un diretto riconoscimento da parte 
dell’anticorpo stampato sulla linea del dispositivo diagnostico. Dati preliminari 
supportano lo sviluppo di un saggio rapido per proteine di Borrelia nell’urina di 
pazienti caratterizzato da alta sensibilità e specificità.  
In conclusione, questo lavoro di tesi raccoglie evidenze sperimentali 
dell’applicazione della tecnologia Nanotrap allo sviluppo di test antigenici per la 
malattia di Lyme. Le Nanotrap aumentano la sensibilità analitica di western blot, 
ELISA, spettrometria di massa e saggio immunologico a flusso rendendo possibile 
la misurazione di proteine batteriche, altrimenti invisibili, nell’urina di pazienti. Questi 
risultati dimostrano che l’uso di Nanotrap è indispensabile per saggi antigenici per la 
malattia di Lyme e in generale presentano un concetto valido per malattie 
trasmissibili causate da diversi agenti eziologici (tubercolosi, malattia di Chagas, 
toxoplasmosi etc...).  
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ABSTRACT 
 
In the recent years a lot of emphasis has been placed on the discovery and better 
detection of clinically relevant biomarkers. Biomarkers are crucial for the early 
detection of several diseases, and they play an important role in the improvement of 
current treatments, thus reducing patient mortality rate. Biofluids account for 60% of 
the human body mass and can be a goldmine of significant biomarkers. 
Unfortunately, low abundance biomarkers are difficult to detect with mass-
spectrometry or immunoassays because of their low concentration in body fluids, 
their lability, and the presence of high-abundance proteins (i.e. albumin and 
immunoglobulins). In order to overcome these physiological barriers, we developed 
nanoparticles made of poly(N-isopropylacrylamide) (NIPAm) and functionalized with 
affinity reactive baits that one single step capture, concentrate and preserve labile 
biomarkers in complex body fluids (i.e. urine, blood, sweat, CSF). The design, 
synthesis and application of the Nanotrap hydrogel particles are described in this 
thesis. The novelty of the technology relies in the fact that in the past hydrogel 
nanoparticles have been studied and used as a drug delivery tool, whereas our 
application focuses on their capturing abilities instead of the releasing of specific 
drug molecules. Once the functionalized nanoparticles are incubated with a 
biological fluid, low molecular weight biomarkers are captured by the affinity baits 
while unwanted high abundance analytes are excluded. The potentially relevant 
biomarkers are then concentrated into small volumes and analyzed. The 
concentration factor (up to 10000 fold depending on the initial volume) enhances the 
effective sensitivity of mass-spectrometry and immunoassays and permits to detect 
previously invisible proteins thus improving biomarker discovery and diagnostic 
testing. This thesis discusses the use of hydrogel nanoparticles to develop a urinary 
antigen test for the detection of Lyme Borreliosis. There is a clinical need to improve 
the diagnostic specificity of early stage Lyme assays in the period prior to the 
mounting of a robust serology response and to develop a diagnostic tool to monitor 
therapy success. Borrelia burgdorferi is the causative agent of Lyme disease. Using 
our hydrogel particles (Nanotraps) we evaluated the presence of urinary Borrelia 
Outer surface protein A (OspA) C-terminus peptide in early stage LB before and after 
treatment, and in patients suspected of late stage disseminated LB. We employed 
Nanotraps to concentrate urinary OspA and used a highly specific anti-OspA 
monoclonal antibody (mAb) as a detector of the C-terminus peptides. We mapped 
the mAb epitope to a narrow specific OspA C-terminal domain OspA236-239 
conserved across infectious Borrelia species but with no homology to human 
proteins and no cross reactivity with relevant viral and non-Borrelia bacterial 
proteins. 268 urine samples from patients being evaluated for all categories of LB 
were collected in a LB endemic area. The urinary OspA assay, blinded to outcome, 
utilized Nanotrap particle pre-processing, western blotting to evaluate the OspA 
molecular size, and OspA peptide competition for confirmation. OspA test 
characteristics: sensitivity 1.7 pg/mL (lowest limit of detection), %coefficient of 
variation (CV)=8%, dynamic range 1.7-30 pg/mL. Pre-treatment, 24/24 newly 
diagnosed patients with an erythema migrans (EM) rash were positive for urinary 
OspA while false positives for asymptomatic patients were 0/117 (Chi squared p<10-
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6). For 10 patients who exhibited persistence of the EM rash during the course of 
antibiotic therapy, 10/10 were positive for urinary OspA. Urinary OspA of 8/8 patients 
switched from detectable to undetectable following symptom resolution post-
treatment. Specificity of the urinary OspA test for the clinical symptoms was 40/40. 
Specificity of the urinary OspA antigen test for later serology outcome was 87.5% 
(21 urinary OspA positive/24 serology positive, Chi squared p=4.072e-15). 41 of 100 
patients under surveillance for persistent LB in an endemic area were positive for 
urinary OspA protein. OspA urinary shedding was strongly linked to concurrent 
active symptoms (e.g. EM rash and arthritis), while resolution of these symptoms 
after therapy correlated with urinary conversion to OspA negative. Detection of OspA 
was performed using Western blot analysis. In order to obtain a quantitative 
measurement of the antigen, an ELISA was developed. Preliminary results showed 
a lowest limit of detection of 0.5pg/ml and %coefficient of variation 2%, dynamic 
range 0.5pg-30 pg/ml. 3/3 of symptomatic patients that resulted positive with the 
western blot Lyme assay were also found positive when tested on ELISA. Another 
promising format under development uses Mass Spectrometry Multiple Reaction 
Monitoring (MRM) for the detection of multiple Borrelia proteins after Nanotrap 
processing. Developing a diagnostic test against a panel of analytes will improve 
clinical sensitivity and understanding of staging of disease. MRM is a prime 
technology that yield multiplex measurement of more than 100 peptides in a single 
sample. A sensitivity of 5pg/ml and high reproducibility in human urine spiked with 
OspA was observed. Lastly, partially degradable Nanotraps were employed to 
produce a prototype of Lateral Flow Immunoassay (LFI) which exploits the use of 
antigen displaying nanoparticles for a point of care test for Lyme disease. This 
technology will ensure high accuracy and sensitivity while allowing for rapid testing 
of Lyme disease antigens in the urine of patients in the doctor office. 
In summary, this study presents data supporting the successful use of the Nanotrap 
technology to develop a more accurate and sensitive test for Lyme disease that can 
diagnose the disease before seroconversion and that can be used to monitor therapy 
success. Nanotraps increase the effective analytical sensitivity of western blot 
analysis, ELISA, mass spectrometry MRM and lateral flow immunoassay. This is a 
concept that can be extended to communicable diseases with different etiologic 
agents (e.g. Tuberculosis, Chagas disease, Toxoplasmosis, etc.). 
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1. INTRODUCTION 
 
1.1 BIOFLUID BIOMARKERS FOR EARLY DETECTION AND 
BETTER PROGNOSIS 
 
Many diseases including cancer are currently detected only in later stages 
when enough damage has already been induced to the patient and the 
chance of a successful treatment is dramatically reduced1. The identification 
of novel biomarkers, as well as the improvement of the detection sensitivity 
of current analytical platforms, could have a great impact for the early 
diagnosis and the cure of many life-threatening diseases. On a cellular level, 
disease like cancer are characterized by several changes in the cellular 
networks that can be recognized by difference in mRNA, micro-RNA and 
protein profiles2,3. Generally an increase of abundance of specific biomarkers 
in body fluids (i.e. proteins/peptides or their prost-translational modifications) 
is often associated to the presence of an active disease. The reason is that 
many classes of proteins or fragments of proteins are shed into the body 
fluids that surround the organ and transported to different parts of the body 
by diffusion or convection. As a consequence, changes in protein expression 
profiles that can be found in body fluids can be considered ‘disease 
fingerprints’ of altered cellular networks2. The peptidome, or low-molecular-
weight (LMW) proteome, is of particular interest because it may contain a 
high number of clinically relevant markers yet to be discovered. It is in fact 
important to note that LMW proteins are able to passively diffuse through the 
endothelial cell barrier of blood vessels, a barrier that effectively prevents the 
passive perfusion of molecules above 60 kDa4. Because biofluids account 
for 60% of the body mass5, they represent a goldmine of significant 
biomarkers whose discovery could greatly increase the possibility of early 
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diagnosis, better monitoring of disease progression and development of 
more successful treatments.  
As a consequence there is a particular focus in developing and improving 
analytical techniques for the analysis of biofluids that could allow the 
discovery of new biomarkers or could increase the sensitivity of detection of 
biomarkers that are currently used in clinical tests6–8.  
Body fluids are divided in intracellular and extracellular which include fluids 
that are excreted or secreted as a consequence of physiological and 
pathological body functions as shown in Figure 1 (Ahn, S. et al, 2007). 
Different body fluids and their distribution. In Proteomics of Human Body 
Fluids p.30. The extracellular fluid include the tissue interstitial fluid (TIF) 
(around 75%), the blood plasma (around 25%), the fluid of bone and dense 
connective tissue and, the smallest component, named trans-cellular fluid. 
Trans-cellular fluids are separated from plasma and interstitial fluid by 
cellular barriers. Examples of these fluids are cerebrospinal fluid, ocular fluid, 
joint fluid, peritoneal fluid, pleural fluid, breast ductal fluids and bladder urine9. 
The TIF sorrounds tissues and exchange molecules with the intracellular 
fluid, while plasma is in constant communication with all the 
microenviroments throughout the body and constantly exchanges signals 
and nutrients directly or via lymphatic system. Although plasma and serum 
are the richest source of potential biomarkers and reflect the state of all 
tissues, other biological fluids (such as CSF, urine, sweat, saliva…) can be 
significant in the description or a particular pathological state. 
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Figure 1. Different body fluids and their distribution. (Source: Ahn, S. et al.,2007) 
 
Each body fluid has a peculiar composition which depends on the specific 
functions and includes proteins, salts, and variables amounts of glucose, 
urea, and other substances. Proteins from tissues are found in biological 
fluids, and their concentration varies depending on the fluids. In the tissues, 
proteins secreted or shed from cells, reach the lymphatic system from the 
TIF. Then lymph fluids from various regions of the body, drain into the 
circulatory system, where the tissue protein will result diluted several folds. 
Approximately 2.5 L of lymph drains into the systemic circulation per day, 
whereas about 3 L of plasma, approximately 5 L of blood, is ejected from the 
heart every minute. The concentration of a biomarker thus decreases from 
TIF to blood. Sedlaczek et al. observed a differential enrichment of CA125, 
an ovarian cancer marker, in different body fluids from patients with ovarian 
carcinoma. According to this study, the median value of CA125 is 
approximately 64-fold higher in cyst fluid than in serum10. 
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1.1.1 Proteomic approaches to the analysis of body fluids 
Mass spectrometry is considered the gold standard technology for 
discovering new biomarkers in bodily fluids. Five are the main steps involved 
in the analysis of body fluids: 1) sample collection and storage; 2) sample 
enrichment (removal of high abundance proteins); 3) protein separation; 4) 
protein analysis; 5) protein identification and quantitation.  
Sample collection and storage 
Sample preparation plays a fundamental role in the proteomic analysis 
pipeline. Standardized procedures regarding sample collection, processing 
and storage are crucial in order to guarantee precision and reproducibility of 
the results. A number of phenomena can occur after collection such as 
degradation, modification, and precipitation3,11,12. Different anti-coagulants, 
protease inhibitors are often added depending on the biological fluid and the 
analytical method that will be used. Freezing and thawing procedures are 
also crucial in preserving the original characteristics of the bio-sample. 
Removal of the high abundant proteins and sample enrichment 
Protein concentration in biological fluids can span for 12 orders of magnitude 
while on the other hand the dynamic range of mass spectrometers covers 
only 5 orders of magnitude. For this reason high abundant proteins such as 
albumin can mask less-abundant proteins, thus decreasing the chance of 
detecting them. In order to overcome this issue, several depletion methods 
have been developed. Immunoaffinity depletion columns, for example, have 
been previously employed in order to deplete the samples from high 
abundant proteins before analysis. Depletion of high abundant proteins is 
usually performed by affinity columns based on dye ligands or antibodies for 
albumin removal13 and protein A or G for the removal of immunoglobulins. 
Ammonium sulfate precipitation (ASP) has also been utilized as a method 
for removal of highly abundant proteins from blood plasma with good 
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reproducibility14. Another approach that significantly reduces the dynamic 
concentration range of proteins present in a complex sample is based on 
peptide libraries or selective capture. A large peptide library is created 
through the use of combinatorial chemistry and immobilized on a solid 
surface. Because the library contains 206 hexapeptide ligands, each protein 
or peptide should be able to bind at least one of the ligand. Because of their 
high concentration, high-abundance proteins saturate their specific ligands 
and the excess will be washed away. As a consequence a greater fraction of 
the LMW analytes will be bound to the library compared to the HMW 
abundant proteins and their relative concentration will be increased15.  
An alternative method used to reduce the dynamic range is selective 
capturing. This method exploits the unique properties of a selected group of 
proteins for the enrichment. Immunoprecipation for example employs the 
affinity of an antibody to its target proteins to selectively bind and enrich 
proteins and proteins isoforms, phosphorylated proteins and protein-protein 
complexes15. Protein glycosylation is an abundant and biologically significant 
posttranslational modification - commercially available lectin affinity 
chromatography columns and, immobilization methods based on hydrazide 
chemistry are widely used for the purification of glycoproteins16,17.  
Phosphorylation plays a pivotal role in the regulation of many biological 
processes, such as cell growth, division, and signaling. Dysregulation of 
these phosphorylation-mediated signaling pathways has been found to be 
the underlying basis of many human diseases such as cancers and heart 
diseases18–20. Commonly used phosphopeptide enrichment methods can be 
grouped into chemical and affinity based methods. The three major methods 
to capture phosphopeptides include immobilized metal affinity 
chromatography (IMAC), reversible covalent binding, and metal oxide affinity 
chromatography (MOAC). Oxides that have been applied towards selective 
phosphopeptide enrichment include titanium dioxide (TiO2), zirconium 
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dioxide (ZrO2), aluminum oxide (Al2O3), and niobium oxide (N2O5). Aluminum 
hydroxide has also been used21.  
Another recent technique called activity based protein profiling (ABPP) uses 
protease inhibitors to act as affinity ligands in order to enrich selective 
classes of proteins based on their activity22. 
Protein separation 
After performing an enrichment of LMW proteins depleting the HMW high-
abundance protein from the sample, additional separation processes are 
required. While several methods for sample fractionation such as 
ultrafiltration, combination of ultrafiltration and chromatography are used on 
body fluids, the most universally applicable method for separating proteins is 
2D polyacrylamide gel electrophoresis (2D-PAGE). 2D electrophoresis is a 
technique that combines a protein separation along a first dimension based 
on the isoelectric point of the proteins in the sample (Isoelectric Focusing 
IEF), and a second separation on a second dimension as a function of the 
protein molecular weight (gel filtration). 2-DE can be used to separate more 
than 5000 proteins at the same time and those can be also identified through 
Coomassie brilliant blue or silver staining23. Unfortunately 2-DE is not 
sensitive enough for biomarker detection (1-10ng) and suffers from issues 
related to lack of reproducibility and resolution, and low sensitivity.  
Liquid chromatography is another very common separation technique used 
in analytical chemistry, the separation is based on the partition coefficient of 
analyte between a stationary phase (Solid or Liquid) and a mobile phase 
(Liquid). The solid phase is placed in a column and the mobile phase where 
the analytes are dissolved flows through the column. The mobile phase 
speed is dependent on its own chemo-physical properties as well as the one 
of the stationary phase, and the analyte. Different stationary phases are 
available and allow to perform different types of separation. Examples are 
normal phase (NP), reverse phase (RP), Size-exclusion chromatography 
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(SEC), ion-exchange chromatography (IEC), immunoaffinity 
chromatography (IAC), or hydrophilic interaction chromatography (HIC) 
columns. Reverse phase high pressure liquid chromatography (RP-HPLC) is 
the most widely used technique used for sample fractionation in proteomic 
analysis. In this particular technique the stationary phase is often a 
hydrophobic material, Octadecysilyl (C18Si-)(ODS) column, and the mobile 
phase is often water combined with organic solvents such as methanol or 
acetonitrile. Analytes are separated through the increasing of the organic 
component in the liquid phase because of their hydrophobicity. Reverse 
phase chromatography is often coupled with mass-spectrometry.  
Another approach to protein fractionation is called shotgun method. In this 
method all the proteins are digested to peptides that are then separated with 
2D high performance liquid chromatography 2D-HPLC24,25. 
Protein analysis and quantification 
MS is considered a go-to method for the identification of proteins and 
peptides in complex biological samples. MS measures the mass-to-charge 
ration, m/z) of the molecules (ref T) permitting their identification, sequencing 
and characterization of post-traslational modifications. The mass 
spectrometer is composed by an ion source, a mass analyzer, and a 
detector. 
The ion source allows for the ionization of the analytes; two of the most 
common techniques used to ionize proteins and peptides are Electrospray 
ionization (ESI) and matrix-assisted laser desorption (MALDI). In ESI the 
ionization happens at atmospheric pressure, and the ions are transferred into 
the mass spectrometer. One of the advantage of this technique is that high 
molecular weight compounds can be observed at low m/z values because 
multi-charged analyte ions are produced during the process. In MALDI the 
analytes are ionized through laser pulses and it is best suited for the analysis 
of relatively simple protein mixtures and proteins with high molecular weight. 
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Ionized proteins and peptides are then analyzed by a mass analyzer 
according to their m/z. Different kind of analyzers are: Quadrupole (Q), Ion 
Trap (IT), Fourier Transform ion cyclotron resonance (FT-ICR) and Time of 
Flight (TOF). 
Each of these technologies, exploit a different physics principles and 
separate ions based on their behaviors in electric fields and/or in vacuum. 
Once the ions are produced and analyzed, they are registered by an ion 
detector. The Ion detector generates a signal from incidents ions by either 
generate secondary electrons or by inducing a current generated by a 
moving charge. The ion signal is amplified, and based on the method applied, 
the detector is called Electron Multiplier or Photomultiplier. All advanced 
modern mass spectrometers use photomultiplier ion detectors. 
Protein identification follows two paradigms: top-down and bottom-up (REF 
T). A top-down approach involves the direct ionization of undigested intact 
proteins. An ion source which is normally ESI or MALDI is often used. Using 
an ESI source, the ions generated have multiple charges, thus the resulting 
spectra are very complex. Because proteins do not have a stable mass value 
but a mass distribution due to the presence of stable isotopes the resulting 
spectrum appear complicated and the identification requires higher 
resolution and accuracy. As of today, only Fourier Transform Ion Cyclotron 
resonance (FT-ICR) analyzers reach the required level of accuracy. 
Furthermore a top-down approach requires the use of an efficient method of 
fragmentation of whole proteins. A top-down approach allows to achieve 
higher total sequence coverage of proteins than a bottom-up approach, 
however expensive instruments and sophisticated data processing software 
are required. 
Bottom-up approaches are normally used for proteomic analysis. In these 
methods, both the mass and the sequence of peptides are used to identify a 
particular protein. Proteins are first digested with proteases, the masses are 
25 
 
then measured and a mass profile is created, then they are compared to a 
database that contains sequences of predicted proteins belonging to a 
particular species that is examined. The comparison between the 
experimental and theoretical mass is called peptide mass fingerprinting. 
Because many peptides can have a very similar molecular weight within the 
methods error limit, it is necessary to know the sequence of the peptides as 
well as their masses. Information about the sequence are obtained by 
performing sequential mass analysis using MS-MS instruments. In the first 
MS analysis peptide ions that fall into a specific m/z interval are selected, a 
fragmentation step then produces a number of fragment per selected ion. 
The m/z of those fragments is then measured with a second MS analysis. 
MS-MS analysis allow the identification of a single precursor with a high level 
of confidence because even though analytes can have the same mass, it is 
very unlikely that they will also have the same fragments. 
With this approach only 20-40% coverage of a particular protein is obtained. 
Not all the peptides are detected because they can be too small or too large, 
or not all the proteins are ionized. Because a MS-MS analysis produces 
several thousands of peptides they can exceed the analytical capacity of the 
mass spectrometers. Protein quantification based on mass spectrometry is 
becoming increasingly popular. Protein quantification is particularly important 
in order to know which proteins are up or down regulated during particular 
stages of a disease and quantification based on 2D gels is often not accurate 
or sensitive. MS-based quantitation is often performed using calibrator 
proteins or peptides that are isotopically enriched with 13C, 15N or 18O that are 
then mixed with the samples and analyzed together. A comparison between 
the reference peak and the analyte peak is used for quantification26. 
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1.2 HYDROGEL NANOTRAPS 
 
The identification of novel biomarkers as well as the improvement of the 
detection sensitivity of current analytical platforms could have a great impact 
for the early diagnosis and the cure of several diseases including cancer. 
Unfortunately, while studies focusing on the discovery of low abundance 
biomarkers are increasing, the results are not very encouraging considering 
that very few candidates have been clinically validated in the recent 
years27,28. Primary physiological and technical roadblocks thwarting 
biomarker discovery can be summarized as follows: 
 
1- Several relevant biomarkers exist in body fluids in extremely low 
concentrations (attomolar) that fall below the detection limits of mass-
spectrometry and conventional immunoassays. In its early stage, a 
diseased tissue releases only a small amount of biomarkers. 
Furthermore only a small sample volume, usually few µl, containing a 
very low number of the relevant molecules can be loaded for analysis on 
MS and immunoassays29. 
2- Biomarkers are often masked by high-abundance proteins that are 
several orders of magnitude more concentrated3,30. Proteins like albumin 
and immunoglobulins in fact account for more than 90% of the plasma 
proteins and exist in a billion fold excess compared to several biomarkers 
which are often non-covalently and endogenously associated with these 
resident proteins. 
3- Biomarker stability poses a challenge due to the presence of endogenous 
or exogenous proteases which make candidate biomarkers subject to 
degradation immediately after sample collection31. Therefore an 
important question relates to how biological fluids can be successfully 
transported and stored without incurring into the loss of clinically relevant 
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proteins. This becomes even a more important issue when we consider 
the large repository of serum and body fluids collected from several 
different hospitals or institutions where samples are collected and 
shipped at different temperatures or without freezing. 
 
Hydrogel Nanotraps have been proposed as a novel and successful tool that 
allows to overcome the previous technical and physiological challenges 
regarding the biomarker purification and preservation29,32–34. Hydrogel 
Nanotraps are a technology with a large applicability in biology and medicine 
and they have been often described as good candidates for drug delivery35–
37 and in-vivo imaging38. In contrast to their common application as a drug 
delivery tool, we employed hydrogel Nanotraps in order to capture, instead 
of releasing target analytes.  
Our hydrogel Nanotraps are polymers that contain a large fraction of water 
in their structure, and are formed by hydrophilic organic monomers that are 
cross-linked into a network by covalent interactions. This open-meshwork 
core can be functionalized with several organic dyes that act as high affinity 
(Kd<10-11) baits for different macromolecules such as proteins and peptides. 
Hydrogel Nanotraps are in fact able in one single step, in solution, to 
concentrate target analyes improving the sensitivity of detection of analytical 
instruments as well as preserving the biomarkers from proteases. Nanotrap 
chemistry can be tailored in order to specifically attract and sequester 
relevant and low abundant proteins and peptides while excluding high 
abundance proteins like immunoglobulins and albumin29.  
As shown in Figure 2 (Magni, R. et al., 2014) virtually all the target proteins 
present in a body fluid sample are sequestered by the Nanotraps and are 
then eluted in small volumes, usually few µl, with the use of specific elution 
buffers that have a composition compatible with the assay that will be used 
for the following analysis. As a results of their increased concentration, many 
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previously invisible proteins can be successfully detected by mass-
spectrometry, western blotting and other immunoassays32,34,39,40. Although 
hydrogel Nanotraps have been widely applied to  capture proteins and 
peptides, their physical and chemical properties can be modified in order to 
target all the major categories of body fluid bioanalytes including such as 
nucleic acids and metabolites as well as entire viruses41. Nanotraps are a 
very versatile technology that can allow with a simple pre-processing step to 
increase the sensitivity of current diagnostic test34,39, as well as allowing the 
discovery of new and clinically relevant biomarkers29,32,42.  
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Figure 2: Nanotraps harvest and concentrate low abundance proteins from complex biological 
fluids. a) Workflow for harvesting proteins. Total processing time is approximately 1.5 hr. 
Proteins in solution are concentrated from blood, serum, plasma, urine, sweat, saliva, or other 
body fluids (1000-fold concentration depicted). (Source: Magni, R. et al., 2014). 
 
1.2.1 ARCHITECTURE OF HYDROGEL NANOTRAPS 
Hydrogel Nanotraps are characterized by high homogeneity in size 
distribution (diameter of 300 - 1000nm) and form a stable suspension in 
aqueous solution. They have a spherical physical structure, they are formed 
by the free radical polymerization of monomers and cross-linking agents43,44 
and they show specific physicochemical properties that are different from 
simple polymer solutions. Their dimension is dependent on several condition 
such as temperature, pH, electric field strength, light, ionic strength and 
solvent. Because 99% of the Nanotrap is composed by water, protein and 
peptides can freely penetrate. For our applications we synthesized hydrogel 
Nanotraps that are made by the co-polymerization of N-isopropylacrylamide 
(NIPAm) and co-monomers like Acrylic Acid (AAc) and Allylammine (AA), 
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vinil sulfonic acid (VSA) but other monomers such as boronic acid, and N-
Allylannine can be included in the structure (Figure 3).  
 
 
Figure 3. Hydrogel Nanotrap synthesis. Hydrogel Nanotraps are formed by the co-
polimerization of N-Isopropyacrylamide (NIPA) and monomers like Acrylic Acid or Allylamine 
in the presence of a cross-linking agent such as N, N-Methylenbis Acrylamide. 
 
The presence of co-monomers is used to tailor Nanotraps to provide unique 
chemo-physical characteristic such as pH sensitive size variation, affinity or 
repulsion of particular proteins or analytes, and ability to chemically bind 
several functional groups post-polymerization. The structure of the Nanotrap 
can be modified in order to provide a different permeability and porosity. The 
porosity determines a molecular weight cut-off size that excludes high MW 
proteins from entering the Nanotrap and it is obtained by changing the molar 
ratio between the monomer and the cross-linker. When added to a body fluid 
the Nanotraps behave as a molecular sieve, physically excluding high 
molecular weight proteins (i.e. albumin and immunoglobulin) (Figure 4). Each 
31 
 
class of particle will sequester and concentrate a class of analytes below the 
molecular cut-off recognizable by the bait.  
 
           
Figure 4. Structure of core-shell hydrogel Nanotrap. The porous structure allows LMW 
proteins to enter while excludes HMW proteins. The presence of an outer shell actively 
excludes unwanted protein such as albumin and albumin fragments. The core is functionalized 
with chemical affinity bait that are able to attract and immobilize target biomarkers. 
 
1.2.2 Use of commercial dyes as high affinity baits for proteins 
Organic dyes have been used widely in the textile industry and their 
chemistry has been extensively studied. Several dyes show strong affinity 
for protein fibers such as cotton, wool or other fibers, depending on the class 
of the dye. The binding mechanism can differ, but often a strong affinity is 
established between the dye and the fiber (Figure 5). These dyes usually 
contain reactive groups such as hydroxyl (-OH), chloride (-Cl), amine (-NH2), 
sulfonate (SO3H), and aromatic rings. These groups often play important 
roles in their binding to proteins and peptides, which is typically achieved by 
a combination of ionic, hydrophobic, and electrostatic interactions, along with 
stabilizing Van der Waals interactions which are maximized when the 3-D 
structure of the dye matches with the one of the target protein. 
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Figure 5. Dye interaction with fibers. Example of a dye (Direct Red 28) and mechanism of 
interaction with cellulose (cotton). Hydrogen bonds are formed when the two azo likages are 
separated by ~10.2-10.8 Angstroms 
 
Different classes of organic dyes have been previously used in proteomics 
and analytical chemistry to bind proteins, as inhibitors of protein-protein 
interactions45, and to remove some specific proteins like albumin from 
complex matrices. In affinity chromatography, ligands are particular 
molecules that possess the ability to bind specific analytes or classes of 
analytes. Normally ligands are immobilized on an insoluble support made of 
polymeric material and they are often very specific, but because they require 
several steps of preparation and purification, they are also very expensive. 
Dye ligands on the contrary represent an inexpensive alternative to 
conventional ligands used in affinity chromatography and show a high affinity 
toward many different proteins. Several studies focusing on the affinity of 
dyes and proteins have been performed. For example Dextran blue was 
shown to have affinity for kinases and Cibacron blue was immobilized on 
Sephadex in order to purify pyruvate kinase46,47. The dye-ligands commonly 
used in affinity chromatography are often formed by a chromophore groups 
linked to a functional group such as sulfonic acid, carboxylic, ammonium 
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chloride, or metal-complexing groups. Many dyes employed for purification 
purposes have triazine moieties, C3H3N3, in which the three carbon atoms 
are highly positively charged. Dye ligands can also be chemically modified 
adding particular functional groups in order to target specific proteins. 
Cibacron blue specificity towards certain classes of proteins is due to mainly 
hydrophobic interactions and the binding is stabilized by electrostatic 
forces45,48,49. Most of the dyes available have never been tested in affinity 
chromatography or for protein capture.  
It has been shown that the affinity of the dye for carrier bound biomarkers is 
higher than the affinity of the biomarker for the carrier protein and it is 
dependent on the isoelectric point of the proteins and the dissociation 
constant of the Nanotraps50. Acrylic acid is negatively charged at pH higher 
than 3.5 and so able to attract proteins and peptides positively charged. 
Allylammine on the other hand act as a bait for carrier proteins that have a 
negative charge.  
Triazine derived textile dyes (Cibacron blue F3G-A, Procion red H8BN) 
represent a class of dyes that have shown strong affinity for proteins51. The 
mechanisms used to bind proteins is still unclear. In the case of Cibacron 
and related dyes blue hypotheses include: a) the interaction between the 
dinucleotide fold structural domains of proteins with the dye, which can 
assume a conformation that mimics the orientation and the anionic group 
characteristic of NAD52; b) non-polar pockets surrounded by hydrophilic 
amino acids residues that can interact with the aromatic rings of the dyes or 
positively charged groups which binds the sulfonate residue53; c) a mixture 
of ionic and hydrophobic forces. 
A menu of baits (Figure 6) has been selected and successfully immobilized 
onto the Nanotraps in order to selectively bind and concentrate a diverse 
classes of biomarkers, such as proteins, peptides, glycolipids, nucleic acid 
and lipids. 
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Figure 6. List of dye baits. Representation of few examples of chemical dyes that can be 
incorporated into the hydrogel Nanotraps. 
 
Because of the bait chemistries that selectively interact with the 3-D 
conformation of target proteins with very high affinity, dye-functionalized 
Nanotraps are able to virtually deplete the entire content of the target 
biomarker from the solution in only few minutes32,50,54.  
Each bait shows a different affinity for different classes of proteins, and if the 
Nanotraps are used to sequester a wide spectrum of analytes, a mixture of 
differently functionalized Nanotraps can be used29 (Figure 7).   
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Figure 7. Different batches Nanotraps functionalized with several commercial dyes.  
 
When a high affinity binding is established between a dye and a protein, the 
equilibrium is shifted towards the bound state and the dissociation constant 
is low (KD<10-12 M) (Figure 8). 
 
 
 
Figure 8. Nanotrap particles are characterized by a very high surface area ratio and high 
binding capacity. Dye baits are covalently immobilized in the core of the Nanotrap and are 
able to form high affinity non-covalent interaction with different classes of proteins. In the 
binding equilibrium between ligands and proteins, high binding affinity and high density of 
ligands ensure high on rate and very low off rate.  
 
Hydrogel Nanotraps that do that do not contain any chemical bait have 
inefficient capture equilibrium because many target proteins are not “free” in 
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the bloodstream, but they are instead associated with high-abundance 
resident proteins such as albumin via non-covalent interactions. The 
efficiency with which these proteins are captured is therefore affected by the 
rate at which this equilibrium is reached. On the other hand, chemical baits 
that have been incorporated into the Nanotrap compete with high-abundance 
resident carrier proteins for the binding of the target biomarker.  
 
1.2.3 Nanotrap characterization 
To assess the quality of a Nanotrap batch, a strict quality control needs to be 
performed; particle size variation with temperature, uniformity of their size 
distribution, as well as dye incorporation need to be evaluated. 
The volume phase transition temperature (VPTT) is a property of the 
hydrogel which consist of a change in volume at a particular temperature55. 
NIPAm Nanotraps swell at temperature below 32°C and shrink when the 
temperature increases. The VPTT is dependent upon different conditions 
such as the amount of cross-linker, the solvent, the ionic strength of the 
surrounding medium and the type of co-monomer used. For example if AAc 
(pKa=4.35) is present, the size changes when the pH>4.35 because of the 
charge repulsion that is created. 
In this thesis particle size was determined by photon correlation 
spectroscopy (PCS) using a light scattering detector (LSD) (submicron 
particle size analyzer, Beckam Coulter)( Figure 9). PCS is based on 
“Rayleigh scattering” which is the scattering of a light or electromagnetic 
radiation by a particle much smaller than its wavelength. The fluctuation in 
the intensity of the laser beam is function of the particle size. Particles 
diameters are measured in water (refractive index=1.333, diluent 
viscosity=0.890 cP) and a test angle of 90° is used. Values are then 
converted to particle size via the Stokes-Einstein relationship. Change 
regarding the molar ratio of reagents used in the Nanotrap synthesis allow to 
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produce Nanotraps of different sizes. For our study the average dimension 
ranges between 300nm and 1µm. 
 
 
Rept# Mean [nm] P.I. Diff.Coef 
[m2/s] 
Counts/s Baseline 
error 
1 1097.4 -1.065 4.47e-13 1.02e+5 4.50% 
2 1042.8 -1.230 4.70e-13 1.01e+5 1.21% 
3 1024.0 -1.422 4.79e-13 9.95+4 0.33% 
Average 1054.7  
± 31.11 
-1.239  
± 0.146 
   
 
Figure 9.  Example of Nanotrap size measurement through light scattering. Hydrodynamic 
diameter of a batch of Remazol brilliant blue functionalized Nanotrap particles was 1054.7 +/- 
31.11 nm.  
 
1.2.4 Measuring uniformity of size distribution through Atomic Force 
Microscopy 
The uniformity of Nanotrap size distribution was measured with atomic force 
microscopy as shown in Figure 10 (Luchini, A. et al., 2010). AFM is a 
microscope that measure a sample surface “feeling” it with the use of a very 
sharp probe. This sharp tip is mounted on the end of a cantilever that moves 
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on the surface of the sample. When the tip approaches the sample surface 
a combination of forces, including Van der Waals, electrostatic, capillary and 
double layer interactions are generated and cause a deflection of the 
cantilever. A laser beam is directed to the upper surface of the cantilever and 
reflected onto an array of photodiodes. Once the tip moves over the sample 
surface the deflection of the cantilever changes the reflection of the laser and 
the intensity of the beam striking the photodiodes varies in relation to the 
roughness of the sample surface. Modern AFM can operate in two modes: 
contact mode and dynamic mode. In the first one the tip is in contact with the 
sample surface, while in the second the tip does not make contact with the 
sample surface but the cantilever oscillates at a resonant frequency that is 
perturbed by the forces acting between the tip and the sample surface. While 
contact mode is preferred for characterizing the roughness of metal and other 
material surfaces that cannot contaminate the tip, the dynamic mode is 
preferred when cells, or biological molecules that could contaminate the tip 
need to be visualized. 
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Figure 10. Atomic force microscopy (AFM) of hydrogel Nanotraps. The scale bar (visible on 
the right-hand side of each picture) shows Nanotrap heights, which range between 76 and 
270 nm. The variability of the measured values is probably due to the fact that the picture was 
acquired under dry status so the particles are distorted from their normal spherical shapes. 
(Source: Luchini, A. et al., 2010) 
 
1.2.5 Size sieving and exclusion of high-abundance proteins 
The pore size of the Nanotraps can be tuned in order to selectively capture 
low molecular weight proteins by adjusting the degree of cross-linker used. 
That is very useful in analytical chemistry because the LMW peptidome is 
regarded as a rich source of potential biomarkers. Proteins with a molecular 
weight lower than the pore size cut-off will be able to enter the core of the 
Nanotraps and interact with the affinity bait. Since albumin is present in 
million fold excess relative to the proteins and peptides of interest, it is crucial 
to design a Nanotrap that can actively exclude albumin and albumin 
fragments from entering. 
VSA was used as a co-monomer in the preparation of hydrogel Nanotraps to 
assess its influence in actively exclude albumin. The incorporation of 
sulfonate groups into the substrate reduces proteins adsorption to the 
surface due to the negative charge they carry in aqueous media56. 
VSA shelled Cibacron Functionalized Nanotraps were synthesized in order 
to determine if the BSA repelling properties could be exploited in a biological 
fluid using a core-shell architecture. In an experiment conducted by 
Tamburro et al.29, it was shown how CB core/VSA shell Nanotraps were able 
to exclude albumin while retaining high affinity for other proteins, CB-core 
particles, VSA-core particles and CB-core/VSA-shell particles were 
incubated with serum samples. Eluates from the Nanotraps were then loaded 
on a gel and silver stained as well as run on mass-spectrometry. As shown 
in Figure 11 (Tamburro, D. et al., 2011), the use of VSA shelled Nanotraps 
decreased the number of unwanted human serum albumin (HAS) fragments 
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and did not affect the sequestration of target proteins by the CB bait in the 
core.  
Number of peptide hits of HAS as well as the low abundant marker Apo-CIB 
were measured through mass-spectrometry in unprocessed serum sample 
as well as in the eluated from the three Nanotrap batches. The eluate from 
CB functionalize Nanotraps showed 131 HAS peptide hits, more than 10 
times less than in crude serum. VSA and CB-VSA showed only 9 and 5 
peptide hits for HAS. Interestingly the number of target proteins such as Apo-
CIB that were undetected in human serum because of the presence of high 
abundance proteins, were detected in all the three batches of Nanotraps 
reaching the highest peptide hits in the CB-VSA Nanotraps. 
 
             
Figure 11. Core-shell hydrogel Nanotrap enrich LMW proteome while excluding abundant 
HMW proteins. and exclude On the left: Cibacron blue F3GA (CB) core- Vinylsulfonic acid 
(VSA) shell particles greatly enhance the low molecular weight protein concentration in whole 
blood (lane 2) with respect to serum (lane 1) while fully excludes abundant albumin, albumin 
peptides and immunoglobulins. On the right: the number of peptide hits for Albumin and Apo-
CIB proteins measure in eluates from serum incubated with CB-core particlse, VSA-core 
particles and CB-core/VSA-shell particles. The presence of VSA shell excluded unwanted 
peptides such as albumin without reducing the particles’ affinity for a wide range of interesting 
peptides and proteins. (Source: Tamburro, D. et al., 2011)29 
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1.2.6 Protection of biomarkers from degradation 
One of the major problem associate to biomarker discovery and 
measurement is represented by the degradation by exogenous and 
endogenous proteases. As shown in Figure 12 (Tamburro et al., 2009), 
several chemokines (MEC/CCL28, SDF-1B/XCL12b, CCL24) were 
incubated with trypsin at 37°C in the presence or absence of Nanotraps. 
Results showed that once captured in the Nanotraps, because immobilized 
to the affinity bait, labile biomarkers such as chemokines are immune to 
protease recognition and cleavage. Once the proteins are captured inside 
the Nanotraps they become immune to degradation by exogenous and 
endogenous proteases33.  
 
Figure 12. Proteins sequestered in the Nanotraps are protected 
from enzymatic degradation. Interleukin 8 (IL8) diluted in 
artificial sweat was incubated with excess trypsin at 37 °C in 
presence or absence of disperse yellow 9 (DY9) functionalized 
particles. SDS PAGE analysis revealed that in absence of DY9 
particles, the IL8 band disappeared and a fainter band at lower 
molecular weight appeared indicating the presence of a 
degradation product (lane 2). In presence of DY9 particles, IL8 
is fully protected from trypsin degradation (lane 5). Incubation 
of IL8 with sweat at 37 C alone caused the intact IL8 band to 
disappear (lane 3) while the DY9 particles yielded a full density 
band for the intact protein (lane 4), suggesting that IL8 was 
protected from degradation at 37 °C. (Source: Tamburro, D. et 
al., 2011).  
 
1.2.7 Nanotrap processing increases biomarker concentration  
Bait-functionalized hydrogel Nanotraps are a very versatile tool for the pre-
processing of several biological fluids such as blood, serum, cerebrospinal 
fluid, saliva, sweat, tears, urine32–34. Before processing relevant clinical 
samples it is mandatory to optimize each Nanotrap parameters in order to 
obtain ideal results. Some important parameters are: selection of the dye, 
Nanotrap ratio to sample volume, elution buffer composition. It is advisable 
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for this reason to create before sample processing a dose-response curve 
that could provide useful information regarding the reproducibility of the 
results and the limit of detection. Because the different dyes act as molecular 
baits thanks to a combination of hydrophobic and electrostatic forces 29, their 
affinity towards specific proteins cannot be predicted. For this reason a panel 
of different dyes should be tested and the capturing and elution efficiency 
measured as a preliminary step. Also, depending on the nature and the 
strength of the interaction between the capture protein and the chemical 
baits, different elution buffers should be selected case by case, in order to 
obtain the maximum recovery of the interest analyte. Tamburro et al.29 
describe the screening of Nanotraps functionalized with a panel of 15 
different baits in their ability to capture a list of 13 known low abundance 
biomarkers in order to determine whether the uptake of proteins by the 
particles was dependent on the specific chemical structure of the dye. Each 
chemical bait exhibited a unique pattern of captured proteins with different 
efficiency (Figure 13).  
 
 
Figure 13. Differently functionalized Nanotraps have affinity for biomarkers. Nanotraps 
functionalized with 17 different molecular baits show preferential high affinities for 13 specific 
low abundance biomarkers among which interleukin 6 (Tamburro, D. et al., 2011)29. 
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In addition it is important to mention that the elution buffer, especially if 
detergents are present, needs to be chosen to ensure to the compatibility 
with the downstream assay.  
The concentration factor obtained using hydrogel Nanotraps is a function of 
the starting volume of the sample. The following formula shows how the 
detection limit of an assay directed toward a particular analyte can be 
enhanced by the use of hydrogel Nanotraps. 
 
Cmin=L/(Vi/Vf)=L/c 
 
Where Cmin represents the lowest amount of analyte that can be normally 
detected by that specific assay, L is the lowest limit of sensitivity of the assay, 
Vi is the initial volume of the sample before processing, Vf is the final volume 
of the sample after the elution and c is the concentration factor obtained by 
the ration between the initial and the final volume. Let’s assume that we are 
targeting a particular protein in urine33. If our urine sample has an initial 
volume 50 mL, and the captured proteins are finally eluted into 50 µL, we 
obtain a concentration factor of 1000. Assuming that the assay we are using 
has a detection limit of 100 pg/mL, then the Cmin of the assay after Nanotrap 
processing becomes 0.1pg/ml. This is a hypothetical example and shows 
how hydrogel Nanotraps can dramatically increase the effective sensititvity 
of any analytical platforms. 
 
1.2.8 Antigen-displaying Nanotraps  
The use of Nanotraps containing degradable cross-linker is a novel concept 
that permits to combine the concentration ability of the Nanotraps to lateral 
flow immunoassay (LFA) and ELISA. Partially or fully degradable Nanotraps 
can be synthesized and could serve for different purposes. In regular 
Nanotraps, because of their small pore size, high molecular weight proteins 
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are prevented to enter the core structure. Because immunoglobulins are too 
big to enter the particles, an elution step to extract proteins from the 
Nanotraps is required before performing an immunoassay4,32,40,54. Partially 
degradable Nanotraps offer the advantage to increase the Nanotrap pore-
size, allowing the antibodies to directly access the target analyte, while still 
keeping some of the characteristics of the Nanotraps, such as capability of 
being centrifuged at relatively low speed and re-suspended in smaller 
volumes. Also, because of an intrinsic affinity of the Nanotraps to 
functionalized high-binding ELISA plates, they can be deposited on a multi-
well plate and directly analyzed. Fully degradable Nanotraps on the other 
hand are optimal when centrifugation steps are no longer required and the 
absence of a Nanotrap sterical hindrance could actually negatively affect the 
assay. 
Partially degradable Nanotraps are mixed with the bio-fluid of interest and in 
minutes capture the target analytes.  A degradable cross-linker such as 
Dihydroxyethylenebis-acrylamide (DHEA) can be degraded through an 
oxidizing reagent, NaIO4 (sodium periodate), causing an increase in the 
particle pore size that allows the antibody used in the ELISA or LFA to directly 
access the antigen captured by the particles (Figure 14). Several other 
strategies can be used in order to synthesize Nanotraps that can be 
degraded under different chemical conditions.  
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Figure 14. Partially degradable nanotraps are able to expose the captured antigens for direct 
antibody binding in several types of immunoassays. a) In presence of oxidizing conditions (i.e. 
NaIO4) Nanotraps can be partially dissolved. b) scheme of an ELISA through immobilization 
of partially degradable nanotraps. c) scheme of a lateral flow immunoassay using degradable 
nanotraps. Nanotraps can flow thorough the membrane, once the antigen displaying 
nanotraps reach the antibody line, they are immobilized and allow for colorimetric detection.  
 
Another degradable crosslinker is bis(acryloyl)cystamine (BAC). Previous 
studies have already shown the possibility to incorporate BAC as a cross-
linker in the synthesis of NIPAm based hydrogels57. Because of the presence 
of the disulfide bond in the BAC structure, the Nanotrap can be degraded in 
the presence of reducing conditions (Figure 15). The use of a disulfide 
containing cross-linker was employed to enable erosion of drug carriers in a 
triggered fashion, while also offering thiol groups within the hydrogel for 
bioconjugation and controlled assembly58,59. Disulfide bond incorporation 
during Nanotrap synthesis can be challenging, because numerous side 
reactions that disrupt the sulfur−sulfur bond can occur. The disulfide bond 
may be homolytically cleaved at high temperatures, resulting in sulfur radical 
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formation during the synthesis. Additionally, the disulfide bond may enable a 
chaintransfer reaction, wherein a radical attack at the disulfide leads to the 
formation of a thioether, with a second sulfur radical released as a result. 
 
 
   
Figure 15. Schematic representation of a partially degradable Nanotrap using BAC as a 
crosslinker. The disulfide bond of the BAC is cleaved using reducing reagents such as β-
Mercaptoethanol or Dithiothreitol. 
 
Pyrazolone containing dyes, characterized by the presence of two acidic 
groups, can also be used to cross-link allylammine containing polymers. 1-
4-Sulfophenyl)-3-methyl-5-pyrazolone was conjugated with vanillin in order 
to obtain an orange dye that possesses a carboxylic group on one end and 
a sulfonic group on the other. In basic/neutral condition both groups are 
negatively charged and can create strong ionic bonds with allylammine 
groups thus acting as a cross-linker between polymeric strands of NIPAm. 
By reducing the pH of the particle containing solution the carboxylic end will 
become protonated, inducing a partial degradation of the Nanotrap. A further 
drop in pH will induce also the sulfonic group to detach, leading the particle 
to complete erosion (Figure 16). 
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Figure 16. Pyrazolone containing dyes as degradable crosslinkers. The primary ammines of 
the two parallel poly(Nipam) strands react with the carboxylic and the sulfonic group of the 
pyrazolone dye at neutral/basic pH. The strong ionic bond formed allow to act as a crosslinker 
and the reaction can be easily visualized by a change in color of the solution from yellow to 
orange. 
 
Fast blue B is a dye that can be easily incorporated into previously 
synthesized hydrogel Nanotraps and shows affinity with different classes of 
proteins. Its chemical structure also makes it a suitable candidate as a 
cleavable cross-linker. Fast blue B forms an azo-compound with NIPAm and 
once the polymeric strands of NIPAm are cross-linked, the azo-bond can be 
cleaved by the use of sodium dithionite as a reducing agent (Figure 17). 
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Figure 17. Schematic representation of incorporation and cleavage of Fast Blue B. Fast Blue 
B is used not only as a high affinity dye but also as a cleavable crosslinker. Once the complex 
is formed, degradation occurs through incubation of the Nanotraps with sodium dithionite. 
 
1.2.9 Application of hydrogel Nanotraps for biomarker discovery 
Nanotraps have been successfully employed for the identification of specific 
biomarkers related to different cancers; previous studies conducted in our 
laboratory focused on the investigation of prostate, ovarian4, soft tissue 
sarcoma60, melanoma32 and pediatric brain tumors. The following paragraph 
illustrate an example of how a biomarker discovery study could be performed 
by using hydrogel Nanotraps. 
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1.2.10 Exploring the CSF proteome in children affected by brain tumors  
Central Nervous System (CNS) tumors are the second most common 
pediatric malignancies, accounting for approximately 25% of all childhood 
neoplasms. They comprise several groups of tumors, with different histology, 
arising in different sites of the Central Nervous System61. Several studies 
have shown that pediatric brain tumors often have a very distinct 
pathogenesis and biology compared to the adult counterpart, even in the 
presence of an indistinguishable histopathology62. Cerebrospinal fluid (CSF) 
is a very valuable source of biomarkers for brain tumors and represents a 
potential indicator of pathological processes that happen in the CNS. CSF 
biomarker discovery poses some physiological and technical challenges: low 
protein levels (total protein concentration 1.5 to 6 mg/mL), dynamic range 
(up to approximately 12 order of magnitude), and the presence of highly 
abundant proteins masking the less abundant ones. Core-shell capturing 
hydrogel Nanotraps can overcome these challenges capturing, preserving 
and concentrating candidate low molecular weight, low abundance proteins 
in solution, in one step, improving the effective sensitivity of mass-
spectrometry by several orders of magnitude. Cerebrospinal fluid from 27 
pediatric brain cancer patients at initial diagnosis and 13 pediatric oncology 
controls (extra-CNS non Hodgkin lymphoma) were processed with core-shell 
hydrogel Nanotraps and then analyzed with reverse-phase liquid 
chromatography/electrospray tandem mass spectrometry (MS/MS). The MS 
data was searched against a human protein database NCBI (National Center 
for Biotechnology) with Mascot software. Spectral counting analysis was 
accomplished using Scaffold software (Proteome Software Inc.). Protein 
identiﬁcation was performed with SEQUEST. The data were searched 
against a fully tryptic indexed, human protein database maintained by the 
National Center for Biotechnology Information. Gene ontological annotations 
for selected proteins was performed using the Database for Annotation, 
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Visualization and Integrated Discovery (DAVID) as well as IPA Ingenuity 
System. After label free spectral counting (scaffold analysis) of the LC-
MS/MS results, a total of 559 NCBI annotated proteins were identified in both 
case and control groups. This first list of proteins was searched against the 
public CSF proteome database www.biosino.org/bodyfluid in order to identify 
proteins that were not known to exist in CSF. Of the 559 unique proteins that 
were identified in both cases and controls, 147 (26%) were previously not 
known to exist in CSF. 
Starting from the 559 non redundant proteins indentified by the LC-MS/MS 
analysis 486 were eventually considered in the statistical analysis as the 
remaining 91 were not expressed or were always expressed in all the 40 
subjects. The designed statistical selection procedure allowed the 
identification of 47 proteins with a significantly statistical result (alpha 
level=0.05)63. Then, by taking into consideration both the biological function 
and the statistical relevance, a final list of 26 top-proteins was eventually 
selected (Supplementary table 1).  
Fourteen of the 26 selected top-proteins were chosen for validation by WB, 
RPPA and ELISA methods, on the base of antibody availability and reliability. 
Six proteins (PCOLCE, COL1A1, GFRalpha2, ITIH4, NPDC1, IGFBP4) were 
eventually validated. All of them reported a good capability to discriminating 
metastatic cases from controls (AUC values from 0.76 to 0.99). Some of the 
proteins we found associated with the status of the subject (cases or only 
metastatic vs controls) were known to be involved in the process of 
extracellular matrix (ECM) remodeling, including collagen XVIII and 
procollagen C-endopeptidase, and have previously been associated with 
tumor progression and worse prognosis64,65. Statistical analysis between 
non-metastatic and metastatic patient samples also highlighted potentially 
relevant proteins such as GDNF family receptor α-2 (GFRα2); GFRα1 and 
GFRα3 were previously reported to have a role in tumor growth and 
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invasiveness66. Among the candidate biomarkers were also identified 
Dickkopf homolog 3 related to Wnt/β-catenin pathway and involved in 
tumorigenesis67, prosaposin previously found over-expressed in breast and 
prostate cancer and melanoma inhibitory activity expressed in a variety of 
malignant tumors of mainly neuroectodermal origin68.  
In conclusion, combining a unique dataset of CSF from pediatric cancer 
patients with a novel enabling nanotechnology allowed us to identify 
candidate biomarkers that could generate important insights for diagnosis, 
prognosis and molecular stratification of CNS pediatric tumors. These finding 
will be first confirmed by using more standard methods such as Western Blot 
analysis and then validated in independent series of subject. 
 
1.2.11 Hydrogel Nanotraps for the development of diagnostic tests 
Hydrogel Nanotraps can be successfully applied to a plethora or biofluids 
including urine. Urine is an ideal biological fluid for clinical analysis because 
can be collected easily and in large amounts without performing any invasive 
procedure. Although urine analysis is often proposed as an alternative to 
blood collection, the very low concentration of analytes of interest, and the 
presence of interfering substances, has challenged the development of 
urine-based diagnostic tests as well the discovery of clinically relevant 
biomarkers. Through the application of recent proteomic technologies, 
several hundreds of proteins have been lately identified in urine as potential 
disease biomarkers63,69. The discovery of several new urine biomarkers 
brought to light some of the weaknesses of this biological fluid, such as the 
total protein variability due to hydration state and kidney function, low 
concentration of biomarkers that may be present one hundred to one 
thousand times less than in blood (which because of glomerular filtration are 
not proportional to the blood concentration), and the rapid degradation of 
biomarkers. Our group applied hydrogel Nanotraps to amplify the sensitivity 
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of diagnostic tests in urine. In a paper published by Luchini et al.40 urine was 
used as a viable biofluid for noninvasive measurement of Human Growth 
Hormone (hGH) secretion. Because of the very low concentration of hGH in 
urine (1pg/ml range), current commercially available immunoassay are not 
suitable for the detection in this biofluid. Hydrogel Nanotraps were used to 
concentrate hGH in urine so that its levels could be measured with a clinical 
grade standard immunoassay designed for serum (Immulite 1000, Siemens). 
A population of healthy young adults (age 18–30, N=33, median 21, M: 
F=39%:61%, with no reported medical therapies) was used to determine the 
hGH baseline using the Nanotrap enhanced immunoassay was applied to 
evaluate the baseline value of urinary hGH. Results showed that Nanotrap 
sample preprocessing effectively improved the lower limit of detection of the 
Immulite hGH assay by more than 50 fold, shifting the linear range of the 
assay to encompass the expected value of urinary hGH. The full process 
between run and within run CV% was 7.9 and 9.0%, respectively.  
Nanotrap preprocessing constitutes a reliable mean of measuring urinary 
hGH with a clinical grade immunoassay, now establishing a normal baseline 
value for hGH in urine. An important question can now be addressed as to 
whether the excretion of hGH in the urine has a longer time course than the 
spike of hGH in serum following exogenous administration. Moreover it will 
now be possible to study factors that affect urinary hGH doping that would 
otherwise be missed with serum testing. 
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1.3 APPLICATION OF HYDROGEL NANOTRAPS FOR HIGH 
SENSITIVITY MEASUREMENT OF URINARY OUTER SURFACE 
PROTEIN A IN EARLY STAGE LYME BORRELIOSIS 
 
Lyme disease (also known as Lyme Borreliosis) is a bacterial infection 
caused by the bacteria belonging to the genus Borrelia, that is transmitted by 
Ixodes sp. ticks to humans70. B. burgdorferi sensu stricto (s.s.) is particularly 
predominant in the Americas, and B. afzelii and B. garinii, in addition to B. 
burgdorferi s.s., in Europe and Asia. Other two Borrelia species are known 
to be pathogenic, B. baverensis and B. spielmanii and three are suspected 
B. valaisiana, B. bissettii and B. lusitaniae71. B. afzelii and B garinii account 
for most Lyme Borreliosis infections in Europe, while B. garinii is the most 
diffused in Asia. Whereas B. afzelii is mostly associated with skin 
manifestations, B. garinii seems to be the most neurotropic, and B. 
burgdorferi seems to be the most arthritogenic72. B burgdorferi genome was 
the first to be sequenced73. Because of an almost complete absence of 
biosynthetic pathways, the microorganism is suggested to be fully dependent 
on its environment for nutritional requirements. Nonetheless, Lyme Borrelia 
can be grown in vitro in highly enriched culture media74,75. 
 
1.3.1 Ecology of the spirochete and the tick vector 
The tick Ixodes ricinus is the main vector in Europe, Ixodes persulcatus in 
Asia, Ixodes scapularis in northeastern and upper midwestern USA and 
Ixodes pacificus is the vector in western USA76.  Their life cycle is made of 
four-stages—egg, larva, nymph, and adult (Figure 18, Stanek, G. et al., 
2012) —feeding only once during every active stage.  
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Figure 18. Developmental stages of Ixodes ricinus tick. From left to right: larva, nymph, adult 
female, adult male. (Source: Stanek, G. et al., 2012). 
 
Male ticks rarely feed and never engorge. While a host animal passes 
through the vegetation, unfed ticks use their mouthparts to attach to the 
animal skin. The feeding process takes few days (about 3 days for larvae, 5 
for nymphs, and 7 days for adult females), then the ticks drop off their host 
and live on the soil requiring humidity of 80% for survival. The ticks take 
several months to develop into their next developmental stage, or, in the case 
of adult females, lay about 2000 eggs. The tick’s life cycle varies between 2 
years and 6 years depending on climate77. Borrelia is passed to the host 
through the tick saliva during feeding. A feeding period of more than 36 h is 
usually needed for transmission of B. burgdorferi by I. scapularis or I. 
pacificus ticks78–80 while the transmission of .B afzelii by I. ricinus, however, 
can be faster.  
In endemic areas, Lyme disease can be transmitted in either peri-urban 
areas or rural areas used for forestry and recreational activities81. The 
lifecycle of the different tick species have distinct seasonality. I. ricinus and 
I. persulcatus, nymphs and adults become active in early spring and continue 
to seek hosts until mid-summer, or even later in favourable environments. I. 
ricinus has also a second peak of activity in the autumn. I .scapularis nymphs 
are active from early summer to early autumn, but the adults do not become 
active until autumn and remain so through winter until early spring, apart from 
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periods when temperatures are too low for activity (<3°C). I. pacificus seem 
to have a cycle similar to I. ricinus80. The main host for Lyme Borrelia are 
small mammals, such as mice and voles, and some species of birds. Deer 
are essential for the maintenance of tick populations but as well as cattle are 
incompetent hosts for Borrelia. Once a small populations of deer is present 
in a tick habitat Lyme borreliosis risk increases because of the presence of 
other hosts, including reservoir competent animals. However, if most animals 
in a habitat are not competent the likelihood of Lyme disease decreases 
because the ticks will feed mostly on those animals and not become infected. 
Risk of infections for humans is high from late May to late September, 
coinciding with the tick’s life cycle and the increasing recreational use of tick 
habitats by the public. A typical habitat for the transmission of Lyme Borrelia 
often consists of areas of deciduous or mixed woodland, occasionally 
coniferous, with a layer of decaying vegetation on the ground, providing 
enough humidity for the development and survival of ticks, and supporting a 
range of potential vertebrate reservoir hosts. . Unlike other spirochete-borne 
infections where vertical transmission of the bacteria from the mother to the 
fetus through the placenta is well documented82, data regarding 
transplacental transmission rate through the placenta remain controversial. 
According to CDC, Lyme disease infection during pregnancy may potentially 
lead to infection of the placenta and possible stillbirth; however, no negative 
effects on the fetus have been documented if proper antibiotic treatment is 
administered to the mother.83 
 
1.3.2 Geographic distribution 
In the United States about 30,000 new Lyme disease cases are reported 
annually, but a number almost 10 times higher is estimated to be unreported 
by the CDC84. The spreading of the disease beyond its endemic foci is 
predicted to accelerate with climate change. Climatic variables and climate 
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change are found to be associated with tick survival and their geographic 
distribution85. Cases occur primarily in the northeast and upper midwest 
regions of the US; however, ecologic and environmental changes have 
catalyzed a gradual geographic expansion86. In the US, most cases of Lyme 
disease have been recorded in coastal and riparian regions of southern New 
England, southeastern New York, New Jersey, eastern Pennsylvania, 
eastern Maryland, Delaware, Virginia and parts of Minnesota and 
Wisconsin87. The incidence in the ten states with the highest numbers of 
cases averaged 302 cases per 100,000 persons between years of 1991 and 
200688. In Canada, Lyme disease became nationally notifiable in 2009 and 
since then the number of cases more than doubled in four years, from 144 in 
2009 to 338 in 2012, which means an increase in incidence from 0.4 to 1.0 
cases per 100,000 population. Endemic LD occurs in British Columbia and 
in the eastern and central Canadian provinces of Nova Scotia, New 
Brunswick, Quebec, Ontario and Manitoba where it is continuing to emerge89.  
In Europe, 85,000 cases of LB are estimated each year; however, the 
reporting in Europe is inconsistent and many infections go undiagnosed90. 
The highest incidence has been recorded in the Scandinavian countries and 
in central and eastern Europe, especially in Germany, Belgium, Austria, 
Slovenia, and Czech republic between the years of 2009 and 201291. The 
highest annual incidence is 80 cases per 100,000 persons or higher reported 
for Slovenia (155/100,000), Austria, Southern Sweden, Netherlands and 
Switzerland. Incidence lower than 20 cases per 100,000 persons have been 
reported in France and Poland92. The lowest incidences are in UK 
(0.7/100,000) and Ireland (0.6/100,000). Cases have been reported in over 
60 countries and endemic foci in North America, Europe, and Asia93 (Figure 
19, Stanek, G., et al., 2012).  
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Figure 19. Global distribution of Lyme disease. The distribution shows that LD has extended 
to many countries around the world beyond the endemic foci. Reported LD activities that were 
mapped include diagnosed cases as well as infected ticks, infected animals, and seropositive 
human samples. The dark gray shading signifies countries with (at least) some reported LD 
activity, and the presence of activity is known only at the country level. The lighter gray shading 
represents areas in which Lyme disease has been reported at the sub-national level in 
particular regions of some countries. The lightest gray represents counties with rare or 
unknown activity. (Source: Stanek, G et al., 2012). 
 
Lyme disease is also endemic in several areas of Italy90. Several species B. 
afzelii, B. garinii, and B. burgdorferi s.s. and B. valaisiana were identified in 
several provinces of the Northeast of Italy. Even though mountain regions 
are the more at risk for the incidence of Lyme disease, evidence of I. ricinus 
harboring Borrelia have been identified in the Po river region of Italy showing 
that its distribution extends to the plains such as the Po river valley and 
potentially to suburban areas94.  
  
1.3.3 Pathogenesis 
Borrelia burgdorferi is carried in the midgut of unfed Ixodes ticks. During 
feeding, of the mammal host’s blood, the spirochaetes increase in number 
and incur phenotypic changes, such as the expression of outer surface 
protein C (OspC), that allows the invasion of the tick’s salivary glands. This 
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process takes days and it’s the reason why the transmission can occur only 
after a delay. Expression of OspC plays an essential role in the infection of 
a mammalian host, but the mechanisms is still unknown95,96. The infected tick 
then deposits spirochaetes into the skin of a host animal and later Borrelia 
disseminate from that site through blood to other body sites. Once the 
infection is established a humoral and cellular immunological response is 
triggered in the human or animal host. Unfortunately, because of the 
bacteria’s ability to down-regulate the expression of specific immunogenic 
surface exposed proteins, such as OspA and to alter rapidly through 
recombination of a surface lipoprotein known as variable major protein-like 
sequence expressed (VIsE) the Borrelia can escape the immune system and 
infection can persist. Borrelia’s abitlity to bind to various components of the 
extracellular matrix also contribute to its persistence97–99. Because Borrelia 
does not produce any toxins the tissue damage in patients derives from host 
inflammatory reactions and the intensity of the inflammatory response is 
depends on the different Borrelia genospecies100. Host genetic factors have 
an important role in the expression and severity of infection in animals, the 
only role established in man is in the development of antibiotic refractory 
Lyme arthritis, which is seen most often in patients with specific HLA-DR 
alleles98. 
The immunopathology of Lyme disease is still a major challenge. Although it 
induces strong immune activation, e.g., in phases of arthritis, the spirochete 
can persists in the organism and lead to a chronic pathology in the 
immunocompetent host. The inflammatory episodes suggest the presence 
of anti-inflammatory mechanisms and the long phases of latency suggest 
immune-evasion. Several studies proposed that Borrelia modulates the 
host's immune system in order to evade immune clearance. Evidence that 
Borrelia could indeed render human PBMC tolerant, i.e., was shown by 
Diterich et al.101. They in fact demonstrated that Borrelia render PBMC 
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hyporesponsive to subsequent stimulation with heterologous stimuli such as 
the TLR2 agonist LTA or the TLR4 agonist LPS. The OspA C-terminus 
domain plays an important role in Bb induced immune tolerance, induction 
of the inflammatory response through TLR2101,102, and host immunologic 
recognition103. 
 
1.3.4 Clinical Symptoms  
Borrelia infection and can lead to serious complications including chronic 
joint inflammation104, cognitive defects105, heart irregularities106, and memory 
loss107. The most common and earliest clinical evidence of Lyme disease is 
a skin lesion called erythema migrans (EM), which appears to be present in 
approximately 70-80% of patients108. EM normally occurs in the first 2 weeks 
after the tick bite. It manifest as an expanding red or bluish-red patch (≥5 cm 
in diameter), with or without central clearing. The advancing edge is very 
distinct, often intensely colored. Diagnosis is made on the basis of history 
and visual inspection of the skin lesion. Culture or PCR of skin biopsy can be 
done but it is not needed for routine clinical practice. Relatively common 
symptoms are early complications (neurologic Lyme disease; 10-15% of 
patients) which manifests as facial nerve palsy, lymphocytic meningitis, and 
radiculopathy109, myopericarditis that typically occurs in form of heart block 
(1-2%)110 and Lyme arthritis (approximately 30%).  Cardiac and neurologic 
symptoms normally occur within weeks to a couple of months after the tick 
bite111. Cardiac symptoms manifest through an acute onset of atrioventricular 
(I–III) conduction disturbances, rhythm disturbances, and sometimes 
myocarditis or pericarditis. Lyme arthritis manifests through recurrent attacks 
or persisting objective joint swelling in one or more large joints. Migratory 
monoarticular or pauciarticular arthritis affecting large joints normally 
appears after 6 months after the tick bite112. Other less frequent symptoms 
are: Borrelial lymphocytoma manifesting as a painless bluish-red nodule or 
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plaque, usually on ear lobe, ear helix, nipple, or scrotum and it’s more 
frequent in children (especially on ear) than in adults; ocular manifestations 
such as conjunctivitis, uveitis, papillitis, episcleritis, keratitis. Diagnosis of 
Lyme disease is tipically made by recognition of erythema migrans coupled 
with serological testing based on a two-tier approach (an immunoenzymatic 
test followed by a Western blot confirmatory test).   
 
1.3.5 Treatment 
In-vitro studies showed that Borrelia are susceptible to tetracyclines, most 
penicillins, many second-generation and third-generation cephalosporins, 
and macrolides while show resistance to specific fluoroquinolones, 
rifampicin, and first-generation cephalosporins113–115. 
Erythema migrans will resolve naturally without antibiotics, but antibiotic 
treatment is recommended to prevent later stages of dissemination. 
Doxycycline, amoxicillin, phenoxymethylpenicillin, and cefuroxime axetil are 
highly effective and are the first line of treatment while macrolides such as 
azithromycin are less effective and only administered as second-line 
treatment113. Doxycycline is the only antibiotic that showed in several study 
its efficacy with only 10 days of treatment116. Doxycycline, is contraindicated 
in children younger than 8 years and in women who are pregnant or 
breastfeeding113. Erythema migrans can manifest as an increase in the size 
or intensity within 24 h from the beginning of the treatment. Fever, when 
present, often resolve within 48 h and the skin lesion usually disappears 
within one or two weeks. Fatigue or arthralgia could take longer to resolve 
even up to three months116. Parenteral antibiotic treatment is recommended 
when patients are admitted to the hospital for Lyme neuroborreliosis and as 
an initial treatment for those with cardiac Lyme borreliosis. Ceftriaxone is the 
first choice because of its efficacy against Borrelia in vitro, and also because 
it crosses the blood–brain barrier well, and has a long serum half-life. 
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Alternative choices are cefotaxime and intravenous penicillin. Studies 
showed that oral doxycycline is as effective as ceftriaxone for any of the 
primary manifestations of early Lyme neuroborreliosis117,118.  
Symptomatic patients with cardiac Lyme borreliosis and those with high-
grade first-degree atrioventricular block (PR interval of ≥300 ms), and 
second-degree or third-degree atrioventricular block, should be admitted to 
hospital and closely monitored. Complete heart block generally resolves 
within 1 week and less after treatment and conduction disturbances within 6 
weeks113. Studies showed that patients whose arthritis is not improved after 
the first cycle of antibiotics can be re-treated with a second course of oral 
antibiotics, and parenteral antibiotic treatment in case of absence of any 
substantial clinical response113. 
 
1.3.6 Chronic Lyme disease 
Persistent symptoms related to patients infected by Bb are often referred as 
chronic Lyme disease syndrome. The Infectious Diseases Society of 
America (IDSA) and the International Lyme and Associated Diseases 
Society (ILADS) differ in their recommendations for the clinical assessment 
and treatment of persistent Lyme Borreliosis. IDSA recognizes that Lyme 
disease can be painful and that the disease is not always properly identified 
or treated. They recognize that some patients may continue to experience 
prolonged Lyme disease symptoms even after a course of antibiotic therapy 
has killed the Lyme disease bacterium. They remain concerned that a 
diagnosis of so-called “chronic Lyme disease,” suggesting that active 
infection is ongoing, is not supported by scientific evidence and the treatment 
of long-term antibiotic therapy will be harmful for patients. They advocate that 
standard courses of antibiotics (between 10-28 days depending on the 
manifestation of Lyme disease) are effective to clear the infection in the vast 
majority of cases but they recognize that some patients continue to 
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experience Lyme symptoms, such as arthritis, after the infection has been 
cleared by standard antibiotic therapy. According to peer-reviewed studies, 
these stubborn symptoms may be due to persisting inflammatory responses, 
by genetically predisposed individuals, to bacterial debris left in the body after 
the infection is cleared as well as joint damage caused by the initial infection. 
One study focusing on patients with antibiotic-refractory late Lyme arthritis 
found that these symptoms may persist for nine years, but the incidence and 
severity of these symptoms do decrease over time and eventually stop. 
During the first year following the first onset of illness, 90% of patients had 
bouts of arthritis, and the number of individuals who continued to have 
recurrences decreased by 10–20% each year119. 
On the contrary ILADS members believe in the existence of chronic Lyme 
disease. They sustain that persistent infection has been demonstrated in a 
mouse model by Hodzic et al, in which the Bb could survive an exposure of 
30 days of ceftriazone and still remain infectious. The microbiology of 
Borrelia needs to be considered when discussing the bacterial survival 
potential. Borrelia can evade the immune system not only by antigenic 
variation, immune suppression and “cloaking”120 in host derived proteins but 
also by residing in intracellular locations, body sites such as brain and eyes. 
By residing in endothelial cells, neurons and glial cells121,122 the bacteria 
would be unaffected by penicillins and cephalosporins and higher doses of 
intracellular antibiotics might be needed. 
 
1.3.7 Clinical Diagnosis 
Diagnosis of the erythema migrans is performed by visual inspection. EM 
presents as a erythemaotous skin lesion that develops at the site of a tick 
bite (Figure 20)111. These lesions can be homogenous in color or have a 
central clearing bull’s eye-like. 
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Figure 20. EM Rash. Example EM rash from the cohort of patients that participated in this 
study (Courtesy of SS).  
 
Lyme diagnosis based on symptomatology is often coupled with serological 
testing. Unfortunately serological detection of antibodies in presence of 
erythema migrans is characterized by a low sensitivity, usually less than 
40%112.  A Lyme disease test can fall into three categories: serum antibody 
tests, antigen tests, PCR for bacterial nucleic acid. 
 
1.3.8 Serological testing 
The discovery of B. burgdorferi as the cause of Lyme disease in 1982 was 
followed by the development of several tests both by clinical and private 
laboratories. Because of the low number of bacteria that enter the 
bloodstream the development of a PCR based test has been particularly 
challenging123,124. For this reason most of the test development entailed the 
indirect detection of the infection by measuring the antibody response of the 
patient. Because the first tests lack of standardization and concordance of 
results, it became very clear that no test was sufficient on its own. In order to 
obtain a better reproducibility and specificity a 2-tiered algorithm was 
developed as shown in Figure 21 (Elitza ST, 2016). 
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Figure 21. CDC guidelines for a serological detection of Lyme Disease. The two-tier approach 
uses a sensitive enzyme immunoassay (EIA) or immunofluorescent assay (IFA) followed by 
a Western immunoblot. Positive or equivocal samples by EIA or IFA should be tested with 
western immunoblot. Specimens negative by a sensitive EIA or IFA don’t need to be tested 
further. When western immunoblot is used during the first 4 weeks of disease onset (early 
LD), both immuno- globulin M (IgM) and immunoglobulin G (IgG) procedures should be 
performed. A positive IgM test result alone is not recommended for use in determining active 
disease in people with illness greater than 1 month's duration because the likelihood of a false-
positive test result for a current infection is high for these people. If a patient with suspected 
early LD has a negative serology, serologic evidence of infection is best obtained by testing 
of paired acute- and convalescent-phase serum samples. (Source: Elitza ST, 2016)  
 
The first tier consist of an enzyme immunoassay EIA or IFA that if results 
positive or equivocal is followed by western blot as the second tier125. The 
first-tier consist of measuring the overall antibody response of a patient (both 
IgM and IgG)126. Even though both EIA and IFA are approved by FDA, EIA 
is usually performed because it can be easily automated and it provides a 
quantitative value which translates in objective cut-off values123. The majority 
of EIAs use a whole-cell sonicate of B. burgdorferi as antigen. Unfortunately, 
because of cross-reactivity with antigen from the host and or other 
pathogens, the specificity is far from being optimal123. New EIA that use fewer 
antigens instead of whole-cell lysate have recently become commercially 
available, one example is the variable-major protein-like sequence 
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expressed (VIsE) lipoprotein and its sixth invariable region, the C6 peptide127.  
In patients within the 4 weeks from suspected infection that result positive for 
EIA, separate IgM and IgG western blot are recommended as a second step 
testing125. The second tier consist in performing a western blot to test the 
patient antibodies against a preselected bacterial antigens. The type of 
western blot performed is dependent upon the time course of the illness. 
Because IgM response appears first and it is generally directed at the most 
immunogenic antigens, IgM along with IgG response is run in patients that 
have been manifesting symptoms for less than 30 days.  If the symptoms 
have been manifesting for more than 4 weeks, IgG western blot alone is 
recommended. IgM WB testing should not be performed or, if performed, the 
result should not be considered, because IgM seroreactivity can remain 
detectable for months to years following disease resolution. According to 
CDC guidelines, a positive IgM western immunoblot result is indicated by the 
scored presence of >2 of 3 bands (21–24, 39, and 41 kDa), and a positive 
IgG result is indicated by the scored presence of >5 of 10 bands (18, 21–24, 
28, 30, 39, 41, 45, 58, 66, and 93 kDa). If initial test is negative but early 
neurologic and cardiac symptoms remain, serologic testing might be 
repeated after 2-4 weeks. Because a 2-step test is time and cost inefficient, 
various improvement have been attempted. One approach consists in the 
use of fewer cross-reactive antigens to develop EIA. For example the use of 
the C6 peptide EIA which uses a highly invariant region of ViSE (variable 
major protein-like sequence expressed), showed higher specificity compared 
to whole cell lysate based EIA127,128.  Still C6 based EIA alone doesn’t reach 
the specificity of the two tier test and for this reason is not recommended in 
most cases except for the detection of Lyme disease in patients that were 
exposed to European tick strains129,130 (Borrelia garinii and Borrelia afzelii). 
Another antigen that shows an increased sensitivity in diagnosing Lyme 
disease is PepC10, an invariant epitope of Outer Surface Protein C131. Other 
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strategies to improve the specificity are currently under development. The 
diagnostic accuracy of serologic assays is dependent on multiple factors 
such as the timing of the specimen collection in respect to the disease state, 
the kinetics of antibody expansion to the particular infectious agent, the 
selection of immunodominant target peptides and the assay methodology. In 
the Early localized stage of Lyme disease normally characterized by the 
presence of EM rash, only 10 to 50% of patients with culture-confirmed early 
LD show a detectable antibody response123,132. Other studies show that 
sensitivity of 2-tiered testing is low (30%–40%) during early infection while 
the antibody response is developing (window period) and sensitivity 
increases to 70% for disseminated Lyme disease. For this reason a serologic 
test performed soon after the tick bite or the detection of the EM rash is not 
recommended because results are often negative. Also the testing after 
treatment can in many case result negative because of the short exposure 
of the humoral immune system to the bacteria. Both ELISA and western 
blotting don’t have an adequate sensitivity. Serological testing alone has 
been found to only be 77% specific when coupled with symptomatic 
analysis133. 
A possible method for diagnosis could entail the screening of ticks found on 
a patient for the presence of B. burgdorferi performing PCR for total B. 
burgdorferi genes (e.g., OspA and Ly1 Chromosomal gene). Nonetheless 
even the presence of a positive tick does not necessarily mean that the 
infection is established in the patient. 
Beyond the low specificity, a serological test has other limitations. Since 
humoral response is long-lasting the treated patients who have resolved the 
infection can remain seropositive for several months or years, and a 
serological test following a previous infection would not be meaningful. Also, 
a serological test has limited utility for monitoring therapy success. In patients 
who are known to be seropositive, another kind of test is necessary to 
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ascertain if persisting Lyme disease or deranged immunological response to 
an original. symptoms are due to the presence of active Lyme disease. 
Likewise an alternative test would be helpful for the diagnosis of patients that 
previously contracted Lyme disease. 
 
1.3.9 Laboratory testing: other approaches 
Attempts to use CSF for intrathecal antibody production against Borrelia or 
detection of bacterial DNA have been performed but resulted in a very poor 
sensitivity134,135. CXCL13 has been proposed as a marker of neurologic Lyme 
disease in CSF but the sensitivity and specificity achieved are still too low to 
use it as a routine test136–138, furthermore to be relevant the CSF should be 
obtained before administering any antibiotics. Testing the intrathecal 
antibody production is particularly important in Europe where multiple 
Borrelia species and high background seroprevalence reduce even further 
the success of a serologic analysis139. However negative results for 
intrathecal antibodies don’t necessarily rule out the possibility of an active 
disease.  
Other approaches aimed at improving sensitivity for the early detection of 
Lyme disease consist in the identification of proteins, nucleic acids and 
metabolites in serum of patients affected with Lyme disease. PCR could be 
used to determine the presence of nucleic acid of B. burgdorferi in different 
biological tissues such as synovial fluid, blood, serum CSF, skin biopsy. 
Synovial fluid PCR reaches a sensitivity of 75% in case of Lyme arthritis123, 
while PCR on CSF samples is much less sensitive, studies show a sensitivity 
of only 38% in patients with early neuroborreliosis and even lower for late 
neuroborreliosis140. Researchers have reported also the possibility to use an 
immune-PCR, which combines the sensitivity of PCR with EIA-based 
antibody detection141. PCR in blood showed very high specificity but very low 
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sensitivity123,142. Because of these issues, PCR has not been standardized 
for Lyme disease, although some clinical laboratory offer PCR testing.  
Another approach to improve the detection of early stage Lyme disease 
involves the identification of diagnostic proteins and metabolites in serum of 
patients with Lyme disease. These proteomic and metabolomics 
approaches, are particularly appealing because they also have the potential 
to identify biomarkers indicative of cure143,144. Bacterial culture are also not 
recommended for clinical purposes considering that B. burgdorferi is a slow-
growing organism and current culturing methods are labor-intensive and 
have poor sensitivity.  
Presence of background seropositivity is a major concern when testing for 
Lyme disease. Seropositivity due to previous exposure can be the result of 
the presence of IgG and IgM in the patient even after several years after the 
infection or due to a false positive result. 
 
1.3.10 Development of a urinary Lyme antigen test 
For the reasons mentioned above there is a strong clinical need to improve 
the specificity of diagnosis for the early stage of Lyme disease, particularly 
in the period preceding the mounting of a serologic response. It would be 
also very important to understand with higher certainty if the first round of 
therapy has been successful or a second round should be required because 
of Borrelia persistence. Ideally the Lyme disease test would utilize a non-
invasive body fluid such as urine or saliva and would have a sufficient 
sensitivity to detect the infection in its early stage (before seroconversion). 
Previous studies investigated the possibility to develop an antigen assay 
tests but failed to reach adequate sensitivity and specificity.  
In order to address these needs we evaluated the presence of Outer surface 
protein A (OspA) from B. burgdorferi in urine, using harvesting hydrogel 
Nanotraps in combination with a highly specific antibody which recognize a 
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very narrow epitope of present in the C-terminal region Osp236-239. This 
particular OspA sequence is conserved among several pathogenic species 
of Borrelia. Moreover this particular epitope does not show sequence 
homology with human proteins or other tick-borne pathogens. 
OspA was shown to have a central role in the early stage of pathogenesis103; 
evidence of antibodies against OspA was found in patients in the early stage 
of the disease. Another study shows the presence of OspA in the urine of 
mice as early as 72 hours after the infection with Borrelia burgdorferi145. 
OspA is produced as Borreliae enters the tick vector and is the major surface 
protein during midgut colonization. OspA mutant bacteria showed a reduced 
survival rate in immunocompetent mice, while in naïve mice it was able to 
proliferate. OspA was in fact suggested to have a critical antibody shielding 
role once the infection of the host occurs. OspA sequence is also conserved 
among different species of Borrelia146,147. Sequencing of different strains 
showed that although some sequence variability is present in the middle 
region, the N-terminus and C-terminus are highly conserved. As shown in 
Figure 22 (Benjamin J. et al., 2002), OspA is a 273 amino acid protein that 
folds in an elongated conformation spanning 80 Å from end to end. OspA 
binds to the surface of the spirochete at the N-terminus via a lipid anchor. 
The structure consists of 21 consecutive antiparallel β-strands followed by a 
short α-helix in the C-terminus and can be divided into two discrete domains: 
a sandwich domain at the N-terminus and a barrel domain at the C-terminus 
connected by a long central b-sheet. The presence of an extended surface 
close to the lipid anchor suggest the presence of a contact point to a different 
protein on or in the B. burgdorferi membrane. The long cleft on the C-
terminus suggests the possible binding with a ligand. 
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Figure 22. 3D structure of OspA. OspA is characterized by and elongated shape, spanning 
80A ° from end to end, consisting of 21 antiparallel b-strands that fold hairpin style into 4 
antiparallel b-sheets plus a single COOH-terminal a-helix. (Source: Benjamin, J., 2002) 
 
1.3.11 Detection of OspA peptides in urine using multi-affinity capturing 
hydrogel Nanotraps 
The focus of this study is to detect OspA peptides containing the C-terminus 
domain in urine of patients affected by Lyme disease. Because of low 
specificity and sensitivity, previous attempts of developing an antigen test 
remain controversial. Previous immunoassays may have employed 
polyclonal antibodies148 raised against Borrelia lysate that may have not been 
directed towards a specific and highly conserved epitope of OspA that lack 
homology with other human or bacterial proteins belonging to different 
spirochetes. PCR and attempts to culture the bacteria from blood failed due 
to the low titer of Borrelia in the host149. Also, it has been suggested that 
Borrelia can be sequestered and persist in joint tissue150. The amount of 
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Borrelia antigen in urine is estimated to be very low and previous studies did 
not address the importance epitope selection in order to overcome low 
sensitivity and specificity issues. In order to overcome the previous 
physiologic and immunologic barriers and achieve high sensitivity and 
specificity, we combined our nanotechnology that capture and concentrate 
low abundance analytes allowing to reach high detection sensitivity with a 
monoclonal antibody highly specific for a narrow epitope in the C-terminus 
region of the OspA. Our Nanotrap particles consist of hydrogel Nanotraps 
containing high affinity chemical baits for the capturing of OspA. Once 
immersed in urine, Nanotraps are able to rapidly capture and concentrate 
virtually all the bacterial antigen present in the solution (Figure 23b, 23c). The 
sequestered OspA can be eluted from the Nanotrap and measured by 
immunoassay or mass spectrometry (Figure 23d).  
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Figure 23. Application of Nanotrap particles to capture, concentrate and preserve OspA in 
urine and increase the sensitivity of immunoassay. A) Nanotrap are functionalized with a baits 
that has high affinity for low abundance and low molecular weight antigens such as OspA. B) 
Nanotrap particles are incubated with urine of patients containing Lyme disease antigens 
(yellow “c”). C) Nanotrap are separate from urine through centrifugation. D Lyme antigens 
captured in the Nanotrap are then eluted into a small volume (0.015 mL). D) Nanotrap pre-
processing increases the sensitivity of any analytical technology by a concentration factor e. 
Assume that the initial volume is  V = 40 mL and the final elution volume is v = 0.015 mL, the 
concentration factor e = V/v = 40/0.015 = 2,667. 
 
The amount of OspA captured is function of the sample volume, the 
concentration factor is dependent on the initial volume of the solution and the 
final volume used to elute the antigen from the Nanotraps. In previous studies 
we proved how our Nanotraps can sequester, preserve and concentrate 
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antigen, enhancing immunoassay sensitivity of several hundred fold without 
increasing the background50. For this study we selected the anti-OspA mAb 
clone 0551, verified the specificity, and assessed the lack of cross-reactivity 
with human and other bacterial species. After assay validation we were able 
to apply our enhanced immunoassay for the detection of OspA in 151 
patients suspected of Lyme disease and 117 healthy controls 
(Supplementary 2).  
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2. AIMS OF THE PROJECT 
 
Discovery and improved measurements of clinically relevant biomarkers is 
crucial for understanding the pathophysiology of several diseases as well as 
for improving their detection and prognosis. Biofluids account to 60% of the 
body mass, and contain a plethora of low abundant biomarkers that often fall 
below the detection limit of mass spectrometry and standard immunoassays. 
Beyond their low concentration, biomarkers are often masked by high 
abundance proteins and are subject to the rapid degradation by exogenous 
and endogenous proteases.  
Nanotraps functionalized with high affinity chemical baits have been 
proposed as a solution for these physiological roadblocks, and in few 
seconds, in solution, are able to capture, concentrate and preserve low 
abundance biomarkers in complex biological fluids. Nanotraps have been 
successfully employed by our group for the processing of different biofluids.  
 
2.1 Aim 1. Synthesis, characterization and performance evaluation of 
Nanotraps 
The first aim of this thesis consists in the synthesis and characterization of 
Nanotraps and their functionalization with novel classes of dyes that have 
never been employed for protein chemistry. Nanotraps are agnostic to the 
downstream assay and require an elution step that helps release the protein 
cargo for further analysis. The synthesis of hydrogel Nanotraps using a 
degradable cross-linker may display the antigen to an antibody directly 
without the need of an elution step. For these reason we incorporated during 
Nanotrap synthesis several cross-linking reagents that could undergo 
degradation following certain chemical conditions. 
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2.2 Aim 2. Development of a Nanotrap-based urinary antigen test for 
Lyme disease 
Lyme disease is a tick-borne disease of endemic proportions in several areas 
of the United States and Europe. Serological tests for Lyme disease lack 
sensititvity and specificity particularly in the early stage of the disease. Also, 
attemps to create an antigen test for Lyme disease failed in the past because 
of the low concentrations of Borrelia biomarkers in body fluids. For this 
reason the second aim of the thesis consists in the application of harvesting 
Nanotraps for the development of a novel highly sensitive, precise, and 
specific urinary antigen test for Lyme disease. Differently engineered 
Nanotraps, different immunoassay formats, as well as mass-spectrometry 
are used to detect OspA, a clinically relevant protein that is highly expressed 
during the early stage of the infection. Experiments are first performed in 
model solution consisting of urine of healthy volunteers spiked with OspA. In 
parallel, clinical urine samples of patients suspected of different stages of 
Lyme disease were collected in several clinical practices in Virginia and sent 
to George Mason University for Nanotrap processing. Clinical samples are 
processed and results of serological testing, treatment modalities and 
outcome are correlated with the presence of OspA detected in urine.  
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3. MATERIALS AND METHODS 
 
3.1 NANOTRAP SYNTHESIS AND DYE COUPLING 
 
Hydrogel Nanotraps, poly(N-isopropylacrylamide-co-acrylic acid) and 
poly(NIPAm-co-AA), are synthesized by precipitation polymerization151. 
(poly(NIPAmco-AAc)) are covalently functionalized with amino-containing 
dyes using amidation chemistry, while amine-containing hydrogel Nanotraps, 
poly(NIPAm-co-AA), are covalently functionalized by nucleophilic 
substitution of the amine groups in the Nanotraps and the leaving group od 
the dye. An outer shell containing vinylsulfonic acid (VSA) copolymer can 
also be synthesized on the dye-functionalized particles by a second 
polymerization reaction. 
 
3.1.1 Synthesis of poly(N-isopropylacrylamide-co-acrylic acid) 
4.750 g of N-isopropylacrylamide (NIPAm) and 0.400 g of N, N′-
methylenebisacrylamide (BIS) were dissolved in 500 mL of MilliQ water and 
filtered under vacuum into a three neck round bottom flask. 0.525 g of Acrylic 
Acid (AAc) were added, and the solution was purged with nitrogen for 30 min 
under medium stirring and then heated up to 70 °C. 0.276 g of Potassium 
Persulfate (Sigma Aldrich) was dissolved in 5 mL of H2O and added to the 
reaction in order to initiate the polymerization. The reaction was kept for 6 h 
at 70 °C. Particles were washed 5 times by centrifugation (19,000 rcf, 50 min, 
room temperature) with MilliQ H2O in order to eliminate unreacted monomer. 
Particles were resuspended in a total volume of 600 mL of water.  
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3.1.2 Dye coupling of AAc Nanotraps 
Particles functionalization is performed by condensation of the primary amine 
contained in the dye to the carboxylic group of the AAc present in the 
Nanotraps. The reaction can be conducted in a water-based solvent for the 
following dyes: Acid Blue 22 (AB2, Sigma), Remazol Brilliant Blue R (RBB, 
Sigma), Acid Black 1 (AB1, Sigma), Brilliant Blue R250 (BB, Fisher), 
Toluidine Blue O (TBO, J.T. Baker), Rhodamine 123 (R12, Sigma), Disperse 
Yellow 3 (DY3, Fluka), and Disperse Blue 3 (DB3, Sigma). The protocol is 
the same for the incorporation of each dye, although the amount of dye used 
should be adjusted to maintain the molarity. Briefly, 40 mL of particles were 
centrifuged and the pellet was re-suspendend in 40 mL of 0.2M NaH2PO4 pH 
5. The particles were transferred into a round bottom flask and 2 mL of 1% 
sodium dodecyl sulfate (SDS, Sigma) 1648 mg of N-(3 Dimethylaminopropyl) 
N′ ethyl carbodiimide hydrochloride (EDC; Fluka Analytical) and 1224 mg of 
solid N-Hydroxysuccinimide (NHS; Sigma-ALBrich) were added. The 
reaction was kept for 15 minutes at room temperature under medium stirring, 
then the particles were centrifuged, and the pellet resuspended in 0.2 M 
Na2HPO4 pH 8. In parallel, 2 g of Remazol Brilliant Blue were dissolved in 
100 mL of Na2HPO4 pH 8 and filtered twice with 0.2 µm nitrocellulose 
membrane disk filter (Millipore). Particles were then transferred to the dye 
containing solution and the reaction was held overnight at room temperature 
under medium stirring rate. The Nanotrap particles were washed by 
centrifugation (19,000 rcf, 50 minutes, room temperature) 6 times in order to 
eliminate the unreacted dye and then resuspended in a final volume of 40 
mL with MilliQ H2O. 
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3.1.3 Synthesis of poly(N-isopropylacrylamide-co-allylammine)  
9g of N-isopropylacrylamide (NIPAm) and 0.400g of N,N′-
methylenebisacrylamide (BIS) were dissolved in 250 mL of MilliQ water and 
filtered under vacuum into a three neck round bottom flask. The filter was 
then washed with an additional 100 ml of Milli-Q water and collected in the 
same flask. The solution was purged with nitrogen for 30 min under medium 
stirring. 676 µl of Allylammine were added, and the solution was purged for 
another 15 min under medium stirring and then heated up to 70 °C. 0.100 g 
of Potassium Persulfate (Sigma Aldrich) was dissolved in 5 mL of H2O and 
added to the reaction in order to initiate the polymerization. The reaction was 
kept for 6 h at 70 °C. Particles were washed 5 times by centrifugation (19,000 
rcf, 50 min, room temperature) with MilliQ H2O in order to eliminate unreacted 
monomer. Particles were resuspendend in a total volume of 300 mL of water.  
 
3.1.4 Dye Coupling of AA Nanotraps 
In order to incorporate the dye Cibacron Blue F3GA (CB) dye, CB (0.76 g, 
0.90 mmol) was dissolved in 10 mL of 0.1 M aqueous sodium carbonate. The 
poly(NIPAm-co-AA) particle suspension (10 mL volume) was purged with 
nitrogen for 15 min with a medium stirring rate in a three-neck round-bottom 
flask. Solid sodium carbonate (0.106 g, 1.0 mmol) was added to the 
suspension. The suspension was then stirred at room temperature under 
nitrogen for about 1 min. The CB solution was then added to the poly(NIPAm-
co-AA) particle suspension, and the combined reaction mixture was then 
stirred at room temperature under nitrogen for 48 h. The resulting 
poly(NIPAm/CB) particles were harvested and washed using centrifugation 
(19,000 rpm, 50 min, 25 C).  
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3.1.5 Synthesis of DHEA hydrogel Nanotraps 
N-Isopropylacrylamide(NIPAm,210mg), 
N,N’Methylenbisacrylamide(BIS,32.7mg),1,2-Dihydroxyethylenebis-
acrylamide(DHEA,42.4mg), and Allylamine (AA,158μl) were dissolved in 
65mL of water and filtered into a three-neck round  bottom flask using a 
nitrocellulose membrane disk  filter. The system was purged with nitrogen for 
1 hour at room temperature and medium stirring rate and then heated to 70°C 
before potassium persulfate (KPS,46mg) was added. The system was held 
at 70°C under nitrogen for 4 hours. The Nanotraps were washed five times 
by centrifugation (19000 rpm, 50 min, 25°C).  Remazol Brilliant Blue R Dye 
(3.5g) and Na2CO3 (371mg) were dissolved in 28mL of water and filtered 
twice. The dye solution and 35mL of poly(NIPAm-co-AA) particles were 
transferred to a three-neck round bottom flask and held overnight at room 
temperature and medium stirring rate. 
 
3.1.6 Synthesis of bis(acryloyl)cystamine (BAC) hydrogel Nanotraps 
Synthesis was performed as follows: N-Isopropylacrylamide 
(NIPAm,210mg), N,N’Methylenbisacrylamide(BIS,32.7mg),1,2- 
bis(acryloyl)cystamine  (BAC,42.4mg), and Allylamine (AA,336μl) were 
dissolved in 100mL of water and filtered into  a three-neck round  bottom 
flask using a nitrocellulose  membrane  disk  filter. The system was purged 
with nitrogen for 30 minutes at room temperature and medium stirring rate 
and then heated to 50°C before potassium persulfate (TEMED,1mM) was 
added. The system was held at 50°C under nitrogen for 4 hours. Nanotraps 
were the washed five times to eliminate the unreacted reagents. After the 
particles were washed, B-mercaptoethanol was added 1:1 to the Nanotraps. 
An incubation of 30 minutes is sufficient to degrade BAC changing the 
physical properties of the Nanotraps. 
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3.1.7 Synthesis of pyrazolone Nanotraps 
N-Isopropylacrylamide (NIPAm, Sigma-Aldrich, 4.5 g), was dissolved in 105 
mL of H2O, filtered using a nitrocellulose membrane disk filter (0.45 μm pore 
size, Millipore), and transferred in a three-neck round-bottom flask. The 
solution was purged with nitrogen for 30 min at room temperature, at medium 
stirring rate, and then heated to 70°C. In parallel pyrazolone dye (0.305g) 
was added to 20 ml of Milliq H20 and 136ul of allylammine was added to the 
solution and purged under nitrogen for 10 minutes. Potassium persulfate 
(KPS, Sigma-Aldrich, 138mg) was dissolved in 2.5 mL of H2O and was 
added to the solution to initiate the polymerization. At the same time 
pyrazolone solution was added to the reaction. The reaction was allowed to 
continue for 6 hours. Particles were washed five times by centrifugation 
(19,000 rpm, 50 min, 25 C) to eliminate the unreacted reagents. 
 
3.1.8 Syntesis of Fast Blue B Nanotraps 
N-Isopropylacrylamide (NIPAm, Sigma-Aldrich, 2.375 g), and 
N,N’Methylenbisacrylamide (BIS, 0.1g) were dissolved in 150 mL of H2O, 
filtered using a nitrocellulose membrane disk filter (0.45 μm pore size, 
Millipore), and transferred in a 500ml three-neck round-bottom flask. The 
solution was purged with nitrogen for 30 min at room temperature, at medium 
stirring rate. In parallel fast blue B (0.308g) was dissolved in 400ml of water 
and the solution was purged for 30 min. Acrylic acid (88ul) was added to the 
solution and stirred for other 15 min. The solution containing NIPAm and BIS 
was added using a 60ml syringe to the dye soliutuion and purged for 5 
minutes under nitrogen. Acrylic acid was added (262ul) and the solution was 
allowed to purge for other 10 minutes. The reaction was then brought to 70C. 
Potassium persulfate (KPS, Sigma-Aldrich, 138mg) was dissolved in 2.5 mL 
of H2O and was added to the solution to initiate the polymerization. The 
81 
 
reaction was hold under medium stirring for 6 hours. Particles were washed 
five times by centrifugation (19,000 rpm, 50 min, 25 C) to eliminate the 
unreacted reagents. 
 
3.1.9 Nanotrap characterization 
The temperature dependence of particle size was determined via photon 
correlation spectroscopy (Submicrometer Particle Size Analyzer, Beckman 
Coulter). The measurement of particle diameter was performed using water 
as a diluent (refractive index (RI) = 1.333, diluent viscosity = 0.890 cP). The 
test angle was 90°. Average values were calculated for three measurements 
using a 200 s integration time, and the solutions were allowed to thermally 
equilibrate for 10 min before each set of measurements. Measured values 
were then converted to particle sizes via the Stokes–Einstein relationship152. 
Further characterization of the Nanotraps was performed through atomic 
force microscopy (AFM) using an NSCRIPTOR™ DPN® System (NanoInk). 
Particles solution (1 μg/ml) was deposited on freshly cleaved mica under 
humid atmosphere for 15 minutes and dried under nitrogen before 
measurement. Images were acquired under AC mode using a silicon tip with 
a typical resonance frequency of 300 kHz and a radius smaller than 10 nm. 
Incorporation of dye in the particles was assessed by weighing the dry 
particles before and after dye coupling (supplementary data). 
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3.2 DEVELOPMENT OF A NANOTRAP-BASED LYME DISEASE 
TEST 
   
3.2.1 Ethics statement 
Urine samples were collected under informed consent from patients 
suspected of having Lyme disease at any stage from four different 
community physician practices in Northern Virginia, a high risk geographic 
region for LB. This study met the requirements for IRB approval 
(Pro00008518, Chesapeake IRB). Matched coded clinical records and LB 
serology results were also provided under patient consent. Immunoassay 
testing for urinary OspA utilized Nanotrap particle pre-processing and 
western blotting to evaluate the OspA analyte molecular size, and OspA 
peptide competition was applied to fully confirm a positive test. 
 
3.2.2 Study design and human sample collection 
Subjects with all stages of documented or suspected Lyme disease were 
considered eligible for the study. Mid-stream urine specimens were self-
collected by 268 participants Urine samples were stored at the collection 
sites (Care-ID, VA; Frekko Primary Care, MD; Internal medicine of Northern 
Virginia, VA; Novant Health Virginia Internal Medicine & Primary Care, VA) 
at - 20oC. Samples were frozen within two hours of collection.  Sample were 
then transferred to George Mason University and stored at -80oC.  Whole 
blood from each subject was drawn on the same day as urine collection. 
Each participant donated blood only once. The blood drawing procedure was 
performed at the physician’s office by a registered nurse. Six mL of whole 
blood was drawn into a red top tube. Blood samples were sent to Quest 
Diagnostics for Total Lyme Disease Antibody (EIA) and Lyme IgG and IgM 
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Western Blot tests. Results of serological testing were recorded as well as 
treatment modalities and outcome, and used to correlate serology outcome 
with the presence of OspA detected in urine (Figure 24). Age matched, non-
symptomatic patients with no history of Lyme disease as well as patients 
being evaluated for other non-Lyme infectious diseases were included in the 
control group. In addition, the study set contains Lyme borreliosis patients 
before and after antibiotic treatment. 
 
 
Figure 24. Clinical study design. 
 
3.2.3 Mass spectrometry analysis of B. burgdorferi lysate 
Mass spectrometry analysis was performed using Borrelia burgdorferi Lyme, 
Grade 2 Antigen (ARP American Research Products. 5µg of Lyme antigen 
were reduced through incubation with a 10mM dithiothreitol in 8M urea for 
30 minutes and alkylated with 50mM iodacetamide at room temperature in 
the dark for 20 minutes. The enzymatic digestion ran overnight with 0.5µg 
sequencing grade trypsin (Promega) in 50mM ammonium bicarbonate pH 8 
at 37°C. Digestion was then stopped by adding 5µl of glacial acetic acid. 
Digested samples were then desalted with C-18 Zip Tips (Millipore). Final 
eluates from Zip Tips were then dried with a nitrogen evaporator. Samples 
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were reconstituted in 6 µl of 0.1% Formic Acid and analyzed with a Thermo 
LTQ Orbitrab Mass spectrometer. After sample injection by autosampler, the 
C18 column (0.2 mm × 50 mm, NanoLCMS Solutions) was washed for 2 min 
with mobile phase A (0.1% formic acid), and peptides were eluted using a 
linear gradient of 0% mobile phase B (0.1% formic acid, 80% acetonitrile) to 
50% mobile phase B in 90 min at 500 nL/min, then to 100% mobile phase B 
for an additional 5 min. The LTQ mass spectrometer was operated in a data-
dependent mode in which each full MS scan was followed by five MS/MS 
scans where the five most abundant molecular ions were dynamically 
selected for collision induced dissociation (CID) using a normalized collision 
energy of 35%. Tandem mass spectra were searched against the NCBI 
Borrelia burgdorferi database with SEQUEST software using tryptic cleavage 
constraints. High-confidence peptide identifications were obtained by 
applying the following filter criteria to the search results: Xcorr versus charge 
1.9, 2.2, 3.5 for 1+, 2+, 3+ ions; ΔCn > 0.1; probability of randomized 
identification e0.01. 
 
3.2.4 Epitope mapping of the anti-OspA Monoclonal Antibody  
In order to identify the epitope of the anti-OspA mAb, partial enzymatic 
digestion, western blotting and mass spectrometry analysis were performed 
using Borrelia burgdorferi Lyme, Grade 2 Antigen (ARP American Research 
Products) and anti-OspA mAb clone 0551 (Santa Cruz). Bb (Lyme), Grade 2 
Antigen was derived from Bb Strain B31 cultured in BSK II Medium. 
Microorganisms were harvested from growth medium and washed in PBS 
using low speed centrifugation. The pellet was resuspended in PBS and 
gently sonicated. The antigen preparation was evaluated by gel 
electrophoresis followed by silver staining and in gel trypsin digestion 
followed by mass spectrometry. In this study, partial enzymatic digestion was 
carried out as follows: 80 μL of Bb Lyme antigen Grade 2 (0.2 µg/ml) was 
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acidified with 80 μL of 10 mM HCl (Fisher Scientific). 10 μL of 4 mg/mL pepsin 
solution (Sigma) was added to the sample and incubated for 1 hour at RT. 
After the incubation, the sample was immediately purified with ZipTip 
(Millipore) according to manufacturer instructions and dried with Nitrogen 
evaporator. The dried pepsinized sample was resuspended in 22.5 µL of 
water by repeated pipetting. An aliquot of 2.5 µL was subjected to western 
blot analysis with the anti OspA mAb used above in order to determine the 
smallest OspA pepsin fragment that retains antigenicity toward the antibody. 
The remaining amount of pepsinized Lyme antigen (20 µL) was subjected to 
SDS PAGE fractionation and silver staining. Bands on the low molecular 
weight region of the gel that mirrored the signal on the western blot were cut 
using a razor blade and subjected to in gel digestion. Samples were reduced 
with 500 µL of 10 mM dithiothreitol (DTT, Fisher Scientific) in 50 mM 
ammonium bicarbonate (Fluka) and then alkylated with 500 µL of 50mM 
iodoacetamide (Acros Organic) in 50 mM ammonium bicarbonate at room 
temperature in the dark for 20 minutes. Overnight enzymatic digestion was 
carried out with 0.5 µg sequencing grade trypsin (Promega) dissolved in 60 
µL of 50 mM ammonium bicarbonate pH 8 at 37°C. Solutions were separated 
from the gel pieces and saved in clean Eppendorf tubes. Aliquots of 60 µL of 
extraction buffer (50% acetonitrile, 2% acetic acid (Acros Organic)) were 
added to the gel pieces and incubated at room temperature for 15 minutes. 
Solutions were separated from the gel pieces and combined with the 
previous ones. Samples were then dried using a nitrogen evaporator. 
Samples were reconstituted in 6 µl of 0.1%. Mass-Spectrometry was 
performed with Thermo LTQ Orbitrab Mass spectrometer as described in the 
previous paragraph. 
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3.2.5 Urine sample handling prior to analysis 
All urine used in this study was processed as follows. Urine samples were 
thawed in a water bath at room temperature. Urinalysis was performed on 
urine samples using Siemens Multistix 10SG. Specific gravity was measured 
with digital refractometer (Atago). Urine samples were then centrifuged at 
3,700 rcf for 10 minutes at 25 °C to remove cellular debris. Supernatant was 
transferred in a new tube. Urine pH was measured and adjusted to 5.5 with 
1M HCl when necessary.  
 
3.2.6 Nanotrap particle performance assessment with model solutions 
Bb Lyme antigen Grade 2 (American Research Products) spiked in human 
urine was used as model solution to test Nanotrap particle performance. 
OspA Lyme antigen (1.2 ng) was spiked in 40 mL of human urine collected 
from healthy volunteers and processed as described above and incubated 
with 1:10 Nanotrap particle suspension (5 mg/mL dry weight concentration) 
/ urine solution volume. After 30 minutes incubation, Nanotrap particles were 
separated by centrifugation (16.1 rcf, 10 minutes, 25 °C).  Two washes were 
performed by re-suspending the Nanotrap particles in 1mL of MilliQ H2O and 
centrifuged at 16.1 rcf for 10 minutes at 25 °C. Nanotrap particles were 
incubated with 600 µL of elution buffer (70% acetonitrile (Fisher Scientific), 
10% ammonium hydroxide (Sigma)) for 30 minutes at 25 °C. Samples were 
then centrifuged at 16,100 rcf for 15 minutes at 25 °C; the eluates were 
transferred to new tubes and 50 µL of a 50 mg/mL D-(+)-Trehalose dihydrate 
(Sigma) water solution was added. Eluates were then dried under nitrogen 
flow (Microvap 118, Organomation Associates, Inc) and analyzed by western 
blot. Alternatively 2X Sample Buffer Solution (475 µl 2X Laemli Sample 
Buffer, 25 µl TCEP) in lieu of acetonitrile-ammonium hydroxide elution buffer. 
Nanotrap pellet is vigorously resuspend particle pellet in 30 µl 2X sample 
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buffer solution and heated at 100°C for 10 minutes. Nanotrap are centrifuged, 
supernatant is recovered and analyzed by western blot. 
 
 
3.3 NANOTRAP-ENHANCED WESTERN BLOT FOR DETECTION 
OF URINARY OSPA 
 
3.3.1 Patient urine processing with Nanotrap particles for Western Blot 
In order to analyze patient urine samples, urine samples (40 mL) were 
transferred in Nalgene™ Oak Ridge High-Speed Polycarbonate Centrifuge 
Tubes and incubated with 4 mL of Nanotrap particles (5 mg/mL) for 30 min 
on a rocker at room temperature. Samples were then centrifuged at 19,000 
rcf for 30 minutes at 25 °C. Two washes were performed by re-suspending 
the Nanotraps in 2 mL of MilliQ H2O and centrifuging at 16,100 rcf for 15 
minutes at 25 °C. Nanotrap particles were incubated with 600 µL of elution 
buffer (70% acetonitrile, 10% ammonium hydroxide) for 30 minutes at room 
temperature. Samples were then centrifuged at 16,100 rcf for 15 minutes at 
25 °C; the eluate was transferred to new tubes and 50 µL of D-(+)-Trehalose 
dihydrate solution (50 mg/mL in water) were added. Eluates were then dried 
under nitrogen flow and analyzed with western blot. 
 
3.3.2 OspA detection with western blot  
Dried particle eluates were resuspended in 15 µL of MilliQ water by repeated 
pipetting. 5 µL of 4X sample buffer: 50 mM Tris HCl (Biorad) pH 6.8, 2% 
SDS, 144 mM 2-mercaptoethanol (Fisher Scientific), 10% glycerol (Sigma) 
and 0.01% bromophenol blue (Fisher Scientific) was added and samples 
were heated at 100°C for 10 minutes. Samples were loaded on 4-20% Tris-
Glycine gel (Invitrogen Corporation) and separated by SDS-PAGE gel 
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electrophoresis. Gel was run in Tris-Glycine SDS running buffer using Novex 
X-Cell IITM Mini-Cell (Invitrogen Corporation) at 120 V for 90 minutes. 
Proteins were transferred onto a PVDF membrane (Millipore), blocked with 
a solution of 0.2% I-Block (Applied Biosciences) and 0.1% Tween 20 (Fisher) 
in PBS (Life Technologies). The membrane was incubated overnight with a 
mouse anti-OspA mAb (Santa Cruz, sc-58093, Clone ID 0551). This mouse 
mAb was purified from ascites fluid by protein A chromatography. The final 
preparation was formulated to a protein concentration of 100 μg/ml in 0.01 M 
phosphate buffered saline, pH 7.2 and contained 0.1% sodium azide. The 
mAb was used at a 1:100 dilution in PBS supplemented with I-Block and 
Tween 20.  After mAb incubation, the membrane was washed three times for 
10 minutes with 0.2% I-Block, 0.1% Tween 20 in PBS. The membrane was 
incubated with a peroxidase conjugated goat anti-mouse IgG adsorbed 
against bovine, equine and human serum proteins (Life Technologies,  
#A16090) diluted 1:5,000 in 0.2% I-Block, 0.1% Tween 20 in PBS. Three 
washes of 10 minutes in 0.2% I-Block, 0.1% Tween 20 in PBS were 
performed. Proteins were detected with an enhanced chemiluminescence 
system (West Dura, Thermo Fischer Scientific) on a Kodak MM4000 Imager.  
 
3.3.3 OspA dot blot analysis  
Proteins and peptides (2 µL) were spotted with a capillary tube on a PVDF 
membrane previously wetted in methanol. The membrane was blocked with 
a solution of 0.2% I-Block and 0.1% Tween 20 in PBS. The membrane was 
incubated overnight with anti-OspA mAb clone 0551 diluted 1:100 in 0.2% I-
Block, 0.1% Tween 20 in PBS (4 °C) and then washed three times for 10 
minutes with 0.2% I-Block, 0.1% Tween 20 in PBS. The membrane was 
incubated with a peroxidase conjugated goat anti-mouse IgG adsorbed 
against bovine, equine and human serum proteins diluted 1:5,000 in 0.2% I-
Block, 0.1% Tween 20 in PBS. Three washes of 10 minutes in 0.2% I-Block, 
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0.1% Tween 20 in PBS were performed. Proteins were detected with an 
enhanced chemiluminescence system (West Dura, Thermo Fischer 
Scientific) on a Kodak MM4000 Imager. 
 
3.3.4 In solution competition assay and solid phase immunodepletion 
In order to verify the specificity of band reactivity of the anti-OspA mAb clone 
0551, a competition assay was developed. Prior to staining, the mAb was 
neutralized by incubation with a solution containing excess OspA or synthetic 
peptides containing partial OspA sequences. The mAb that was bound to the 
neutralizing protein or peptide was no longer available to bind to the epitope 
transferred on the western blot membrane. The blocked mAb and the mAb 
alone were used to probe duplicate western blots. All other parameters of the 
western blotting remained the same. The comparison of neutralized mAb to 
mAb alone showed which staining was specific: the specific staining was 
absent from the western blot membrane probed with the neutralized mAb. 
More in detail, 100 µL of anti-OspA antibody (0.1 mg/mL) was added to 900 
µL of 0.2% I-Block, 0.1% Tween 20 in PBS and incubated overnight with 400 
µL (0.1 mg/mL) of a custom made recombinant OspA (Genecopoeia). In 
parallel, Bb Lyme antigen Grade 2 (0.5 ng) was separated by 1-D gel 
electrophoresis and then transferred onto Immobilon PVDF membranes as 
previously described. OspA-saturated and un-modified antibodies were used 
to probe the PVDF membranes. Competition assays were also performed 
neutralizing the anti OspA mAb with Bb Lyme antigen Grade 2 (37 μg), 80 
kDa OspA chimera recombinant protein (12 μg, Genway), and peptide 
fragments mimicking the antibody epitope (60 μg, Supplementary Table 3, 
Peptide 2.0).  
The peptide OspA219-235 (Peptide 2.0) was utilized for solid phase affinity 
depletion of the mAb clone 0551. The peptide (300 μg) was deposited on 
ELISA plate wells. The wells were washed with PBS supplemented with 0.1% 
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Tween 20 and the excess peptide removed. The wells were then blocked 
with PBS supplemented with 0.2% I-Block, 0.1% Tween 20. The mAb clone 
0551 (3 μg) was incubated with the solid phase adsorbed peptides overnight 
at 4 °C under rotation. After incubation, the supernatant was recovered and 
brought to a volume of 3 mL in PBS supplemented with 0.2% I-Block and 
0.1% Tween 20. In parallel, 600 pg of Bb Lyme antigen Grade 2 were spiked 
in urine and processed through the Nanotrap particles. The immunodepleted 
mAb and the mAb alone were used side by side to stain membranes 
containing the Nanotrap particle eluates.  
 
3.3.5 Reproducibility and sensitivity of the urinary OspA Lyme assay  
In order to assess intra-assay reproducibility of the urinary OspA Lyme 
assay, nine experimental replicates were performed in one day as follows. 
Bb Lyme antigen Grade 2 (1.2 ng) was spiked in 40 mL of urine collected 
from healthy volunteers and incubated with 4 mL of Nanotrap particle 
suspension (5 mg/mL). Samples were processed as described above and 
the Nanotrap particle eluates were analyzed by western blot using anti-OspA 
mAb clone 0551. 
In order to determine the lower limit of detection and the lower limit of 
quantitation of the urinary OspA assay, different quantities of Lyme antigen 
(1.2, 0.6, 0.3, 0.15, 0.075, 0.038, 0.019, and 0.009 ng) were spiked in 40 mL 
of human urine. Aliquots of 4 mL of Nanotrap particle suspension (5 mg/mL) 
were mixed with the urine samples and processed as described above. 
Nanotrap particle eluates were analyzed by Western blot. The experiment 
was repeated three times in three different days. Multiple batches of 
Nanotrap particles were used in this study. Batch validation and batch to 
batch reproducibility experiments were performed following the same 
protocol described above.  
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3.3.6 Interfering substances and cross-reactivity with relevant non Bb 
infections 
In order to exclude possible cross-reactivity of the mAb clone 0551 with 
interfering substances, a series of Nanotrap experiments were performed 
and analyzed using western blotting. Increasing amount of the following 
antigens were spiked in 40 mL of human urine in presence or absence of 
OspA Lyme antigen: bovine serum albumin, human healthy volunteer whole 
blood, Bartonella henselae lysate (ATCC 49793), Babesia microti (ATCC 
PRA-399), Epstein-Barr virus (EBV) Inactivated P3HR1 Cell Extract 
(Advanced Biotechnologies Inc.; 10-501-001), Herpes Simplex virus-1 (HSV-
1) Inactivated Vero Cell Extract (Advanced Biotechnologies Inc; 10-515-
001), Cytomegalovirus (CMV) HEK293 Cell Lysate (Sino Biological Inc.; 
10202-VCCH1L), Hepatitis C Virus HEK293 Cell Lysate (Sino Biological Inc.; 
10202-VCCH1L). These samples were processed following the protocol 
described above.  
 
3.3.7 Data analysis 
Statistical Chi squared test for equality of proportions was applied in order to 
correlate urinary OspA outcome (detectable or non-detectable) to clinical LB 
diagnosis and serology. Power calculations were performed in order to 
estimate the power of the test, given the number of samples in each group, 
the proportions of urinary OspA outcome, and a significance level of 0.05. 
Calculations were performed using R software (www.r-project.com). 
Western blotting band intensity was quantified with ImageJ software 
(http://imagej.nih.gov/ij/index.html) by selecting the area of interest and 
calculating area, mean and standard deviation of selection per software 
instructions. Blast analysis and protein alignment was performed using 
pBLAST [31]. Search parameters were as follows: query sequence: 
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KTSTLTISVNSKKTTQLVFTKQDTITVQKYDSAGT, Database Name: non 
redundant, Program: BLASTP 2.2.31+.  
 
 
3.4 NANOTRAP ENHANCED ELISA FOR THE DETECTION OF 
URINARY OSPA 
 
3.4.1 Nanotrap processing of urine samples for ELISA  
Urinalysis was performed on the urine sample and pH was adjusted to 5.5. 
Urine samples (40 mL) were transferred in Nalgene™ Oak Ridge High-
Speed Polycarbonate Centrifuge Tubes and incubated with 200 µL of 
Nanotrap® particles (5 mg/mL) for 30 min at room temperature. Samples 
were then centrifuged at 19,000 rcf for 30 min at 25 °C. One wash was 
performed by re-suspending the Nanotraps in 1 mL of MilliQ H2O and 
centrifuging at 16,100 rcf for 15 min at 25 °C. Nanotrap® particles were 
incubated with 100 μL of elution buffer (Octylthioglucoside 2%+0.5% n-
Dodecyl β-D-maltoside in PBS) for 20 min at room temperature. Samples 
were then centrifuged at 16,100 rcf for 15 min at 25 °C; the eluate was saved 
at -80°C overnight. 
 
3.4.2 Elution Buffers 
Performance of different elution buffers at different concentrations were 
tested in 40 ml of urine spiked with Lyme antigen following the protocol listed 
above. 
Elution buffers evaluated were: 
• n-Octyl-β-D-thioglucopyranoside (OTG) at 2%, 5%, and 10% in PBS 
• Sodium Lauroyl Sarcosinate (Sarkosyl) at 2% in PBS 
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• Sodium Lauryl Sulfate (SLS) 2% in PBS 
• Dithionite at 0.1M, 1%, 0.5%, 0.1%, and 0.01% in water 
• N-octyl-β-D-glucoside (OBG) at 5%, 2%, 1%, and 0.5% in PBS 
• Chaps at 5%, 2%, 1% in PBS 
• 15% Methanol in water 
• 30% Isopropanol in water 
• 0.1M Ammonium Carbonate 
• 0.1M Ammonium Acetate 
• 0.1M Dithiothreitol (DTT) 
• 0.5M Imidazole 
• Tissue Protein Extraction Reagent (T-PER) 
 
3.4.3 HRP-labelling of Anti-OspA monoclonal antibody 
100 µl of monoclonal antibody Virostat 0551 (1mg/ml) were HRP-labelled 
using the Lightning-link HRP conjugation kit (Innova Biosciences Cat#701-
0000). 10µl of LL-modifier reagent were added to 100µl of the antibody and 
mixed gently. The antibody sample (with added LL-modifier) was pipetted 
directly onto the lyophilized material and resuspended gently by withdrawing 
and redispensing the liquid once or twice using a pipette. The vial was left in 
incubation for 3 hours at room temperature (20-25⁰C). After incubating for 3 
hours, add 10µl of LL quencher were added to the solution and the 
conjugated antibody was stored at 4°C. 
 
3.4.4 OspA detection with ELISA 
200µL of Virostat capture antibody 1:100 in PBS was deposited on the ELISA 
plate and incubated at 37oC for 30 minutes. The plate was washed for 5X 
with 300µl of wash buffer (PBS, 0.05% tween). 200µl of I-Block was pipetted 
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into each well and incubated at room temperature for 1.5 hours. The plate 
was washed 5X with 300µl of wash buffer. Lyme antigen was diluted to 
prepare control samples. Standards, controls, and samples were pipetted 
into the appropriate wells and incubated at room temperature for 2 hours. 
Detection antibody (Thermo Scientific, PA173006) was diluted 1:200 in I-
Block and the plate was washed 5X with 300µl of wash buffer. 200µl of 
detection antibody was pipetted into each well and incubate at room 
temperature for 1.5 hours. Plate was washed 7X with 300µl of wash buffer. 
100µl of TMB substrate was pipetted into each well and incubate in the dark 
at room temperature for 12-16 minutes. 50µl of stop buffer was pipetted into 
each well and absorbance was read at 450nm with on the plate reader. 
Other detection antibodies were evaluated: abcam, ab156277; abcam, 
ab20757; thermo Scientific. PA1-27289.  
 
3.4.5 Reproducibility and sensitivity of ELISA 
40 ml urine in duplicate were spiked with Lyme antigen in three different 
concentrations (5, 1, 0.5, 0 pg/ml). Elution was performed with OTG 2%. A 
dilution curve of the Bb antigen was produced in parallel spiking 2ng/ml, 
0.4ng/ml, 0.2ng/ml in OTG 2%. Linearity was observed in the spike-ins 
samples with and without Nanotrap processing. To test the reproducibility of 
the urinary OspA Lyme ELISA assay, two experimental replicates of urine 
samples spiked with Lyme antigen in four different concentrations (2.5, 1.25, 
0.62, 0 pg/ml) were processed in different days by two different operators. 
Samples were processed as described above and the Nanotrap particle 
eluates were analyzed by ELISA. In order to determine the lower limit of 
detection and the lower limit of quantitation, different concentration of urine 
controls spiked with Lyme antigen (0-500 pg/ml) and loaded on the ELISA 
plate. In parallel, different amount of Lyme antigen (0-2.5 pg/ml) were spiked 
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in human urine and processed through Nanotraps and measured with the 
ELISA.  
 
 
3.5 NANOTRAP-ENHANCED LFA FOR THE DETECTION OF 
URINARY OSPA 
 
3.5.1 Testing antigen-displaying Nanotraps with dot blot 
Remazol functionalized Nanotraps (100 μL) were added to 1 mL urine spiked 
with OspA (10 ng/mL) and incubated for 30 minutes. Samples were 
centrifuged and washed twice. DHEA oxidation was performed adding 100 
μL of solution of NaIO₄ (27 mg of NaIO₄ in 1mL 0.05M citrate) to 100 μL of 
Nanotraps and incubating for 10 minutes. Samples were centrifuged, 
resuspended in 50 μL water, and diluted (1:1, 1:2, and 1:4 dilutions)  before 
being immobilized on the nitrocellulose membrane and  incubated  for  one  
hour  at  room temperature  in  I-Block. The membrane was incubated in 
primary antibody (Borrelia burgdorferi OspA, Virostat 1:100) and secondary 
antibody (Life Technologies, Catalog #A16090, 1:5000). The membrane was 
then developed with ECL SuperSignal and the image was captured using 
Kodak imager. 
 
3.5.2 Testing antigen-displaying Nanotraps with western blot 
1ml of urine was then spiked with OspA (10 ng/ml). 200 μL of michea Brilliant 
Blue Nanotraps were then added to the urine, incubated for 30 minutes at 
room temperature and centrifuged (16.1 rcf, 15 min,  25°C). Samples were 
washed twice with water and then centrifuged (16.1 rcf, 15 min, 25°C).  
DHEA  oxidation  was  performed  by  adding  200  μL  of solution of  NaIO₄ 
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(27  mg  of  NaIO₄  in  1mL 0.05M  citrate) to 200 μL of Nanotraps and 
incubating for 10 minutes. Particles were centrifuged (16.1 rcf, 15 min,  
25°C),  resuspended in 20 µl  sample   buffer, and heated   at 100°C for 10 
minutes. Gel electrophoresis was performed and proteins were transferred 
onto an Immobilon PVDF membrane. The membrane was incubated for 60 
minutes in 5% milk, and subsequently in primary antibody (Borrelia 
burgdorferi OspA, 1:100) and secondary antibody (Life Technologies, 
Catalog #A16090, 1:5000). The membrane was drained and coated with 2mL 
Chemiluminescent ECL SuperSignal and developed with Kodak imager. 
 
3.5.3 Lateral flow immunoassay development and optimization 
DHEA Remazol Brilliant Blue R Nanotraps (200µl) were oxidized adding 200 
μL of solution of NaIO₄ (54 mg of NaIO₄ in 1mL 0.05M citrate) and incubated 
for 10 minutes. Nanotraps were centrifuged (16.1 rcf, 15 min, 25°C) and 
washed twice with 200 µl of water. Nanotraps were then incubated with OspA 
(0.5, 1, 1.5, 2 and 4 ng) for 30 minutes. The  solution  was  centrifuged (16.1  
rcf,  15  min,  25°C)  and  washed  twice  with  water. Nanotraps were 
resuspended in 200µl of water. Nitrocellulose  membranes  were  spotted  
with  4µl  primary  antibody 0551 creating a thin antibody line  and  dried  at  
37°C  for  10  minutes. The membranes were then incubated in PEG blocking 
solution  (50mg/mL in  water)  for  30  minutes  before  being  washed  twice  
with  PBS  Tween 0.1%).   The  membranes  were  dried again  at  37°C  for  
10  minutes,  and  then  placed  in  the  lateral flow device with filter pads 
overlapping it at either end (Figure 25). A solution of 100µl of particles and 
400µl water was placed directly on the sample pad and allowed to run 
through the nitrocellulose membrane. Different membrane materials tested: 
nitrocellulose, glass fiber filter without binder resin, polyethersulfone, MF-
Millipore Filter, and Isopore filter. Different blocking agents were tested: PBS 
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supplemented with 0.2% (w/v) I-Block and 0.1% Tween 20, polyethylene 
glycol (PEG), and acrylic acid Nanotraps. 
 
 
Figure 25. Schematic representation of a Nanotrap-based lateral flow. The urine sample is 
placed on the sample bad and allowed to flow through the nitrocellulose. The oxidized 
Nanotraps on the conjugate pad capture the antigen present in the fluid and flow to the 
membrane. Once the Nanotrap reaches the antibody line, the exposed OspA cargo will be 
bound by the antibody and it will result in the formation of a colored line. 
 
 
3.6 NANOTRAP-ENHANCED MULTIPLE REACTION MONITORING 
FOR THE DETECTION OF URINARY OSPA 
 
3.6.1 Selection of Elution Buffer for mass spectrometry analysis 
In order to select the best elution conditions compatible with mass-
spectrometry 10 replicates of 40 ml of urine spiked with 320 pg of Lyme 
antigen were processed as described above until the elution step. Elution 
was then performed resuspending the Nanotrap pellet using 20µL of the 
three different elution buffers: sample buffer, Protease Max (Promega, 1% in 
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ammonium bicarbonate) and Rapigest (Waters, 1% in ammonium 
bicarbonate). Incubation was either performed for 20 minutes at room 
temperature or for 10 minutes at 100°C. Each condition was performed in 
duplicate except for the samples eluted with sample buffer. One duplicate of 
sample eluted with Rapigest and ProteaseMax were processed for mass 
spec (see sample preparation for mass spectrometry below), while the other 
duplicates as well as the samples eluted with sample buffer were used for 
western blot and efficiency was assessed as densitometric analysis.  
 
3.6.2 Sample preparation for mass spectrometry 
40 mL of urine were spiked with 2.5, 5, 10, 25, 50 and 100 pg/mL of Borrelia 
antigen grade 2 in duplicate. Samples were incubated with the Nanotrap 
particles, washed according to the patient processing sample (p. 85), one set 
was then eluted with 20ul of sample buffer and the other was eluted 20ul of 
1% Rapigest SF surfactant (Waters)in 50 mM ammonium bicarbonate and 
5% TCEP. The first set was loaded on an electrophoresis gel and western 
blot was performed. In the second set of samples the elutions were acidified 
with 0.1% TFA for 30 minutes in order to degrade the surfactant and the 
resuspended with 180 ul of 50mM ammonium bicarbonate. Samples were 
alkylated with 50mM iodacetamide at room temperature in the dark for 20 
minutes. The enzymatic digestion ran overnight with 0.5µg sequencing grade 
trypsin (Promega) in 50mM ammonium bicarbonate pH 8 at 37°C. Digestion 
was then stopped by adding 5µl of trifluoracetic acid (TFA). Digested 
samples were then desalted with C-18 Zip Tips (Millipore). Final eluates from 
Zip Tips were then dried with a nitrogen evaporator. Samples were 
reconstituted in 6µl of 0.1% Formic Acid added with 100fmol angiotensin 1. 
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3.6.3 MRM analysis 
OspA was monitored for peptide GYVLEGTLTAEK using precursor 640.84 
2+ and transitions 719.40, 848.43, and 961.52. OspB was monitored for 
peptide ATIDQVELK using precursor 508.78 2+ and transitions 422.74, 
731.40, and 844.48 (Figure 2). Results were analyzed using Skyline (Univ. 
of Washington) and reported as the area under the curve for transition 961.52 
from peptide GYVLEGTLTAEK and transition 844.48 from peptide 
ATIDQVELK. After desalting with Pierce C18 spin columns, all samples were 
analyzed by LC-MRM on a Thermo Quantum Ultra triple quadrupole and 
Orbitrap Fusion Tribrid mass spectrometers. Samples were loaded onto a 
1mm x 150mm Hypersil Gold 3μm particle C-18 reversed phase column with 
an Accela autosampler (Thermofisher Scientific) fitted with a 10 µL sample 
loop. The LC pump was an Accela operated at 160 µL/min, and effluent will 
be directed into the mass spectrometer using an IonMax source. After 
sample injection, the column was washed for 5 min with 98% mobile phase 
A (0.1% formic acid), and peptides were eluted using a linear gradient of 2% 
mobile phase B (0.1% formic acid in acetonitrile) to 50% mobile phase B in 
40 min. The instrument divert valve was switched to waste before and after 
the peptides eluted in order to keep the source free of excess salts and 
debris. Both Q1 and Q3 resolution were set to 0.7 FWHM. Q2 contained 
1.5mTorr of argon. Phosphorylated Angiotensin II (DRV(pY)IHP, Protea 
Biosciences) was measured in urine for analytical verification. Results were 
analyzed using the program Skyline (University of Washington) and reported 
as the area under the curve for optimized transitions. 
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4. RESULTS 
 
4.1 HYDROGEL NANOTRAP SYNTHESIS AND 
CHARACTERIZATION 
 
Allylammine and Acrylic Acid core Nanotraps were synthesized. N-
isopropylacrylamide-co-allylammine Nanotraps were then functionalized 
with Cibacron Blue, and Remazol Brilliant Blue. N-isopropylacrylamide-co-
acrylic acid Nanotraps were functionalized with Trypan Blue, Remazol 
Brilliant blue, Reactive Blue 221, Bismark Brown, Diamine Green. Partially 
degradable Nanotraps using 1,2-Dihydroxyethylenebis-acrylamide (DHEA), 
bis(acryloyl)cystamine (BAC) hydrogel Nanotraps, pyrazolone and Fast Blue 
221 (as crosslinker) were also synthesized. Nanotraps were characterized 
and dynamic diameter was measured with light scattering. Allylammine 
hydrogel Nanotraps size measured 253.2 ± 3.13 nm in diameter (Figure 26). 
Because dyes are small organic compounds after functionalization of 
Allylammine-core Nanotraps with Remazol Brilliant Blue dye, no significant 
increase in size can be noted (Figure 26). 
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Figure 26. Light scattering measurements of Allylammine-core Nanotraps. Average diameter 
was 253.2 ± 3.13 nm (upper panel). Light scattering measurements of Allylammine-core 
Nanotraps functionalized with Remazol Brilliant Blue dye. Average diameter was 259.4 ± 2.02 
nm. The functionalization does not significantly increase the Nanotrap size (lower panel). 
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4.1.1 Size variation of partially degradable Nanotrap  
When exposed to the environmental condition that allows the cleavage of the 
crosslinker, Nanotraps undergo a partial degradation. Their structure 
becomes loose and the pore size increases allowing antibodies to directly 
access the target antigen in situ obviating the need of an elution step. The 
change in the physical structure of the Nanotraps can be observed visually 
as a color/opacity change of the Nanotraps solution and as well as a change 
in their hydrodynamic diameter. 
DHEA cross-linked Nanotraps 
N-isopropylacrylamide (NIPAm) Nanotraps were synthesized via dual cross-
linking (degradable N,N’-(1,2-Dihydroxethylene)-bisacrylamide [DHEA] and 
nondegradable N,N’-methylenebis(acrylamide) [BIS]  crosslinkers), and  then 
functionalized with Remazol Brilliant  Blue  dye. DHEA can be degraded 
through an oxidizing reagent, NaIO4 which causes an increase in Nanotrap 
diameter and pore size (Figure 27). 
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Figure 27. Light scattering measurements of DHEA containing Nanotraps. DHEA Nanotraps 
functionalized with Remazol brilliant blue show an average diameter of 987±16.01 nm before 
oxidation via sodium periodate (upper panel). After DHEA oxidation the diameter increases to 
1119.2±40.87 nm (lower panel). 
 
Sample Name: AK14B1 71414
Comments: 
Operator: RM SOM / SOP Name: 072507som25deg.som
Temperature: 25.0°C Diluent: WATER
Start Time: 14-Jul-14 03:05:08 PM End Time: 14-Jul-14 03:21:36 PM
Auto SDP: Yes Diluent Viscosity / RI: 0.890 cP / 1.333
Angle:
Run Time(auto):
Sample Time(auto):
Prescale(auto):
90.0 °
200s
15 us
4 
Unimodal Results Summary
Rept#.
 
Mean
(nm)
P.I.
 
Diff.Coef
(m²/s)
Counts/s
 
Baseline
Error
Overflow
 
 Rept.1 990.9 0.157 4.95e-13 8.70e+04 1.09%    0
 Rept.2 1005.1 0.196 4.88e-13 8.48e+04 1.32%    0
 Rept.3 966.4 0.033 5.08e-13 8.02e+04 0.13%    0
Average 987.5 ± 16.01 0.129 ± 0.069
  
  260  3860  660  1060  1460  1860  2260  2660  3060  3460
Size (nm)    [linear]
rept.1
rept.2
rept.3
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n
s
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Sample Name: AK14B1broken
Comments: 
Operator: TV SOM / SOP Name: 072507som25deg.som
Temperature: 25.0°C Diluent: WATER
Start Time: 15-Jul-14 05:02:51 PM End Time: 15-Jul-14 05:19:19 PM
Auto SDP: Yes Diluent Viscosity / RI: 0.890 cP / 1.333
Angle:
Run Time(auto):
Sample Time(auto):
Prescale(auto):
90.0 °
200s
16.5 us
4 
Unimodal Results Summary
Rept#.
 
Mean
(nm)
P.I.
 
Diff.Coef
(m²/s)
Counts/s
 
Baseline
Error
Overflow
 
 Rept.1 1168.4 0.397 4.20e-13 6.47e+04 1.62%    0
 Rept.2 1117.9 0.109 4.39e-13 6.26e+04 -0.01%    0
 Rept.3 1068.3 0.439 4.59e-13 6.30e+04 0.38%    0
Average 1118.2 ± 40.87 0.315 ± 0.147
  
  240  5040  740  1240  1740  2240  2740  3240  3740  4240  4740
Size (nm)    [linear]
rept.1
rept.2
rept.3
In
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n
s
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Light scattering results show an increase in the hydrodynamic diameter of 
the particles after oxidation of ~10-15%, with an increase in effective sieving 
cut off from 50,000 to 300,000 Da which can easily allow the access of an 
antibody. 
BAC cross-linked Nanotraps 
BAC cross-linked Nanotrap undergo partial degradation in presence of 
reducing conditions. 100 µL of β-mercaptoethanol was added to 100 µL of 
the Nanotraps and incubated for 30 minutes. Light scattering results show 
an increase in the hydrodynamic diameter of the particles after reduction of 
~20-25% (Figure 28). 
 
 
Sample Name: BAC
Comments: 
Operator: RM SOM / SOP Name: 072507som25deg.som
Temperature: 25.0°C Diluent: WATER
Start Time: 26-Oct-16 02:47:42 PM End Time: 26-Oct-16 03:20:37 PM
Auto SDP: Yes Diluent Viscosity / RI: 0.890 cP / 1.333
Angle:
Run Time(auto):
Sample Time(auto):
Prescale(auto):
90.0 °
200s
8.5 us
16 
90.0° Unimodal Distribution
Unimodal Results Summary
Rept#.
 
Mean
(nm)
P.I.
 
Diff.Coef
(m²/s)
Counts/s
 
Baseline
Error
Overflow
 
 Rept.1 498.4 0.424 9.84e-13 5.48e+05 1.17%    0
 Rept.2 520.4 0.637 9.43e-13 5.80e+05 3.57%    0
 Rept.3 514.6 0.495 9.53e-13 5.34e+05 1.81%    0
Average 511.1 ±  9.29 0.519 ± 0.089
  
  110  2410  410   710  1010  1310  1610  1910  2210
Size (nm)    [linear]
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Figure 28. Light scattering measurements of BAC containing Nanotraps. BAC Nanotraps 
functionalized with Remazol brilliant blue show an average diameter of 511.1±9.29 nm before 
oxidation via sodium periodate (upper panel). After BAC oxidation the diameter increases to 
645.9±6.02 nm (lower panel). 
 
Pyrazolone Nanotraps 
Pyrazolone was successfully incorporated into the Nanotraps as a cross-
linker. Light scattering results show an increase in the hydrodynamic 
diameter under acid condition of ~15-20%. Hydrodynamic diameter resulted 
703 ± 2.42 nm and 841.4±38.54 nm before and after acid treatment 
respectively (Figure 29). 
 
 
Sample Name: AAc RM
Comments: 
Operator: RM SOM / SOP Name: 072507som25deg.som
Temperature: 25.0°C Diluent: WATER
Start Time: 24-Aug-15 12:24:51 PM End Time: 24-Aug-15 12:41:19 PM
Auto SDP: Yes Diluent Viscosity / RI: 0.890 cP / 1.333
Angle:
Run Time(auto):
Sample Time(auto):
Prescale(auto):
90.0 °
200s
10 us
8 
90.0° Unimodal Distribution
Unimodal Results Summary
Rept#.
 
Mean
(nm)
P.I.
 
Diff.Coef
(m²/s)
Counts/s
 
Baseline
Error
Overflow
 
 Rept.1 654.0 -0.253 7.50e-13 3.89e+05 0.12%    0
 Rept.2 639.5 -0.063 7.67e-13 4.27e+05 0.06%    0
 Rept.3 644.2 -0.050 7.61e-13 4.29e+05 0.26%    0
Average 645.9 ±  6.02 -0.122 ± 0.093
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Figure 29. Light scattering measurements of pyrazolone containing Nanotraps. Nanotraps 
have been synthesized with pyrazolone as a cross-linker. Reducing the pH of the solution 
promotes the degradation of the Nanotraps. Hydrodynamic diameter was 703 ± 2.42 nm 
before treatment (upper panel) and 841.4±38.54 nm after treatment (lower panel). 
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Fast Blue B Nanotraps 
Fast Blue 221 can act not only as a high affinity dye but also as a degradable 
cross-linker was successfully incorporated into the Nanotraps as a cross-
linker. Once NIPAm strands are cross-linked by the Fast Blue B, the azo-
bond can be cleaved by the use of sodium dithionite as a reducing agent.  
Hydrodynamic diameter resulted 590.9 ± 6.80 nm and 727.8.4 ± 2.49 before 
and after reducing treatment respectively thus showing an increase under 
reducing conditions of ~20-25% (Figure 30). 
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Figure 30. Light scattering measurements of Fast Blue B Nanotraps. Nanotraps containing 
Fast Blue B as a cross-linker show an average diameter of 590.9 ± 6.80 nm before reduction 
via sodium dithionite (upper panel). After treatment with sodium dithionite the diameter 
increases to 727.8.4 ± 2.49 (lower panel). 
 
 
4.2 NANOTRAP ENHANCED WESTERN BLOT FOR THE 
DETECTION OF LYME DISEASE 
 
4.2.1 Mass spectrometry sequencing of Borrelia burgdorferi Outer 
Surface Protein A 
In this study we used Bb Lyme antigen Grade 2 as our primary source of 
OspA. A dilution (ranging from 100ng to 100ong) of a recombinant purified 
OspA protein (Genecopoeia) was analyzed by SDS-PAGE and silver 
staining (Figure 31). The band intensities were quantified using ImageJ 
software and a calibration curve was built. A linear regression curve was 
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fitted (y=5.39x+12281, R2 = 0.9873). 500 ng of Bb Lyme antigen Grade 2 
were loaded on the gel (Lane 2) and compared to the recombinant OspA 
calibration curve (Lanes 3-7). From this procedure we estimated that 81% of 
Bb Lyme antigen Grade 2 total protein content is OspA. In gel protein 
digestion and mass spectrometry (MS) analysis verified the predominant 
presence of tryptic peptides belonging to OspA in the bands at ~30 kDa and 
~60kDa present both in the Bb Lyme antigen Grade 2 and in the recombinant 
OspA. In particular, tryptic peptides containing the epitope for mAb clone 
0551 OspA236-239 were present in both bands (MS-MS spectra are 
reported in the insert).   
 
 
Figure 31. Mass Spectrometry analysis of Bb Lyme antigen Grade 2 (American Research 
Products). 81% of the total protein of the Bb Lyme antigen Grade 2 is constituted by OspA. A 
calibration curve was performed using OspA recombinant protein and band intensity of 500ng 
of Bb Lyme antigen Grade 2 was compared to the calibration curve obtained. Highest intensity 
bands at approximately 30 and 60 kDa were digested and analyzed by mass-spectrometry. 
Both resulted to be OspA as a single protein as well as a dimer. (Source: Magni, R. et al., 
2015) 
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4.2.2 Mass spectrometry sequencing and peptide competition reveals 
the OspA C‑terminal epitope recognized by the anti‑OspA mAb 
Bb Lyme antigen Grade 2 was partially digested with different proteolytic 
enzymes such as trypsin, pepsin and GluC. Protease derived fragments 
were split in different aliquots. One aliquot was analyzed by western blotting 
using the anti-OspA monoclonal antibody 0551. In parallel the other aliquots 
were run on a SDS gel and silver stained. The band in the SDS-page 
mirroring the smallest peptide fragments were cut out of the gel and 
processed for mass spectrometry analysis (Figure 32). In presence of trypsin 
digestion the lysate did not produce clear and detectable bands that could 
be cut out of the gel and analyzed. Although clear bands were produced at 
lower molecular weight using GluC, after analyzing them with mass 
spectrometry, no proteins were identified probably due to the poor ionization 
efficiency. On the contrary pepsin digestion produced visible fragments that 
could be identified by mass-spectrometry. 
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Figure 32. Proteolytic digestion for mapping the OspA epitope. Bb Lyme antigen was partially 
digested with pepsin and the loaded on two SDS-gel. One was used for western blot and 
incubated with mAb 0551, the other was silver stained. The smallest band mirroring the WB 
was cut out of the gel and analyzed by mass spectrometry. (Source: Magni, R. et al., 2015) 
 
 
The fragment KTSTLTISVNSKKTTQLVFTKQDTITVQKYDSAGT 
(OspA219-253, Figure 33 and Supplementary Table 3) was the smallest 
sequence that reacted with the mAb clone 0551. This sequence is located 
on the C-terminal region of the protein.  
 
 
Figure 33.  Cristallography structure of the OspA. The identified epitope is highlighted in red. 
(Source: Magni, R. et al., 2015) 
 
 
Two overlapping peptides, Peptide 5 (OspA219-239) = 
KTSTLTISVNSKKTTQLVFTK and peptide 6 (OspA234-253) = 
QLVFTKQDTITVQKYDSAGT were synthesized and evaluated against 
control peptides from other regions of the molecule for their reactivity with 
the mAb (Figure 34 C). Whereas no detectable signal was obtained for 
different peptides of the OspA, both peptide 5 and 6 showed a detectable 
signal on dot blot (Figure 34 A, B) 
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Figure 34. High specificity of a narrow OspA epitope. a) Dot blot analysis revealed that only 2 
out of 7 synthetic peptides with sequence highlighted in red (c) show reactivity with the anti 
OspA monoclonal antibody used in this study. b) dot blot analysis of a dilution curve of 
peptides 5 and 6. (Source: Magni, R. et al., 2015) 
 
 
The overlapping region of these peptides (OspA236-239 = VFTK) was found 
to be necessary and sufficient for antibody recognition via dot blot (Figure 
35). The flanking regions, highly variable in the Borrelia burgdorferi sensu 
strictu and across different Borrelia species were devoid of immunoreactivity 
with the mAb clone 0551 (Figure 35).  
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Figure 35. Reactivity of mAb against synthetic OspA peptides. Synthetic peptides mimicking 
the OspA236-239 region interact with the mAb in a dose dependent manner (dot blot analysis, 
1, 2, 3 = Bb Lyme antigen 0.5, 5, and 10 ng, respectively; 4, 5, and 6 = OspA219-253 0.5, 1, 
and 2 μg, respectively; 7, 8, and 9 = OspA219-235 0.5, 1, and 2 μg, respectively; 10, 11, and 
12 = OspA240-253 0.5, 1, and 2 μg, respectively). Negative control peptides (OspA219-235 
and OspA240-253) containing flanking regions but lacking the OspA236-239 sequence were 
devoid of immunoreactivity with the mAb clone 0551. (Source: Magni, R. et al., 2015) 
 
4.2.3 Competition assay shows high affinity between epitope 
containing peptide and mAb 
In order to further prove the specificity of the mAb towards the antigenic 
epitope OspA236-239, peptide solution phase competition and solid phase 
affinity depletion were performed. Peptide containing the putative epitope 
region were able to compete the antibody, while peptides lacking of the 
epitope regions failed to compete the antibody (Figure 36 A). Another proof 
of the specificity of the antibody for the epitope containing peptide was 
obtained through peptide solid phase affinity depletion. Antibody was 
incubated on an ELISA plate coated with the peptide OspA219-253 
containing the epitope recognized by the antibody. After incubation the 
antibody supernatant was recovered and its ability to react with the OspA 
was tested on a western blot. No immunoreactivity in the mAb preparation 
after immunodepletion was observed. This is a further confirmation of the 
absence of non-specific signal in the mAb clone (Figure 36 B). 
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Figure 36. Peptides containing the narrow OspA236-239 region were successfully utilized for 
antibody competition and immunodepletion. A) 600 pg of Bb Lyme antigen Grade 2 were 
spiked in human urine. Samples were processed through the Nanotrap particles and analyzed 
by western blot. Lane 2, 4 and 6 were obtained staining the western blot membranes with the 
mAb clone 0551 alone, the mAb neutralized with OspA219-253 peptide, and the mAb 
neutralized with a combination of OspA219-235 and OspA240-253, respectively. The peptide 
containing the OspA236-239 region successfully competed the mAb, whereas peptide missing 
the OspA236-239 region failed to compete the mAb clone ID 0551. B) Peptide OspA219-235 
was utilized for solid phase affinity depletion of the mAb clone 0551. The peptide (30 μg) was 
deposited on ELISA plate wells. The wells were washed and the excess peptide removed. 
The mAb clone 0551 (3 μg) was incubated with the solid phase adsorbed peptides overnight. 
After incubation, the supernatant was recovered and brought to a volume of 3 mL in PBS 
supplemented with 0.2 % I-Block and 0.1 % Tween 20. In parallel, 600 pg of Bb Lyme antigen 
Grade 2 were spiked in urine and processed through the Nanotrap particles (lane 2 and 4). 
Lane 2 and 4 were obtained staining the western blot membranes with the mAb alone (3 μg) 
and the mAb after immunodepletion, respectively. There is no immunoreactivity in the mAb 
preparation after immunodepletion (lane 4). This is a further confirmation of the absence of 
non-specific signal in the mAb clone 0551 preparation. (Source: Magni, R. et al., 2015) 
 
4.2.4 The anti-OspA mAb epitope is conserved in common pathogenic 
species of Borrelia  
The antigenic epitope OspA236-239 is highly conserved among major 
pathogenic Borrelia strains, these includes: Borrelia burgdorferi sensu 
stricto, several Borrelia burgdorferi sensu lato (Borrelia garinii, Borrelia 
valaisiana, Borrelia bissettii, Borrelia afzelii, and Borrelia spielmanii) and 
additional more recently characterized candidate pathogenic species (Table 
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2, Supplementary Table 4).  BLAST analysis153 performed on the sequence 
of the fragment OspA219-253 TSTLTISVNSKKTTQLVFTKQDTITVQKYDSAGT 
identified by mass spectrometry showed that it was not homologous to any 
human protein and not homologous to any other non-Borrelia spirochetes. 
 
Table 2. Blast search against different species of Borrelia. The identified epitope is highly 
conserved in different species of Borrelia while flanking regions are variable. (Source: Magni, 
R. et al., 2015) 
 
4.2.5 Selection of high affinity bait loaded Nanotraps for capturing Bb 
antigen 
Nanotrap particles were functionalized with a series of chemical baits29,50 that 
bind solution phase analytes with high affinity. 1 ng of Bb Lyme antigen was 
spiked in 500ul of human urine from healthy volunteers and incubated with 
differently functionalized nanotrap: Remazol Brilliant Blue, Reactive Blue 
221, Diamine Green, vinyl phenyl boronic acid, allylamine. The recovered 
amount of protein after Nanotrap processing as well as the initial solution and 
supernatant after Nanotrap protein capturing step were loaded on a gel and 
western blot was performed. Results (Figure 37) show that Lyme antigen 
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was successfully depleted from supernatants and detectable in each elution. 
The eluate from Remazol Brilliant Blue Nanotrap particles show the highest 
intensity suggesting a higher yield of the overall process. Interestingly to be 
noted is that Nanotrap particles with no bait are also able to sequester some 
of the antigen but not concentrate the analyte from the surrounding solvent 
volume, because there is no affinity gradient without the dye bait. 
 
 
 
Figure 37. Remazol Brilliant Blue Nanotrap particles show the highest affinity for OspA among 
the tested dyes. (A) Nanotrap particles Lyme antigen (1 ng) was spiked in 500 µL of human 
urine and incubated with Nanotrap particles functionalized with different dyes. After Nanotrap 
particles processing, Lyme antigen is successfully depleted from supernatants (S) and easily 
detectable in the eluate (E). The A) Lanes 1) ladder; 2) Lyme antigen 0.1 ng; 3) Supernatant 
Remazol Brilliant Blue Nanotrap 1; 4) Eluate Remazol Brilliant Blue Nanotrap 1; 5) 
Supernatant Remazol Brilliant Blue Nanotrap 2; 6) Eluate Remazol Brilliant Blue Nanotrap 2; 
7) Supernatant Reactive Blue Nanotrap; 8) Eluate Reactive Blue Nanotrap; 9) Supernatant 
Diamine Green Nanotrap; 10) Eluate Diamine Green Nanotrap.(B) Nanotrap particles without 
dye bait can volume sequester some antigen but not concentrate the analyte from the 
surrounding solvent volume, because there is no affinity gradient without the dye bait. Lanes 
1) ladder; 2) Lyme antigen 1 ng; 3) Negative control = urine without Bb antigen 4) Supernatant 
vinyl phenyl boronic acid Nanotrap 1; 5) Eluate vinyl phenyl boronic acid Nanotrap 2; 6) 
Supernatant acrylic acid Nanotrap; 7) Eluate acrylic acid Nanotrap; 8) Supernatant allylamine 
Nanotrap; 9) Eluate allylamine Nanotrap; 10) Supernatant Remazol Brilliant Blue Nanotrap; 
and 11) Eluate Remazol Brilliant Blue Nanotrap. (Source: Magni, R. et al., 2015) 
 
4.2.6 Determining the optimal amount of Dye for sample processing 
Remazol Brilliant Blue nanotrap particles were able to efficiently capture and 
concentrate the Lyme antigen. Different amount of Nanotraps which 
correspond to a different amount of nanomoles of dye were incubated in 
500µl of urine spiked with 0.6 ng of Bb antigen. We measured the relationship 
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between the amount of Remazol Brilliant Blue and the % of antigen depletion 
from the solution phase. Among the concentration tested 34, 68, 171, 343, 
686 nmoles of Remazol Brilliant Blue, 686 nmoles showed the highest 
efficiency fully depleting the solution of Lyme antigen and providing clear 
evidence of 100% antigen depletion from the solution phase and saturation 
of binding (Figure 38).  
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Figure 38. Relationship between dye content and capturing affinity. Left panel; Western blot 
showing the relationship between the Remazol Brilliant Blue in the particles and depletion of 
the antigen in the supernatant: 100% antigen depletion from the solution phase and saturation 
of binding. Lane 1: ladder, lane 2: initial solution, lanes 3-7: supernatants after incubation of 
containing increasing amounts of dye containing Nanotrap particles with a urine solution 
containing 0.6 ng of Bb antigen: 34, 68, 171, 343, 686 n moles of Remazol Brilliant Blue dye, 
respectively. Right panel; ImageJ quantification of the optical density in the western blot. Y 
axis: Antigen sequestered in the Nanotrap particles obtained as difference between the initial 
solution (lane 2) and the supernatants (lanes 3–7) of the western blot. X axis: μmoles of 
Remazol Brilliant blue in the Nanotrap particles. (Source: Magni, R. et al., 2015) 
 
4.2.7 Determination of optimal amount of Nanotrap to sample volume 
ratio to optimize OspA capturing 
The volume of Remazol Brilliant blue Nanotrap used to capture OspA can be 
adjusted to the sample volume in order to sequester virtually 100% of the 
target antigen. Different amount of Nanotraps were incubated in aliquots of 
500ul of urine. A volume of 1/10 (V/v ration of Nanotrap suspension volume 
(V) and sample volume (v) (Figure 39). 
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Figure 39. Effect V/v ratio between Nanotraps and sample volume on capturing effciency. a) 
V/v ratio (V=Nanotrap suspension volume, v=sample volume) of 1/10 was optimized in order 
to maximize Lyme antigen capturing. 2 ng of Lyme antigen was spiked in 500 µL urine aliquots. 
Urine samples were incubated with increasing amount of Nanotrap particle suspension (10-
160 µL of Nanotrap at 5 mg/mL concentration). Lanes 1) ladder; 2) Positive control (OspA 
1ng); 3) 10µL of Nanotrap particles; 4) 20 µL Nanotrap particles; 5) 40µL Nanotrap particles; 
6) 80 µL Nanotrap particles; 7) 160µL Nanotrap particles; b) Band intensity was measured 
with ImageJ, plateau is reached with > 40µL of Nanotrap particles. (Source: Magni, R. et al., 
2015) 
 
4.2.8 Reproducibility of  Nanotrap particles performance 
Several Nanotrap batches were used for our study and strict validation 
criteria for each batch have been applied according to CAP CLIA guidelines. 
A criteria for batch to batch validation was CV<10%. Batch validation was 
performed incubating 200µl of Nanotraps in 40 ml of urine spiked with 
decreasing concentration (30pg/ml – 1.7 pg/mL) of Bb Lyme antigen Grade 
2 (Figure 40 A). For a validated batch of Nanotraps a band should be visible 
for each concentration. Comparison between batches is performed spiking a 
dilution curve of the new batch (range is 32pg/mL to 0pg/mL) and two 
concentrations of the previous batch, 1pg/ml and 16 pg/ml (Figure 40 B).   
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Figure 40. Nanotrap particle batch validation and batch to batch reproducibility. a Nanotrap 
particles are incubated with increasing amount of Bb Lysate spiked in 40 mL of urine; Lane 1: 
Ladder; Lane 2: Positive control Bb Lyme antigen Grade 2 1 ng; Lane 3: Positive control Bb 
Lyme antigen Grade 2 0.28 ng; Lanes 4–9: eluate of Nanotrap particles incubated with 
increasing concentrations of Bb antigen in 40 mL of urine: 0; 1.7; 3.5; 7; 15; 30 pg/mL, 
respectively b Performance comparison of two batches of Nanotrap particles, NT294 and 
NT306. Lane 1: Ladder; Lane 2: Positive control Bb Lyme antigen Grade 2 60 pg; Lane 3: 
eluate of Nanotrap particles batch NT296 incubated with 1 pg/mL Bb antigen urine solution 
(40 mL); Lane 4: eluate of Nanotrap particles batch NT296 incubated with 16 pg/mL Bb 
antigen urine solution (40 mL); Lane 5–10: eluate of Nanotrap particles batch NT306 
incubated with increasing concentrations of Bb antigen urine solution (40 mL) 0; 2; 4; 8; 16; 
32, respectively. (Source: Magni, R. et al., 2015) 
 
To further prove the reproducibility of the results with different batches three 
RBB functionalized Nanotraps were spiked with at two different 
concentration (2pg/ml and 16pg/ml) of Lyme antigen Grade 2, processed and 
signals were measured by western blot (Figure 41). Densitometric analysis 
of the bands shows a CV=9%. 
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Figure 41. Performance comparison of multiple batches of Nanotrap particles (%CV = 9 % 
and 5 % at 2 pg/mL and 16 pg/mL Bb antigen in 40 mL of urine, respectively). Lane 1: ladder; 
lane 2: Positive control Bb Lyme antigen Grade 2 16 pg; lane 3: eluate of Nanotrap particles 
batch NT283 incubated with 40 mL of urine without Bb Lyme antigen Grade 2; lanes 4–5: 
eluates of Nanotrap particles batch NT283 incubated with 2 and 16 pg/mL Bb Lyme antigen 
Grade 2 urine solution (40 mL); lanes 6–7: eluates of Nanotrap particles batch NT294 
incubated with 2 and 16 pg/mL Bb Lyme antigen Grade 2 urine solution (40 mL); lanes 8–9: 
eluates of Nanotrap particles batch NT306 incubated with 2 and 16 pg/mL Bb Lyme antigen 
Grade 2 urine solution (40 mL). (Source: Magni, R. et al., 2015) 
 
Overall performance of the nanotrap-based western blot was performed. 
320pg of spiked-in positive control were compared to the signal produced by 
a 40 ml solution of urine spiked with 4 pg/ml. Equal intensity of the bands is 
obtained if the process yields 100% recovery of the antigen after Nanotrap 
capture and concentration. According to the evaluation of different Nanotrap 
batches we were able to obtain recovery yield as high as 93% (Figure 42). 
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Figure 42. Yield of Nanotrap particle pre-processing. Left panel: Lane 1: ladder; lane 2: Bb 
antigen 320 pg, lane 3: eluate of Nanotrap particles batch NT283 incubated with 40 mL of 
urine without Bb Lyme antigen; lane 4: supernatant; lane 5: eluate of Nanotrap particles batch 
NT283 incubated with 8 pg/mL Bb Lyme antigen Grade 2 urine solution (40 mL). Right panel: 
densitometric measure of the bands shows an overall yield of 93%. 
 
Overall performance of the nanotrap-based western blot was performed also 
using sample buffer 2X (5% TCEP) as elution buffer. 320pg of spiked-in 
positive control were compared to the signal produced by a 40 ml solution of 
urine spiked with 4 pg/ml. Densitometric analysis shows a yield of 91% thus 
comparable to the yield previously obtained using the combination of 
acetonitrile and ammonium hydroxide as elution buffer (Figure 43).  
 
              
Figure 43. Yield of Nanotrap particle pre-processing using Sample Buffer 2X as elution buffer. 
Left panel: Lane 1: ladder; lane 2: Bb antigen 320 pg, lane 3: eluate of Nanotrap particles 
batch NT283 incubated with 40 mL of urine without Bb Lyme antigen; lane 4: eluate of 
Nanotrap particles batch NT283 incubated with 8 pg/mL Bb Lyme antigen Grade 2 urine 
solution (40 mL). Right panel: densitometric measure of the bands shows an overall yield of 
91%. 
  
4.2.9 Lack of cross-reactivity with relevant non-Borrelia infections 
Because of the increasing prevalence of other tick-borne infections and the 
incidence of co-infections in Lyme patients, the most prevalent viral, 
bacterial, and protozoan antigens were tested with our method in order to 
exclude the possibility of cross-reactivity. A single band at 31 kDa was 
detected when 40 mL of human urine were spiked with OspA as well as 
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increasing amounts viral lysate from Bartonella henselae lysate (ATCC 
49793), Babesia microti (ATCC PRA-399), Epstein-Barr virus (EBV) Cell 
Extract (Advanced Biotechnologies Inc.; 10-501-001), Herpes Simplex virus-
1 (HSV-1) Inactivated Vero Cell Extract (Advanced Biotechnologies Inc; 10-
515-001), Cytomegalovirus (CMV) HEK293 Cell Lysate (Sino Biological Inc.; 
10202-VCCH1L), Hepatitis C Virus HEK293 Cell Lysate (Sino Biological Inc.; 
10202-VCCH1L). No false positives were detected further proving the 
specificity of our antibody against the OspA epitope (Figure 44).  
 
 
Figure 44. Infection with common non-Lyme pathogens do not generate a false positive for 
Borrelia in the present Nanotrap test. a Herpes simplex 1 and Epstein Barr viral lysates were 
mixed with urine in presence and absence of Bb antigen. Samples were processed with 
Nanotrap particles and analyzed with western blot. Lane 1 ladder, lane 2 Bb antigen 1 ng; 
lanes 3–7 eluates of Nanotrap particles incubated with urine without Bb antigens (lane 3), 25 
pg/mL Bb antigen in urine 40 mL (lane 4), HSV-1 lysate (1 μg in 40 mL of urine) (lane 5), EBV 
lysate (1 μg in 40 mL of urine) (lane 6), HSV-1 lysate (1 μg in 40 mL of urine) plus EBV lysate 
(1 μg in 40 mL of urine) plus Bb antigen (1 ng in 40 mL of urine) (lane7). (B) Hepatitis C and 
Cytomegalovirus viral lysates were mixed with human urine in presence and absence of Bb 
antigen. Lane 1: ladder, lane 2 Bb antigen 1 ng; lanes 3–7: eluates of Nanotrap particles 
incubated with urine without Bb antigen (lane 3), 25 pg/mL Bb antigen in urine 40 mL (lane 4), 
HCV lysate (1 μg in 40 mL of urine) (lane 5), CMV lysate (1 μg in 40 mL of urine) (lane 6), 
HCV lysate (1 μg in 40 mL of urine) plus CMV lysate (1 μg in 40 mL of urine) plus Bb antigen 
(1 ng in 40 mL of urine) (lane 7). c Bartonella henselae and Babesia microti lysates were 
spiked in human urine in presence and absence of Bb antigen. Lane 1: ladder, lane 2: Bb 
antigen 1 ng; lanes 3–9: eluates of Nanotrap particles incubated with urine without Bb antigen 
(lane 3), 25 pg/mL Bb antigen in urine 40 mL (lane 4), Bartonella lysate (1 ng in 40 mL of 
urine) (lane 5), Babesia lysate (10 ng in 40 mL of urine) (lane 6), red blood cells (10 ng in 40 
mL of urine) (lane 7), Bartonella lysate(10 ng in 40 mL of urine) plus Babesia lysate (10 ng in 
40 mL of urine) plus Bb antigen (1 ng in 40 mL of urine) (lane 8), 40 mL of urine of a patients 
with Bartonella positive and Borrelia negative serology at the time of urine collection (lane 9). 
(Source: Magni, R. et al., 2015) 
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4.2.10 Lack of cross-reactivity in the presence of interfering substances 
Interfering substances such as Bovine Serum Albumin and blood 
(hemoglobin) were tested in increasing concentration and showed no cross-
reactivity with the mAb. Increasing amounts of bovine serum albumin ranging 
from 0.31 mg/mL to 20 mg/mL were added to 40 mL of OspA containing 
human urine; urine samples were processed with Nanotrap particles (Figure 
45). Ability of the Nanotrap particles to sequester OspA was not affected by 
increasing concentration of competing proteins in urine. This suggest that the 
presence of abnormally high proteins in the urine of patients, as happens in 
the rare disorder of monoclonal gammopathy (3% incidence in general 
population >50 yo, decreasing with decreasing age), does not interfere with 
the Nanotrap OspA test as well. 
Because several patients that were affected by late stage Lyme disease are 
found to have high level of bilirubin we decided to test if high concentration 
of it in urine could interfere with the results of our test. Bilirubin levels, which 
were tested in the urine with dipstick prior to analysis, did not cause any 
interference with the Nanotrap test. Firstly, the Nanotrap particle urine OspA 
test uses chemiluminescence solid phase based detection whereas bilirubin 
is known to interfere with absorbance readings at  λ ~ 456 nm154 in solution-
phase homogeneous assays. Secondly, the molecular weight of bilirubin is 
~500 Da. This means that bilirubin is too small to be retained in the SDS 
PAGE system (Tris Gly 4-20%) we use to detect the OspA antigen. Bilirubin 
would migrate out of the gel during the electrophoretic run necessary to 
separate the proteins, which have a much higher molecular weight (10,000 
– 100,000 Da).  
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Figure 45. Interfering substances: the presence of a high amount of protein and blood in the 
urine does not interfere with Lyme antigen capture and detection. (A) 320 pg of Lyme antigen 
was spiked in samples of 40 mL of human urine. We tested the interference of albumin present 
in excess up to 10^8 fold. Lanes: 1) ladder; 2) volunteer human urine in absence of OspA 
antigen (negative control); 3) OspA + BSA 20 mg/mL ; 4) OspA + BSA 10 mg/mL; 5) OspA + 
BSA 5 mg/mL; 6) OspA + BSA 2.5 mg/mL; 7) OspA + BSA 1.25 mg/mL; 8) OspA + BSA 0.625 
mg/mL; 9) OspA + BSA 0.31 mg/mL; 10) OspA + BSA 0.15 mg/mL. (B) Lyme antigen 320 pg 
was spiked in urine samples (40 mL). Increasing amounts of whole blood from 0.015 µL to 1 
µL was added to the urine samples; urine samples were processed with Nanotrap particles 
and analyzed using western blot. Lanes: 1) ladder; 2) volunteer human urine in absence of 
OspA antigen (negative control); 3) OspA + 1 µL whole blood; 4) OspA + 0.5 µL whole blood; 
5) OspA + 0.25 µL whole blood; 6) OspA + 0.125 µL whole blood; 7) OspA + 0.062 µL whole 
blood; 8) OspA + 0.031 µL whole blood; 9) OspA + 0.015 µL whole blood; 10) OspA + 0.007 
µL whole blood. (Source: Magni, R. et al., 2015) 
 
 
A 
B 
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4.2.11 Precision and sensitivity of Nanotrap-based OspA western blot 
test 
In order to determine the intra-assay precision, replicate of urine spiked-in 
samples were processed with Nanotrap and western blot was performed. 
Densitometric analysis of the 31 kDa band showed a very high level of intra-
assay precision (n = 4, %CV = 7 %). for the Nanotrap 
concentration/immunoblotting method achieving a lowest limit of detection 
(LLD) of 1.7 pg/mL starting from 40 mL of urine (Figure 46). The dynamic 
range is 1.7–30 pg/mL. 
 
 
 
Figure 46. Lower limit of detection/quantitation and reproducibility of the urinary OspA Lyme 
test. A): Sensitivity studies on three independent replicates: lower limit of detection (LLD) is 
1.7 pg/mL. The lower limit of quantitation (LLQ) is 4.2 pg/mL for a 40 mL urine sample input 
volume. (Background estimate = 1071 AU, standard deviation (SD) = 323 AU. LLD = 
background + 2*SD, LLQ = background + 10× SD; polynomial equation y = −19.026x2 + 1160x 
− 248.76, R2 = 0.9971, was used to estimate the corresponding x value (1.7 pg/mL and 4.2 
pg/mL, respectively)). 1 ladder; 2 Bb Lyme antigen control 1000 pg; 3 Eluate from Nanotrap 
particles incubated with 40 mL of volunteer urine containing no Bb Lyme antigen, negative 
control; 4–10 Eluate from Nanotrap particles incubated with 40 mL of volunteer urine 
containing decreasing concentrations of OspA, 30, 15, 7.5, 3.75, 1.9, 0.9, and 0.47 pg/mL, 
respectively. B): Within run assay %CV is 7 %. Lyme antigen (1200 pg) was spiked in 4 urine 
aliquots (40 mL) and incubated with 4 mL of Nanotrap particles. Band intensity was measured 
with Image J. Within run %CV = 7 %. 1 Ladder; 2 OspA Lyme antigen control 200 pg, 3–6 
Replicates of Nanotrap particle processed spike-in samples. (Source: Magni, R. et al., 2015) 
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4.2.12 Detection of OspA in Ticks 
Nanotrap-based western blot test was used to detect OspA in Ixodes ticks. 
According to studies that follow the growth of Borrelia burgdorferi in ticks 
feeding on mice using confocal fluorescence miscroscopy, the bacteria 
reproduces within the tick gut and by the time that it is transferred to human 
the number of  bacteria is increased from less than 10,000 organisms to more 
than 150,00077,155. Nanotraps have been successfully applied in the past to 
verify the presence of OspA and OspB in tick vectors156. In the previous study 
by Douglas et al. fourteen ticks (females and males collected in Pennsylvania 
and Virginia) were analyzed. Four out of 14 ticks gave a strong positive signal 
in the Nanotrap particle system. The exact same band pattern of OspA 
identified in the extracted tick was also confirmed in this study (Figure 47). 
Several ticks were frozen and pulverized, resuspended in PBS (1mL) and 
processed with Remazol Brilliant Blue functionalized Nanotraps. Eluates 
were analyzed by western blot. Proteins extracted from infected ticks showed 
the presence of a positive band after pre-processing with Nanotrap 
demonstrating the ability of our Nanotrap-based immunoassay to capture 
and detect naturally occurring proteins in single infected ticks. 
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Figure 47. Nanotraps capture OspA in infected ticks. Positive control was made by loading 
100pg of B. burgdorferi lysate. The eluate (tick extract) shows a strong band at ~30 kDa 
indicating that the antibodies reacted with B. burgdorferi protein in the tick, while the eluate 
from empty Nanotraps (negative control) does not show any cross-reactivity. 
 
4.2.13 Detection of OspA in urine from patients suspected of Lyme 
disease 
In order to assess the ability of the Nanotrap test to capture native OspA in 
human urine, a urine sample from a patient with clinical symptoms of Lyme 
disease collected before any antibiotic treatment was processed with 
Nanotrap and tested by western blot. The initial solution (IS) before Nanotrap 
processing was loaded on the gel as well as the elution from the Nanotraps. 
Nanotrap pre-processing results to be necessary for the detection of OspA 
(Figure 48). No signal was detected when samples from healthy donors were 
processed through Nanotraps and analyzed by western blot. 
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Figure 48. (A) Nanotrap particle preprocessing step is necessary to detect an OspA specific 
band in the urine of a patient, clinically positive for Lyme disease. Initial solution (IS) before 
Nanotrap particle processing. Eluate (E) after Nanotrap particle processing. (B) Positive and 
negative controls run with all Lyme patient samples. Lane 2 contains Borrelia protein lysate 
(2 ng) in human urine. Lane 5 is a positive control 4 ng spiked in 40 mL of urine sample. Lane 
6 and 7 are negative controls of 40 mL of volunteer urine processed through the Nanotrap 
particles. C=Borrelia lysate control, IS=initial solution, S=supernatant, E=eluate. (Source: 
Magni, R. et al., 2015) 
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4.2.14 Detection of OspA in early stage Lyme patients with clinical 
evidence of Lyme disease before treatment 
Patients with suspected of early stage cutaneous LB, manifesting the 
characteristic EM rash with or without concurrent symptoms such as fever, 
malaise, or neurologic symptoms (e.g. Bell’s Palsy) were tested with our 
Nanotrap-based immunoassay (Table 3, 4; Supplementary table 2). 
 
Patient characteristics Number 
Asymptomatic non-Lyme (healthy volunteers) 117 
Symptomatic non-Lyme patients (non-Lyme patients in 
infectious disease clinic) 
3 
Untreated, clinical diagnosis of LB (positive diagnosis of 
Lyme disease with EM rash) 
24 
Antibiotic treatment for a clinical diagnosis of LB, Arthritis 
Pos, EM Neg (positive diagnosis of Lyme disease with 
arthritis symptoms) 
6 
EM rash present at the time of urine collection during the 
treatment course 
10 
Post-treatment with alleviation of symptoms (converted to 
EM Neg) 
8 
Patients being worked up for chronic or recurrent LB with 
negative or inconclusive serology 
100 
 
Table 3. Clinical features of patient enrolled in the diagnostic clinical trial. (Source: Magni, R. 
et al., 2015) 
 
All patients resulted positive for serology using the two tier testing algorithm 
according to FDA guidelines. 24/24 patients exhibiting a characteristic 
cutaneous infection (EM rash) at the time of urine collection, were positive 
for urinary OspA peptides containing the C-terminal domain recognized by 
the anti-OspA mAb (Figure 49).  
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Figure 49. Nanotraps capturing of OspA in patients with clinical diagnosis of Lyme disease. 
Lane 1 ladder, lane 2 Bb antigen 1 ng; Lanes 3–12: example of patient urine samples 
demonstrating presence of OspA. Positive OspA bands are normally visible in the 28–30 kDa 
range although lower molecular bands can be detected and successfully competed 
suggesting the presence of smaller-than-full-lenght OspA C-terminal domain containing 
protein fragments in urine. (Source: Magni, R. et al., 2015) 
 
Most of the positive OspA peptide bands were in the range of 28–32 kDa, 
but in some cases smaller fragments and a higher molecular weight band 
(that could be competed) in the range of 20–28 and ~60 kDa were noted 
(Figure 49). Thus the urinary shedding of OspA is likely to include OspA 
antigen modified by proteases. In contrast, none of 117 untreated, non-
symptomatic control patients shed urinary OspA C-terminal antigen (Chi 
squared p value <2.2e−16; significance = 5 %, power 100 %). Samples 
classified negative for OspA did not have detectable bands in the 20–32 kDa 
range (Figure 50).  
 
Figure 50. Nanotrap antigen test results on a representative sub-group of the 117 healthy 
volunteers. Lane 1 ladder, lane 2 Bb antigen 1 ng; Lanes 3–12 example of patient urine 
samples demonstrating absence of OspA. (Source: Magni, R. et al., 2015) 
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For the 24 patients that were EM positive and also urinary OspA positive at 
the time of urine collection, 12 became LB serology positive by CDC criteria 
for early diagnosis157, 5 were serology negative157, 3 were serology equivocal 
and 4 were not done (ND, Table 4). 3 untreated patients who were LB 
serology negative, and EM negative, but positive for joint symptoms and 
fatigue, were negative (0/3) for urinary OspA (Table 4). Specificity of the 
urinary OspA antigen test for later serology outcome was 87.5 % (21 urinary 
OspA positive/24 serology positive, Chi squared p = 4.072e−15, Table 5).  
 
Categories Patients 
subcategories 
(N°) 
Clinical features OspA 
Pos 
OspA 
Neg 
Non Lyme Asymptomatic 
(117) 
EM Neg, serology ND 0 117 
Symptomatic, joint 
pain (3) 
EM Neg, serology Neg 0 3 
Untreated, 
clinical 
diagnosis of LB 
EM Pos (24) Serology:  
12 Pos, 5 Neg, 3 Eq.  
4 ND 
24 0 
Antibiotic 
treatment for a 
clinical 
diagnosis of LB 
EM rash present 
at the time of urine 
collection during 
the treatment 
course (10) 
Serology:  
4 Pos, 6 Neg 
10 0 
 Arthritis Pos, EM 
Neg (6) 
Serology: 6 Pos 6 0 
 Converted to EM 
Neg (8) 
 
Serology: 4 Pos, 4 Neg, 
8/8 
urinary OspA Pos prior to 
therapy 
0 8 
 
 
 
 
Table 4. Urinary OspA results compared to serology, clinical diagnosis and treatment status 
of N = 168 patients suspected of having early stage LB, and healthy controls. OspA pos urinary 
OspA test positive, OspA neg urinary OspA test negative, EM Erythema Migrans, ND serology 
not done. (Source: Magni, R. et al., 2015) 
 
 Serology 
positive* 
 
Serology 
negative* 
 
Serology 
Equivocal** 
 
Total 
OspA Pos 21 17 3 41 
OspA Neg 3 124 0 127 
Total 24 141 3 168 
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Table 5. Correlation of urinary OspA to serology CDC criteria for early stage LB. (Source: 
Magni, R. et al., 2015); * symptomatic and non-symptomatic,pre and post treatment;** 
Symptom Positive for clinical diagnosis of LD 
 
4.2.15 Treated Patients with a clinical diagnosis of Lyme Disease 
We evaluated the urinary OspA shedding of patients who presented to a 
community infectious disease clinic with onset of cutaneous or systemic 
symptoms and were immediately treated with antibiotics based on a clinical 
diagnosis of LB (Tables 3, 4; Supplementary table 2). Urinary OspA was 
scored positive or negative as described above without knowing the clinical 
outcome, and then compared to the clinical diagnosis based on anonymous 
coded patient records. Urinary OspA was compared to LB western blot 
serology for each patient.  
A subset of the treated patients donated a urine specimen at a time in the 
course of antibiotic therapy when the EM rash was still present. 10/10 treated 
patients with a concurrent EM rash at the time of urine collection were 
positive for urinary OspA antigen C-terminal containing peptides. Of these 
10, four (4/10) post treatment were LB serology positive. Six of six (6/6) 
patients undergoing antibiotic therapy for a clinical diagnosis of LB who had 
systemic symptoms such as joint pain or neurologic symptoms, but were EM 
negative, were also positive for urinary OspA. All of these patients became 
serology positive by CDC criteria157. 8 patients who were initially positive for 
urinary OspA antigen were clinically diagnosed as symptom free (resolution 
of EM rash) after a successful course of antibiotic therapy for a clinical 
diagnosis of LB. None (0/8) asymptomatic post treated patients were positive 
for urinary OspA (Figure 51) and four (4/8) were subsequently LB serology 
positive. Thus urinary OspA antigen shedding appears, in this study group, 
to closely parallel the concurrent presence of symptoms.  
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Figure 51. The OspA band is not detectable in the urine of acute stage Lyme patients after 
successful treatment. Lane 1 ladder; lane 2 Bb Lyme antigen Grade 2 in urine 0.1 ng; lane 3 
negative control urine with no OspA; lane 4 Initial solution (=urine without Nanotrap particle 
pre-processing) of patient 120 before treatment; lane 5 eluate of patient 120 before treatment; 
lane 6 Initial solution patient 120 after treatment; lane 7 Eluate patient 120 after treatment. 
(Source: Magni, R. et al., 2015) 
 
4.2.16 Treated patients under clinical evaluation for persistent or 
recurrent LB 
Urinary OspA shedding was further evaluated in a cohort of 100 patients in 
a Lyme endemic geographic region who were under clinical surveillance for 
persistent or recurrent LB. All of these patients had been previously treated 
with antibiotics, and all patients had been followed because of prolonged 
chronic functional symptoms such as arthralgias, neurocognitive symptoms, 
and fatigue. All of these patients lacked a CDC criteria defined LB serology 
positive IgG western blot serum test at the time of urine collection104. 
According to the IDSA (Infectious Diseases Society of America) 2006 and 
2010 guidelines125,158, “To date, there is no convincing biologic evidence for 
the existence of symptomatic chronic B. burgdorferi infection among patients 
after receipt of recommended treatment regimens for Lyme disease.” In 
contrast, according to ILADS (The International Lyme and Associated 
Diseases Society), the diagnosis of persistent Lyme disease is a real 
phenomenon and often requires clinical judgment to be characterized159. Due 
to the frequent nonspecific nature of complaints and insensitivities of 
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diagnostic studies, the clinician is forced to weigh the risk profile of any 
individual presenting with what may be considered Lyme disease. This 
includes the risk of tick exposure and the presenting symptom complex109,160–
165. In this study, urinary OspA scoring was performed blinded to the patient 
diagnosis or clinical findings. After the urine OspA scoring was completed, 
the clinical data was unblinded. For this special group of previously treated 
patients under surveillance for persistent or recurrent LB, 41/100 were 
positive for urinary OspA C-terminal peptides (Figure 32; Supplementary 
Table 5). This percentage of patients with positive urinary OspA is in keeping 
with the range of seven previous studies conducted in endemic areas where 
patients were being evaluated for suspected Lyme disease: 7–31 % active 
disease and 5–20 % previous Lyme disease in endemic areas166–168. 
 
4.2.17 Use of HRP-labelled antibodies for Nanotrap-based 
immunoassays 
HRP conjugation of a primary antibody allows for a direct detection of a target 
antigen without the need of a secondary antibody. As a consequence this 
would facilitate a quicker workflow as only one antibody is used and it would 
eliminate the chance of secondary antibody cross-reactivity (background 
might be reduced). An HRP labeling kit (Lightning-Link®) was used to enable 
the direct conjugation of Horseradish Peroxidase to the Anti-OspA 
monoclonal antibody (0551, Virostat).  Two concentrations, 5ng and 0.5ng of 
OspA were loaded in parallel on a gel electrophoresis. The proteins were 
transferred onto a PVDF membrane. The first half of the membrane was 
incubated with the HRP-labelled primary antibody, the second half was 
incubated with the primary and the secondary antibody following standard 
procedure. Results showed that the signal intensity of the 31 kDa bands for 
the HRP conjugated antibody were comparable to the ones obtained using 
both primary and secondary antibody (Figure 52). 
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Figure 52. HRP-labelled primary antibody. Left) western blot performed using the HRP-
labelled anti-OspA (0551 Virostat) antibody; lane 1, 5ng of Borrelia lysate; Lane 2, 0.5ng of 
Borrelia lysate. Right) western blot performed using primary and secondary antibody; lane 3, 
marker; lane 4, 5ng of Borrelia lysate; Lane 2, 0.5ng of Borrelia lysate. (Source: Magni, R. et 
al., 2015) 
Anti-Borrelia polyclonal HRP-labelled antibodies, abcam, ab156277, abcam, 
ab20757, Thermo Scientific. PA1-27289, Virostat 0304against Borrelia 
Lysate were also tested and efficiencies were compared (Figure 53).  
 
Figure 53. Detection of OspA with commercially available HRP-labelled primary antibodies 
against Borrelia Lysate compared to monoclonal anti-OspA antibody clone 0551 (s. Cruz). a) 
S. cruz 0551; lane 1, marker; lane 2, 10pg Borrelia lysate; lane 3, 100pg of Borrelia lysate. b) 
; lane 4, marker; lane 5, 10pg Borrelia lysate; lane 6, 100pg of Borrelia lysate. c) Virostat 0304 
lane 7, marker; lane 8, 10pg Borrelia lysate; lane 9, 100pg of Borrelia lysate. 
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Detection of Borrelia lysate spike-ins was proven to be successful also with 
these commercially available antibodies. Further analysis and concentration 
optimization is required. Also, because these are not monoclonal antibody 
directed specifically against OspA, more extensive cross-reactivity studies 
towards other antigens as well as interfering substances need to be 
performed. 
 
 
4.3 NANOTRAP-ENHANCED ELISA TEST FOR LYME DISEASE 
 
Western Blot is a labor intensive technique. An ELISA, on the other hand, 
can be easily scaled-up and results can be quantified, making it more 
suitable for clinical diagnostics. Nanotrap technology is agnostic to the 
downstream analytical method but, when transitioning from an immunoassay 
to another, several steps, including reagent selection need to be evaluated 
in order to maximize results. 
 
4.3.1 Antibody optimization 
We compared Virostat and Santa Cruz suppliers of the monoclonal antibody 
clone 551 used in our western blot test, which we have previously validated 
in terms of specificity, affinity, and conservation of antigen epitope across 
Borrelia species. Both Virostat antibody and S. Cruz antibodies were 
deposited on the ELISA plate in triplicate and incubated with 125pg of 
Borrelia lysate. Although the antibody clone is the same, the antibody 
commercialized by Virostat showed a far superior result probably because of 
the absence of gelatin in the preparation. Gelatin and other stabilizer used in 
commercial antibodies are in fact often found to be incompatible with ELISA 
(Figure 54).  
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Figure 54. Optical density signal obtained with two different commercial sources of 
monoclonal antibody clone 0551. Antibody was used at the same dilution and Virostat was 
superior.  
 
4.3.2 Elution buffers screening 
The protocol used for Nanotrap processing of urine samples preceding the 
ELISA is identical to the one used for the western blot with the exception of 
the elution step. The elution buffer used for western blot contains SDS which 
can compete with the antigen for the binding to the antibody169 and for this 
reason cannot be used in ELISA. 40 mL of urine were spiked with 100pg of 
Lyme antigen and processed with Nanotrap. To effectively remove the Lyme 
antigen from the Nanotrap, without affecting the antibody/antigen interaction, 
several detergents in different concentration were tested. A combination of 
2% n-Octyl-β-D-thioglucopyranoside (OTG) and 0.5% n-Dodecyl β-D-
maltoside (DDM) was proven to be the most successful (Figure 55). 
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Figure 55. Elution efficiency of several elution buffers. Elution performance of several 
detergents was evaluated after Nanotrap processing of urine spiked with Lyme antigen. The 
combination OTG 2% and DDM 0.5% yielded the highest recovery of the antigen. 
  
4.3.3 Linearity of the assay 
40 ml urine samples in duplicate, spiked with 5pg/ml (total protein 200pg), 
1pg/ml (total protein 40pg), 0.5pg/ml (total protein 20pg). Elution was 
performed and in parallel a dilution curve of the Bb antigen was produced 
spiking 2ng/ml, 0.4ng/ml, 0.2ng/ml directly into 100 µL of elution buffer. Lyme 
ELISA showed linearity in the concentration range 2,000 – 75 pg/mL. 
Nanotrap particle preprocessing shifts the linearity range of the assay to the 
concentration range 2 – 0.3 pg/mL, thus improving the effective sensitivity of 
>250 fold (Figure 56). A yield of 90% was achieved and verified by western 
blotting. Linearity was R2>0.98. 
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Figure 56. Linearity of the Nanotrap-based ELISA Test. ELISA is linear in the concentration 
range 2,000 – 75 pg/mL before processing. After Nanotrap processing we obtain a linearity 
range 2 – 0.3 pg/mL which means an increase in sensitivity of >250 fold. 
 
4.3.4 Reproducibility 
The inter assay reproducibility was assessed on three replicates performed 
by two independent operators in three different days. Lyme antigen was 
spiked in urine in four different concentrations (2.5 – 1.25 – 0.6 pg/ml – 
0pg/ml); samples were processed with Nanotrap particles and analyzed with 
ELISA (Figure 57). The inter assay %CV was 2%.  
         
Figure 57. ELISA reproducibility experiment. Samples were spiked in duplicate with 4 different 
concentrations: 2.5 (1) – 1.25 (2) – 0.6 (3) -0 (4) pg/ml. Samples A and B were processed by 
two independent operators. 
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4.3.5 Lower limit of detection 
Four concentrations 5-2.5-1.25-0 pg/ml of Lyme antigen were spiked in 40 
ml of urine in triplicate, processed with Nanotraps and run on the ELISA. 
Data obtained were used to estimate the sensitivity of the assay. The lower 
limit of detection (LLD) was 0.3 pg/mL and the lower limit of quantitation 
(LLQ) was 2.9 pg/mL for a 40 mL urine sample input volume. (Background 
estimate = 0.128 AU, standard deviation (SD) = 0.0025 AU. LLD = 
background + 2*SD, LLQ = background + 10× SD; polynomial equation y = 
0.0016x +0.1325, R2 = 0.9984, was used to estimate the corresponding x 
value (0.3 pg/mL and 2.9 pg/mL, respectively)) 
 
4.3.6 Detection of OspA in early stage Lyme patients with clinical 
evidence of Lyme disease and positive for western blot 
In order to evaluate the performance of our ELISA test, a preliminary set of 
patient samples were selected. All the samples were previously collected, 
processed and run on the western blot. The set consisted of 10 control 
samples collected from healthy volunteers, 4 negative patients with high 
background and non-specific bands, and 3 positive patients. No controls or 
negative patients resulted positive for the ELISA, while the 3 positive patients 
according to the western blot were also positive for the ELISA (Figure 58). 
Positive samples showed an OspA concentration ranging between 0.36 
pg/ml and 7.31 pg/ml (Figure 58). A larger number of samples following CAP 
CLIA regulations will be further analyzed in order to evaluate the possibility 
to transition from western blot to ELISA. 
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Patients AU Estimated Total OspA (pg) Estimated OspA [pg/ml ] 
PID 4567 0.336 292.95 7.31 
PID 5031 0.2055 91.25 2.28 
PID 5041 0.144 14.37 0.36 
Negative 0.116 N/A N/A 
 
Figure 58. ELISA test on patient samples. Optical density measured at λ~450 in patients 
previously diagnosed as positive (PID 4567, PID 5031, PID 5041) and a healthy volunteer 
(negative) for the Nanotrap western blot antigen test. While positive samples scored higher 
than the LLD of the assay, the negative samples scored below the LLD even though the signal 
rises slightly above the background. Estimated concentration of OspA in the patients resulted 
to be within the 0.36-7.31pg/mL range. 
 
4.4 NANOTRAP ENHANCED LFA TEST FOR LYME DISEASE 
 
4.4.1 Nanotrap size increases after reducing treatments 
In parallel to the development of an ELISA test we are investigating the 
possibility to develop a novel low-cost and sensitive lateral  flow  assay  
(LFA), a format  ideal  for  point  of  care  applications  in  which  the antigen 
is detected directly on the particles by the biorecognition molecules on the 
nitrocellulose   membrane   of   the   assay.  Because of the meshwork-like 
structure of our Nanotraps the internal surface area vastly exceeds the 
superficial surface. Because the 3D structure and the pore size of the 
Nanotraps depend on the amount of cross-linker, incorporating a degradable 
cross-linker can effectively open up the Nanotrap and display the captured 
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analyte without the need of an elution buffer.  N-isopropylacrylamide 
(NIPAm) Nanotraps were synthesized via dual cross-linking (degradable 
N,N’-(1,2-Dihydroxethylene)-bisacrylamide [DHEA] and nondegradable 
N,N’-methylenebis(acrylamide) [BIS]  crosslinkers, and  then functionalized 
with Remazol Brilliant  Blue  dye. DHEA can be degraded through  an  
oxidizing  reagent, NaIO4, causing an increase in the  particle pore size that 
allows the antibody in the LFA to directly access the antigen captured  by  
the  particles.  Light scattering analysis of degradable Remazol brilliant blue 
Nanotraps before DHEA degradation show an average diameter of 987 ± 
16.01 nm while after degradation the diameter increases to 1119.2 ± 40.87 
nm. 
 
4.4.2 Dot-blot for in-situ recognition of OspA 
100µL of Remazol Brilliant Blue functionalized degradable Nanotraps were 
used to process 500 µl of urine sample spiked with 10ng of OspA. After 
antigen capturing the Nanotraps were exposed to NaIO₄ centrifuged and 
resuspended in 20 µl of water. A serial dilution of the Nanotraps containing 
OspA and empty partially degraded Nanotrap (negative control) as well as 
OspA (positive control starting from 1ng) were then spotted (5µL) on a 
nitrocellulose membrane and dot blot was performed. A strong signal in the 
presence of the partially degraded Nanotraps containing OspA can be 
visualized on the dot-blot thus showing the ability of the antibody to access 
the captured Lyme antigen directly on the Nanotrap following crosslinker 
dissociation; only a faint background signal is visible in the presence of empty 
Nanotraps (negative control) (Figure 59). 
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Figure 59. Partially degradable Nanotraps are able to successfully capture and display OspA 
in solution. The antigen retains the capability to bind to the antibody when it is bound to the 
affinity probe incorporated in the Nanotrap after oxidation. The negative control of oxidized 
particles in the absence of antigen shows only a faint background signal.   
  
4.4.3 Assessing recovery and OspA capturing through western blot 
OspA spiked urine samples were processed with degradable Nanotrap and 
capturing performance before and after degradation was assessed with 
western blot. Complete depletion of the supernatant as well as full recovery 
of OspA is obtained with DHEA Remazol Nanotraps. Nanotrap oxidation 
does not affect the antigen and the band intensity relative to OspA is 
comparable in Nanotraps before and after oxidizing treatment (Figure 60). 
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Figure 60. Western blot directed against OspA using degradable Nanotraps. The first gel was 
loaded left to right as follows: molecular weight maker, positive control, initial solution, 
supernatant, sample A (non-oxidized particles), sample A diluted 1:2, sample A diluted 1:4, 
sample C, sample C (oxidized particles), sample C diluted 1:2, and sample C diluted 1:4.   The 
second gel was loaded left to right as follows: molecular weight maker, positive control, initial 
solution, supernatant, sample B (non-oxidized particles), sample B diluted 1:2, sample B 
diluted 1:4, sample D, sample D (oxidized particles), sample D diluted 1:2, and sample D 
diluted 1:4. Supernatant is depleted. Recovery of OspA is obtained before and after oxidation. 
 
4.4.4 Development of NANOTRAP-BASED Lateral Flow Immunoassay 
Remazol Brilliant Blue partially degradable Nanotraps were incubated with 
urine spiked with OspA. After processing the Nanotraps were placed on a 
lateral flow device previously treated with PEG blocking solution and where 
an antibody line (anti-OspA) was manually spotted. The membranes were 
then checked for the presence of an antibody line (Figure 61). The Nanotraps 
incubated with OspA were shown to quickly flow through nitrocellulose 
membranes to the adsorbent pad at the end of the strip. The Nanotraps then 
successfully bound primary OspA antibody spotted directly on the 
membrane, producing a visible test line on the lateral flow strip. 
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Figure 61. Lateral flow assay with partially degradable Nanotraps. Lateral flow assays 
conducted with poly(NIPAm-DHEA-Remazol Brilliant Blue R) Nanotraps pre-incubated with 
varying concentrations of OspA (from left to right: negative control, 0.5ng/ml, 1ng/ml, 1.5ng/ml, 
2.0ng/ml, and 4.0ng/ml) and run through nitrocellulose membranes blocked with PEG (500 
mg in 10ml water).  Arrows indicate test lines where the OspA primary antibody was spotted 
directly on to the membrane prior to blocking and the antigen sequestered by the Nanotrap 
bound to it. 
 
In  the  future,  characterization  of  the  test  in  terms  of  sensitivity  and 
reproducibility  will  be  performed.  Further optimization of the test will include 
pre-treating the membrane with a surfactant to improve the wicking rate of 
the nitrocellulose membrane and the overall sensitivity of the assay. 
 
 
4.5 NANOTRAP-ENHANCED MULTIPLE REACTION MONITORING 
FOR THE DETECTION OF LYME DISEASE 
 
4.5.1 Selection of new panel of Borrelia burgdorferi antigens 
In order to further improve the specificity of our antigen test, the detection of 
a panel of Borrelia proteins indicative of an active infection instead of a single 
protein would be ideal. Mass-spectrometry analysis of Borrelia burgdorferi 
lysate was performed. After label free spectral counting (scaffold analysis) of 
the LC-MS/MS results, a total of 241 NCBI annotated proteins were identified 
(Supplementary Table 7). OppA, OspB, OspC, OspA, p66, FlaB, BmpA, FliL, 
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Rev, DbpA, VISE, BmpB were selected, based on their importance in 
different stages of the disease, as candidates for a Lyme disease panel for 
a future Nanotrap-based assay (Table 1).  
 
Table 1. Selection of clinically relevant biomarkers for different stages of Lyme disease from 
mass-spectrometry analysis of B. burgdorferi lysate. 
 
Current instrumentation allows for the measurement of many proteins in a 
single sample, making MRM an ideal assay to perform high-throughput 
measurements on a panel of target proteins170,171. Successful application of 
the MRM assay for detection of Borrelia proteins in human skin biopsies has 
been recently reported144, however, direct MRM assay in human blood or 
serum for early detection of Lyme disease poses additional challenges due 
to the extremely low abundance of total circulating Borrelia proteins. 
Preliminary results obtained separating bacterial membrane vesicles from 
the blood of individual affected by Lyme disease through high-speed 
centrifugation suggested the possibility to use MRM detection for B. 
burgdorferi infection172. Although MS MRM is a powerful and absolutely 
specific method for multiplex protein quantification, it has low sensitivity (50 
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ng/mL)173. Our Nanotrap technology, has already proved to be able to 
enhance sensitivity for MRM that ranges from 100 fold to 1,000 fold 
depending on the input volume50. Because of the versatility of Nanotrap 
different downstream assays can be coupled with Nanotrap processing with 
minor modification of the sample processing protocol. In our case, several 
elution buffers were tested in order to find the optimal condition in 
compatibility with mass-spectrometry.  
 
4.5.2 Assessing Elution Efficiency with degradable surfactants that are 
compatible with mass spectrometry analysis  
Several surfactants, that have proven to be valuable elution buffers to extract 
proteins from Nanotraps, are not compatible with mass-spectrometry. For 
this reason we selected a reversible detergent (RapiGest SF surfactant, 
Waters) that we have shown to solubilize and liberate the pathogenic protein, 
but will not interfere with mass spectrometry.  
RapiGest SF helps solubilize proteins making them more susceptible to 
enzymatic cleavage without significantly inhibiting enzyme activity and is 
heat stable for higher temperature digestions. RapiGest SF is compatible 
with enzymes such as Trypsin, PNGase F, Lys-C, Arg-C, Asp-N, Glu-C and 
other enzymes. This reagent is easily removed after use allowing MALDI-
TOF MS, LC or LC/MS analyses of digested samples. Rapigest SF can be 
easily hydrolyzed in acidic solution; its half-life is 8 min. at pH 2 and 60 min. 
at pH 3 (Figure 62). 
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Figure 62. RapiGest SF hydrolyzes in acidic solutions. (Source: Waters, 
http://www.waters.com/waters/en_US/Home/nav.htm?cid=1000941&locale=en_US#FACET
ED_NAVIGATION&locale=en_US) 
 
40 mL of urine spiked with 2.5, 5, 10, 25, 50 and 100 pg/mL of Borrelia lysate 
in duplicate. Samples were incubated with the Nanotrap particles, washed 
according to the patient processing sample (page X). One set was eluted 
with 20ul of 2 X sample buffer (5% TCEP) and western blot was performed. 
The other set was eluted 20µl of 1% Rapigest in 50 mM ammonium 
bicarbonate. Elution were acidified with 0.1% TFA in order to degrade the 
surfactant. Samples were reduced, alkylated and trypsinized and zip-tip 
processing was performed before loading them on the mass-spectrometer. 
OspA was monitored for peptide GYVLEGTLTAEK using precursor 640.84 
2+ and transitions 719.40, 848.43, and 961.52 (Figure 63). Another protein. 
OspB, which is supposed to have an important role in the pathogenesis of 
the disease was monitored for peptide ATIDQVELK using precursor 508.78 
2+ and transitions 422.74, 731.40, and 844.48 (Figure 63). Results were 
analyzed using Skyline (Univ. of Washington) and reported as the area under 
the curve for transition 961.52 from peptide GYVLEGTLTAEK and transition 
844.48 from peptide ATIDQVELK. Peptides GYVLEGTLTAEK (OspA) and 
ATIDQVELK (OspB) were detectable down to 5pg/mL and 10pg/mL, 
respectively. In addition, both peptides demonstrated excellent linearity 
across the entire concentration range up to 100pg/mL, with an R2 of 0.9941 
for peptide GYVLEGTLTAEK, and an R2 of 0.9883 for peptide ATIDQVELK. 
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Figure 63: MRM sensitivity and linearity for nanotechnology enhanced MRM bacterial antigen 
test in urine (Lyme disease). Upper Left: western blot analysis showing OspA and OspB 
proteins in the bacterial lysate. U=urine negative control, IS=initial solution urine containing 
OspA and OspB spike ins, S=supernatant after Nanotrap incubation, P=Nanotrap particle 
pellet after protein elution, E=Nanotrap eluate. Upper and Lower Right: mass analysis of OspB 
and OspA specific transition ions. Minimum detectable concentration in human urine is 10 and 
5 pg/mL, respectively. Lower Left: Linearity of the MRM assay is R2 = 0.9941 and 0.9883 for 
OspA and OspB specific transition ions respectively.   
 
In order to expand the panel of Borrelia antigens that could be detected in 
patients’ urine, other proteins relevant in the first stage of the disease and 
previously identified by Mass-spectrometry in the Borrelia lysate 
(supplementary table 7) will be investigated with the MRM. Aminopeptidase 
will be monitored for peptide GADSNFLSEVLER using precursor 718.85 2+ 
and transitions 1106.58, 992.54, 845.47, 732.38, and 645.35 
(Supplementary table 8). P34 will be monitored for peptide 
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YEDLINPIEPIIPSESPK using precursor 1027.53 2+ and transitions 1533.85, 
1420.76, and 1306.72. FLiL will be monitored for peptide 
LALGYAENNVNELGR using precursor 816.92 2+ and transitions 1115.54, 
1044.50, and 915.46. p66 will be monitored for peptide 
NTNNAAIGSAFLQFK using precursor 798.41 2+ and transitions 1152.64, 
1081.60, 1010.56, 897.48, 840.46, 753.42, and 682.39. OppA will be 
monitored for peptide SWNISEDGIIYTFNLR using precursor 964.48 2+ and 
transitions 1211.64, 1096.61, and 1039.59. BmpA will be monitored for 
peptide IGFLGGIEGEIVDAFR using precursor 846.95 2+ and transitions 
1375.72, 1262.63, 1205.61, 1148.59, 1035.51, 906.46, and 849.44. Flagellin 
will be monitored for peptide NSTEYAIENLK using precursor 641.31 2+ and 
transitions 1080.55, 979.50, 850.46, 687.40, and 503.28. 
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5. DISCUSSION 
 
5.1 HYDROGEL NANOTRAPS ENHANCE THE DETECTION OF 
LOW-ABUNDANCE BIOMARKERS 
Biological fluid samples are thought to contain low-abundance proteins and 
peptides which can provide a rich source of information regarding the state 
of the organism as a whole. Peptidome/LMW proteome is an important 
source of disease-specific information for the early detection of several 
diseases, for a better diagnosis and prognosis and for monitoring drug 
toxicity, and drug abuse. The detection of novel clinically relevant protein 
biomarkers in body fluids represents a huge challenge because of the 
complexity of the circulatory proteome, the low concentration and the lability 
of the candidate biomarkers. Important diagnostic biomarkers may exist in 
extremely low concentration in blood and other bio-fluids. For example early-
stage diseased tissue, such as pre-metastatic cancer lesions, may constitute 
less than a few cubic millimeters and biomarkers shed into the circulation 
from such a small tissue volume will become highly diluted in the entire blood 
volume. Early stage infections may also be difficult to detect because the 
disease agent may not have reached a sufficient titer in the host and its level 
will fall below the detection limit of mass spectrometry and conventional 
immunoassays. Furthermore low abundance biomarkers/proteins are 
masked by the presence of high abundant proteins such as albumin and 
immunoglobulin and they are susceptible to degradation by endogenous and 
exogenous proteinases following venipuncture and sample 
transport/storage.  
Hydrogel Nanotraps represent a powerful tool that can be used to facilitate 
biomarker research. The novel aspect of dye-functionalized Nanotraps is 
their ability to perform both an affinity capture and a size exclusion 
chromatography in one step in solution, allowing to capture and concentrate 
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low abundance analytes. Depending on the goal of the study, unbiased 
biomarker discovery or affinity capture of a target analyte, different affinity 
“baits” - that show preferential affinity with selected classes of proteins - can 
be easily incorporated into the core of the Nanotraps. The ability of the 
Nanotraps to capture and concentrate biomarkers from several mL of 
biofluids while excluding all of the high abundance resident proteins such as 
albumin and immunoglobulins, provides a concentration step that is 
equivalent to injecting several mL of sample into a gel electrophoresis or 
mass-spectrometry at once, thus dramatically increasing the detection 
sensitivity of the assay and allowing to measure previously invisible proteins. 
In this study we evaluated the application of hydrogel Nanotraps for the 
capturing of Borrelia antigens in urine with the final goal to create the first 
highly sensitive urinary antigen test for the detection of Lyme disease.  In this 
study, the Nanotrap pre-processing step was successfully coupled to 
western blot analysis, ELISA, lateral flow immunoassay and MRM to perform 
a qualitative screening for the presence of the bacterial antigen in solution, 
allowing the detection of Borrelia antigens present in urine in concentrations 
as low as 0.3pg/ml.  
Optimization of sample processing parameters prior to testing patient 
specimens is mandatory. An optimum ratio of Nanotraps to sample volume 
needs to be established. A dose-response curve using recombinant proteins 
is also necessary to determine the limits of detection of particular analytes. 
Differently functionalized Nanotraps as well as different elution buffers were 
thus tested in this study in order to determine the ideal Nanotrap for 
harvesting of Lyme antigens in the given specimen.  
In order to avoid the use of an elution buffer and allow the in-situ recognition 
of the antigen bound to the Nanotraps by an antibody a novel prototype of 
partially degradable Nanotraps have been successfully synthesized. Cross-
linkers such as Dihydroxyethylenebis-acrylamide (DHEA), 
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bis(acryloyl)cystamine (BAC), 1-(4-Sulfophenyl)-3-methyl-5-pyrazolone and 
Fast blue 221 allow the formation of hydrogel Nanotraps that could be 
partially degraded under certain chemical conditions resulting in an increase 
in the diameter and pore-size of the Nanotrap which allow high molecular 
weight proteins like immunoglobulins to access the antigen on the Nanotrap 
itself. 
 
5.2 OSPA MONOCLONAL ANTIBODY SPECIFICITY 
In this study, the specificity of the mAb clone 0551 used in the Nanotrap test 
was verified in three ways: (1) peptide competition and immune affinity 
depletion, which revealed absolute specificity for a narrow C-terminus 
sequence of OspA that was conserved in all the Borrelia burgdorferi sensu 
latu species. (2) Viral and bacterial lysates of HSV, EBV, HCV, CMV, 
Babesia, and Bartonella tested at the same antigen concentration as the 
OspA Borrelia antigen were devoid of immunoreactivity with the mAb clone 
0551 and did not interfere with the recognition of OspA. This was done using 
the entire Nanotrap concentration system with test antigens spiked in human 
urine. (3) BLAST sequence analysis of HSV, EBV, HCV, CMV, Babesia, 
Bartonella, Rickettsias, human genome database and other non Borrelia 
spirochetes showed no significant similarity with the defined and verified C-
terminus OspA epitope domain. It’s important to note that the specific domain 
recognized by the mAb clone 0551 is OspA236-239. This region is quite 
distant on the OspA molecule from the region that was shown in the past to 
have sequence similarity with human proteins (OspA154-173 = 
GSGKAKEVLKGYVLEGTLTA174). Based on the conservation of the epitope 
OspA236-239, the specificity of our test should extend to all the pathogenic 
Borrelia species in the US and Europe (Table 2). In the future, it will be 
important to verify the sensitivity and specificity obtained in this study to 
geographically diverse populations. Previously published attempts to 
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measure Bb proteins and nucleic acids in urine175,176 may have been 
compromised by enzymatic degradation and lack of specificity of the 
diagnostic epitope. The Nanotrap particle technology used in this study has 
been previously shown to protect the captured analyte from degradation, 
including nucleic acids39,177.  
 
5.3 SHEDDING OF OSPA PROTEIN IN THE URINE OF PATIENTS 
WITH A DIAGNOSIS OF EARLY STAGE LYME BORRELIOSIS 
A highly sensitive urine antigen test has potential utility in the management 
of Lyme disease. A direct antigen test for the bacteria, instead of a serologic 
test, offers a mean to detect the infection before the immune response is 
mounted. Because previous immunoassays for the detection of bacterial 
proteins in the patient's urine have been judged unreliable due to inadequate 
sensitivity several question remained unanswered.  
The goals of the study were to answer the following questions: Is Bb OspA 
antigen shed in the urine of patients with LB at early stage disease prior to 
the development of a positive serology? What is the urinary OspA 
concentration range? Is the OspA antigen containing the C-terminus epitope 
shed into urine as a full length protein or as fragments? Does the presence 
of OspA in the urine of a patient with an EM rash suspected of having LB 
correlate with the concurrent or later development of positive serology 
(western blot or ELISA)? If urinary OspA is present prior to antibiotic therapy, 
is it reduced or absent after successful therapy (resolution of symptoms)? 
What percentage of patients suspected of having persistent or recurrent LB 
contain urinary OspA C terminal domain antigen? 
Borrelia OspA plays a central role in the survival of the spirochete in the tick 
vector139. During the initial phases of a cutaneous infection following a tick 
bite, OspA is recognized by innate immune cell Toll-like receptor TLR2, and 
together with TLR8, initiates a cascade of proinflammatory cytokines, such 
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as interleukin 1 and T-helper derived cytokines that are thought to mediate 
the initial inflammatory reaction179. OspA is upregulated in response to 
inflammatory cues by host-adapted Bb later in the course of disease180–182. 
In previous studies, specific complexed antibody to whole Bb and 
recombinant OspA were detected in 10 of 11 of the EM positive patients 
compared to 0 of 20 endemic area controls103. IgM was the predominant 
isotype recognizing OspA in these EM patients. Free IgM to OspA was found 
in half the EM cases. IgM to OspA was also detected in 10 of 10 European 
patients with EM who also had reactive T cells to recombinant OspA103. In 
longitudinal studies of serial serum samples from untreated patients 
(collected prior to the use of antibiotic therapy for Lyme disease treatment), 
elevation of IgG reactivity to OspA parallels the rising of the antibody 
response to Bb proteins183,184. Animal models have shown that Borrelia 
antigens are shed into the urine following infection145. For example in early 
studies of Borrelia infection of mice in the wild, 76% of 50 mice (white-footed 
mice Peromyscus leucopus) shed Borrelia antigens, including OspA, into the 
urine145, although the timing of the antigen shedding over time and the 
relative nanomolar concentration of different Borrelia proteins was not 
determined due to the nature of the assay and its sensitivity limits.  In keeping 
with animal model studies, OspA antigen shedding prior to antibiotic 
treatment occurred in the urine of 24/24 patients with a positive EM rash and 
clinical symptoms of LB (Table 4). In contrast, none of 117 untreated patients 
who were non symptomatic, or were non symptomatic and concurrently 
serology negative for LB, shed urinary OspA C-terminal antigen.   
 
5.4 OSPA ANTIGEN IS SHED INTO URINE EITHER AS A FULL 
LENGTH PROTEIN, OR AS A FRAGMENT CONTAINING THE C-
TERMINUS DOMAIN 
Pepsin fragmentation, followed by mass spectrometry sequencing and 
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synthetic peptide competition, identified the anti-OspA mAb binding domain 
to reside in the C-terminus region of OspA (Figure 32, Supplementary Table 
3). In previous studies, IgG titers to OspA (and to a lesser extent, OspB) in 
untreated patients 103 correlate directly with severity of chronic Lyme arthritis, 
while IgG titers to the C-terminal third of OspA (OspA168–273) correlate with 
both severity and duration, suggesting the strongest causal link with epitopes 
contained within this fragment184. The C-terminal quarter of OspA (218-273) 
is also highly conserved among a large number of pathogenic species of 
Borrelia sequenced to date146,147. The specific C-terminus peptide sequence 
(Supplementary Table 3) of the antigenic epitope showed no sequence 
homology with any human protein and did not have any sequence homology 
with non-Borrelia spirochetes. The size of the OspA antigen shed into the 
urine in the present study (Figure 48) was close to the expected size of the 
full length OspA protein (approximately 31kDa) which is small enough to be 
filtered through the kidney glomeruli. In some cases fragments of OspA 
containing the C-terminus fragment epitope were detected below the size of 
31 kDa. The existence of these fragments may indicate in vivo degradation 
of the antigen, since we have established that Nanotrap particle capture fully 
stabilizes the captured analyte and prevents enzymatic degradation29,50,185. 
 
5.5 CORRELATION OF URINARY OSPA PROTEIN WITH POSITIVE 
LYME BORRELIOSIS SEROLOGY AND PERSISTENCE OF 
SYMPTOMS 
The clinical diagnosis of acute early stage LB is often based on the history 
of deer tick exposure and clinical evaluation of skin lesions. Unfortunately the 
skin lesion appearance can be quite variable and the differentiation from 
arthropod bite reactions, gyrate erythemas and other erythematous skin 
conditions can be difficult. In 10% of infected patients LB is not considered 
and many patients are misdiagnosed (in one study 37%177). The literature is 
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mixed in relation to the incidence of Erythema Migrans in acute Lyme 
disease, ranging from as low as 25%186 to as high as 80%127. This potentially 
means that a substantial number of individuals presenting with acute Lyme 
disease will not manifest EM rash but perhaps only nonspecific “flu-like” 
symptoms. In fact, Feder stated that “patients from Lyme disease endemic 
areas who have fever and fatigue, especially within a month following a deer 
tick bite, should be considered for empiric antibiotic therapy for early 
localized Lyme disease”, regardless of whether an EM rash is present185. The 
technology we are presenting may provide additional objective information 
to assist the clinical diagnosis and to monitor antigen shedding during the 
course of therapy. A potential value of the urinary assay reported in this study 
is the evaluation of whether an initial course of therapy is sufficient to 
eradicate the infection. In 1994 Shadick et al.164 evaluated 38 adult patients 
diagnosed with Lyme disease, having fulfilled established serologic criteria 
at the time of the study. Initial antibiotic treatments ranged from 10 to 21 days 
of a standard regimen. Ten of 38 patients with Lyme disease reported 
relapses within 1 year of treatment (fatigue, persistent arthritis or arthralgias, 
headaches, or difficulty with memory and concentration). In 2014, Aucott, et 
al.187 assessed the clinical response of 77 individuals presenting with an 
acute EM rash and completing a standard 3 week course of doxycycline. 
After 6 months, 39 % of this group had persistent functional impairment 
and/or persistence of new symptoms felt to be related to the acute infection. 
In 1999 Oksi et al. reported the clinical relapses of disseminated LB 
confirmed by culture and PCR, with various clinical presentations such as 
arthritis, neuropathy and uveitis163. Potential mechanisms contributing to this 
persistence of B. burgdorferi in human163 and animal models188–191 have been 
identified. These include: immune evasion via physical seclusion of Bb within 
immunologically protected tissue sites such as the CNS, joints and eyes99,190–
192, collagen-rich tissue191, cells193, and biofilms194; alterations in Osp profiles 
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through antigenic variation195–198, phasic variation183, and alteration in Bb 
morphology (including cell-wall deficient forms, spherocytes and ‘cyst’ 
forms)132,199–205; immune modulation via alterations in complement206–208, 
neutrophil and dendritic cell functioning209,210, and changes in cytokine and 
chemokine levels211–213 and innate antibiotic tolerance of some B. burgdorferi 
populations214. Theoretically, Nanotrap technology would have the capacity 
to determine which, if any of these individuals had perpetuation of their 
symptoms due to ongoing infection. Antibodies specific to B. burgdorferi 
proteins can take61 three to four weeks to develop, and early stage Lyme 
disease, prior to the appearance of a serologic titer, is extremely difficult to 
diagnose due to the low sensitivity of current diagnostic tests for B. 
burgdorferi antigen. For this reason, treating physicians worry that Lyme 
serology is unreliable for early stage disease because the development of 
antibodies differs widely, especially in the early stages of the infection126,215. 
In prior studies177, only 43 % had a positive serology at the time of cutaneous 
EM positive LB diagnosis. Thus, the inflammatory reaction manifest in the 
border of the LB EM rash contains proliferating spirochetes and the 
inflammatory infiltrate is the result of innate immune recognition of OspA. By 
definition it would be expected that OspA protein antigen would be shed into 
the circulation and be concentrated in the urine for a significant time period 
prior to the development of a positive serology with 5 IgG bands as specified 
under CDC guidelines126. Prior to antibiotic treatment, in this study, 24/24 
patients with an EM rash contained OspA protein in the urine, verified by 
peptide competition. Our analysis was blinded to outcome. Based on the 
sensitivity and dose response of the assay, the concentration range was 
between 1.7 and 30 pg/mL. 5 of these 24 early stage patients were serology 
negative and 3 had an equivocal serology at the time of urine collection and 
clinical diagnosis. Following antibiotic therapy of patients with a clinical 
diagnosis of LB, 10/14 patients with a positive serology were found to be 
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positive for urinary OspA in this study. Following antibiotic therapy for a 
clinical diagnosis of LB, 10 patients in this study were serology negative. 4/10 
of these post-treatment patients were negative for urinary OspA. Importantly, 
for 10 patients who exhibited persistence of the EM rash during the course 
of antibiotic therapy, 10/10 were positive for urinary OspA. In contrast 4/10 
of these same patients who had the EM rash during antibiotic therapy 
ultimately became serology positive. Urinary OspA measurement of 8 
patients for whom the therapeutic response was judged complete (absence 
of EM rash and absence of symptoms) following antibiotic therapy revealed 
that all 8 patients switched from being urinary OspA positive to urinary OspA 
negative (Table 4). 4 of these 8 patients were subsequently found to be 
serology positive for Bb infection. These data are in keeping with the 
correlation of urinary shed of OspA and the presence of concurrent objective 
symptoms (EM rash). When CDC criteria serology, and in accord with the 
Infectious Diseases Society of America (IDSA), was compared to urinary 
OspA regardless of pre or post treatment status of early stage LB, 87.5 % of 
serology positive were also urinary OspA positive and 88 % of serology 
negative were also urinary OspA negative (Chi squared p value = 4.072e−15; 
significance level = 5 %, power = 99.99 %, Table 5). The remaining 12 % of 
patients who were urinary OspA positive who were serology negative 
demonstrated positive symptoms qualifying for clinical diagnosis of LB and 
may not have yet mounted an antibody response. In this study, 100 % of pre 
and post treatment samples that had active symptoms were found to be 
positive for detectable urinary OspA (40/40, Table 4). Urinary OspA outcome 
(positive) was significantly associated with presence of clinical symptoms 
(EM rash, Chi squared p value <2.2e−16; significance level = 5 %, power = 
100 %). Of these 40 patients, 22 were serology positive by CDC standards 
for early stage disease144. This is in keeping with prior studies showing 
positive serology in approximately 50 % of early stage cutaneous LB 
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patients177. Early prompt treatment of LB is known to blunt the serology 
response because the infection and immune response is being interrupted 
at an early stage216,217. 
 
 
5.6 URINARY OSPA IN PATIENTS SUSPECTED OF HAVING 
“CHRONIC” LB 
Lyme disease is too often diagnosed after the infection is well established 
and the patient has raised an antibody titer against the bacteria B. 
burgdorferi218. Persistent LB, treatment resistant, recurrent, or a new LB is 
also extremely difficult to diagnose when the serologic titer is equivocal or if 
the patient has persistent symptoms (e.g. neurologic, arthritic, or 
dermatologic) in the face of therapy. Unfortunately patients with clinical 
history of LB (serology positive or serology inconclusive) can present with 
articular and neuromuscolar symptoms. Lack of response to treatment can 
theoretically be due to persistence of infection via one or more mechanims 
already discussed, such as sequestration in tissue or biofilm. Given the 
polymicrobial nature of tick borne illnesses, infection with one or more 
different pathogens is a consideration139,219–222. On the other hand, 
persistence of symptoms has been postulated to be the result of a new LB 
infection, or perhaps to improper diagnosis of LB and unrelated co-existing 
musculoskeletal morbidity or to persistence of infection in a sequestered 
tissue such as joint cartilage223, or biofilm224. In this study, we evaluated the 
level of urinary OspA protein in 100 previously or currently treated patients 
with joint, neurologic, and other objective symptoms (Supplementary table 
2). This group of patients were being evaluated for the potential of recurrent 
or persistent infection with Borrelia. Our analysis was blinded to outcome. 41 
of 100 (41 %) patients were positive for urinary OspA protein. This 
percentage of positive urinary OspA, assuming that it reflects a specific 
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infection by Bb that is shedding OspA C-terminal fragments, is in keeping 
with prior studies. Patients evaluated in endemic LB regions who presented 
with arthritis and neurologic symptoms were estimated to have active and 
prior LB (7–31 % active disease and 5–20 % previous Lyme disease in 
endemic areas166–168). IDSA and ILADS differ in their recommendations for 
the clinical assessment and treatment of persistent LB. A highly specific 
antigen test for Borrelia proteins might provide new class of evidence to 
refine the guidelines for diagnosis and treatment of LB. It is widely 
acknowledged that patients suspected of having chronic Lyme borreliosis 
based neurologic or joint symptomatology may not truly have Lyme 
borreliosis, or may have other tick borne diseases. Therefore in patients who 
are suspected of having chronic Lyme disease, as evaluated in the present 
study, there has not been a means to assess the true positive patients. Most, 
if not all, of these patients have a negative Lyme serology by the 2 tier criteria. 
Although we feel confident that a positive outcome of our test reflect the 
presence of an active Borrelia infection, our findings that 41 % of these 
“chronic patients” are positive cannot be defined as a level of sensitivity and 
specificity, since there is not an alternative mean beyond our test to assess 
that these patients could actually have had an active Borrelia infection. 
Importantly, our data provides the first antigenic evidence that at least 41 % 
of these patients may have an active Bb infection. Therefore these data 
contribute significant new information to the debate about chronic Lyme 
disease. 
 
5.7 ALTERNATIVE FORMATS FOR THE DETECTION OF LYME 
ANTIGEN IN URINE: ELISA, LATERAL FLOW IMMUNOASSAY, 
AND MRM 
Successful results have been obtained coupling Nanotrap processing with 
an ELISA assay, which permitted the detection of OspA at concentrations as 
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low as 0.3pg/ml starting from 40 ml of urine. 3/3 samples with clinical 
symptoms and positive on our western blot also resulted positive with ELISA. 
Clinical samples are currently received at George Mason University and are 
processed with Nanotraps and analyzed through western blot. A larger 
number of samples will be tested in parallel with western blot and ELISA, 
following CAP CLIA guidelines, in order to transition from a western blot to 
an ELISA format of the test with the goal of eventually outsource it to 
independent clinical laboratories. MRM coupled with Nanotrap processing of 
urine samples has also shown very promising results, allowing the detection 
of OspA in urine sample (40 ml) at a concentration as low as 5pg/mL. 
Although according to our data this would be sufficient to detect OspA in 
many infected patients, further optimization of the protocol will be necessary 
to lower the detection limit and reduce the number of potential false 
negatives. The development of a novel partially degradable type of Nanotrap 
allowed us to engineer a Lateral Flow Immunoassay that would serve the 
need of a point of care test. These Nanotraps after partial degradation are 
able to flow through a nitrocellulose membrane and expose the OspA cargo 
for the direct recognition by an antibody. Because of the intrinsic color of the 
functionalized Nanotraps, their immobilization due to the antibody 
recognition of the antigen will result in the formation of a colored line on the 
lateral flow immunoassay within seconds from the deposition of the Nanotrap 
on the device.  
 
5.8 SELECTION OF NOVEL BIOMARKERS 
Measurement of a panel of Lyme antigens in the urine of patients with 
different stage of Lyme disease, as opposed to a single antigen, is an 
important clinical goal for surveillance and monitoring of Lyme disease. 
Mass-spectrometry analysis of B. burgdorferi lysate allowed us to select a 
panel proteins that are well represented in the bacterial lysate and are 
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thought to benrelevant for human pathogenesis. According to different 
studies only few antigens are expressed by B. burgdorferi in very early 
infection such as FlaB, p66, RevA, oligopeptide permease A1 (OppA1), 
OppA2, and OppA4 215,225,225–227, while OspC (25 kDa), VlsE, BBK32, FlaA 
(37 kDa), BmpA (39 kDa), FliL, BBG33, LA7, and DbpA proteins still appear 
in the early stage of infection although slightly later125,127,228–233. These 
antigens will be evaluated as potential candidate for our Nanotrap based 
immunoassay and MRM test. 
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6. CONCLUSIONS 
 
Hydrogel Nanotraps covalently functionalized with combinations of molecular 
dye baits offer a one-step technology for biomarker harvesting, 
concentration, and preservation from degradation, with simultaneous 
exclusion of unwanted abundant molecules such as albumin and 
immunoglobulins. Nanotraps can be used to dramatically increase the 
chance of identifying and measuring proteins and peptides from complex 
biofluids such as blood, urine, CSF, sweat, saliva, vitreus and any biologic 
solution-phase sample. Our hydrogel Nanotraps have been used for 
biomarker discovery as well as for the development of new diagnostic tests. 
The results from this study indicate that bait loaded hydrogel Nanotraps are 
suitable to sequester bacterial proteins, such as Lyme disease B. burgdorferi 
antigen in urine and concentrate them in a small volume that can be analyzed 
by immunoassays or mass-spectrometry. Once captured and concentrated 
in the Nanotraps, the Bacterial antigen can be detected using immunoassays 
or MRM with an enhanced sensitivity, more than 400 fold starting from an 
initial volume of 40 mL of urine. Because of the significance of OspA in the 
pathogenesis of Lyme disease we focused on the synthesis and 
functionalization of Nanotraps that could capture this protein with high affinity 
and developed a western blot test that could target a particularly conserved 
C-terminal region of this protein. Our data support the hypothesis that urinary 
OspA protein fragments containing the C-terminal domain occur prior to the 
development of a full IgG serology response, and urinary OspA strongly 
correlates with a clinical diagnosis and active clinical symptoms (e.g. EM 
rash positive) of early stage LB. Because the C-terminal domain is conserved 
among most of the pathogenic species of Borrelia, our Nanotrap-based test 
can potentially be employed for the detection of Lyme disease in the 
Americas, Europe and Asia with a greater chance of success compared to 
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current serological tests that are mostly targeted towards US strains129,130. 
Thus, this technology has the potential to provide clarity in the settings of 
individuals at risk of tick exposure and acutely presenting with either an 
atypical EM rash or without a rash at all, but consistent with the nonspecific 
findings of acute Lyme. Moreover, persistence of objective clinical 
manifestations in these patients was accompanied by continued shedding of 
urinary OspA even during the course of treatment. In contrast, after 
successful resolution of symptoms in promptly treated early stage LB, urinary 
OspA protein became undetectable (Table 4).  
Antigenuria in the setting of chronic persistent symptoms may be due to new, 
acute infectious exposures. Alternatively, antigenuria detected in individuals 
with consistent, persistent symptoms would warrant consideration of an 
ongoing active infection, supportive of the concept of LB in the chronic active 
state.  
PCR analysis of urinary Borrelia, or urinary Borrelia culture was not done, 
because of the very low MRM sensitivity of these tests in human urine149. 
Consequently, a weakness of this study is that a true positive diagnosis of 
LB could only be based on the CDC clinical criteria (e.g. EM rash and other 
objective symptoms), and the development of a later positive serology in 
patients who underwent therapy at the time of the clinical diagnosis of LB. 
Despite this weakness, the strong correlation of urinary OspA with treatment 
response may offer a new class of information to assist the treating physician 
to determine whether a first round of therapy is successful in primary 
cutaneous early stage LB. In a population of patients being under 
surveillance for persistent or recurrent LB, the percentage of positive urinary 
OspA patients is in keeping with previous studies on patients estimated to 
actually have LB in endemic areas. It is impossible to know if urinary OspA, 
assuming that is indicative of Bb infection, is caused by a recurrent or new 
infection. Urinary OspA measurements may provide additional information to 
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assist the clinical workup of patients under investigation of disseminated later 
stages of LB. Considering the interest for the test by independent clinical 
laboratories we are currently transitioning from a western blot test to an 
ELISA. Even though the materials used to synthesize the Nanotraps are 
relatively inexpensive, a western blot format is time consuming and cannot 
be easily scaled-up. An ELISA on the other end could be easily employed by 
diagnostic laboratories, automatized for the processing of a larger number of 
samples thus reducing the cost per patient. In parallel a highly sensitive 
nanotrap MRM test is under development and provided very promising 
preliminary results. A lateral flow immunoassay employing antigen-
displaying Nanotraps that can be used as a point of care test has also been 
successfully tested using model solutions. For the next generation of this 
technology we plan to extend our analyte panel to other Borrelia antigens 
such as OspC, DbpE, DbpA, DbpB, ViSE, flagellin and host inflammatory 
markers, as well as other members of Lyme disease co-infection pathogens.  
  
168 
 
REFERENCES 
1. Petricoin, E. F. & Liotta, L. A. Clinical applications of proteomics. J. Nutr. 133, 
2476S–2484S (2003). 
2. Ahn, S.-M. & Simpson, R. J. Body fluid proteomics: Prospects for biomarker 
discovery. Proteomics Clin. Appl. 1, 1004–1015 (2007). 
3. Petricoin, E. F., Belluco, C., Araujo, R. P. & Liotta, L. A. The blood peptidome: a 
higher dimension of information content for cancer biomarker discovery. Nat. 
Rev. Cancer 6, 961–967 (2006). 
4. Fredolini, C. et al. Investigation of the Ovarian and Prostate Cancer Peptidome 
for Candidate Early Detection Markers Using a Novel Nanoparticle Biomarker 
Capture Technology. AAPS J. 12, 504–518 (2010). 
5. Textbook of medical physiology / Arthur C. Guyton, John E. Hall - Details. 
Trove Available at: http://trove.nla.gov.au/work/6130114. (Accessed: 6th 
April 2016) 
6. Anderson, N. L. & Anderson, N. G. The human plasma proteome: history, 
character, and diagnostic prospects. Mol. Cell. Proteomics MCP 1, 845–867 
(2002). 
7. Tirumalai, R. S. et al. Characterization of the low molecular weight human 
serum proteome. Mol. Cell. Proteomics MCP 2, 1096–1103 (2003). 
8. Veenstra, T. D. et al. Biomarkers: mining the biofluid proteome. Mol. Cell. 
Proteomics MCP 4, 409–418 (2005). 
9. Proteomics of Human Body Fluids. (Humana Press, 2007). 
10. Sedlaczek, P. et al. Comparative analysis of CA125, tissue polypeptide specific 
antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and 
ascitic fluids from patients with ovarian carcinoma. Cancer 95, 1886–1893 
(2002). 
11. Jacobs, I. J. et al. Screening for ovarian cancer: a pilot randomised controlled 
trial. Lancet Lond. Engl. 353, 1207–1210 (1999). 
12. Chang, P., Aronson, D. L., Borenstein, D. G. & Kessler, C. M. Coagulant 
proteins and thrombin generation in synovial fluid: a model for extravascular 
coagulation. Am. J. Hematol. 50, 79–83 (1995). 
169 
 
13. Andersen, J. D. et al. Identification of candidate biomarkers in ovarian cancer 
serum by depletion of highly abundant proteins and differential in-gel 
electrophoresis. Electrophoresis 31, 599–610 (2010). 
14. Mahn, A. & Ismail, M. Depletion of highly abundant proteins in blood plasma 
by ammonium sulfate precipitation for 2D-PAGE analysis. J. Chromatogr. B 
Analyt. Technol. Biomed. Life. Sci. 879, 3645–3648 (2011). 
15. Righetti, P. G., Castagna, A., Antonioli, P. & Boschetti, E. Prefractionation 
techniques in proteome analysis: the mining tools of the third millennium. 
Electrophoresis 26, 297–319 (2005). 
16. Zhang, H., Li, X.-J., Martin, D. B. & Aebersold, R. Identification and 
quantification of N-linked glycoproteins using hydrazide chemistry, stable 
isotope labeling and mass spectrometry. Nat. Biotechnol. 21, 660–666 (2003). 
17. Huang, L. et al. Overexpression of long noncoding RNA HOTAIR predicts a 
poor prognosis in patients with cervical cancer. Arch. Gynecol. Obstet. 290, 
717–723 (2014). 
18. Pierobon, M., Wulfkuhle, J., Liotta, L. & Petricoin, E. Application of molecular 
technologies for phosphoproteomic analysis of clinical samples. Oncogene 34, 
805–814 (2015). 
19. Popova, T. G. et al. Reverse-Phase Phosphoproteome Analysis of Signaling 
Pathways Induced by Rift Valley Fever Virus in Human Small Airway Epithelial 
Cells. PLOS ONE 5, e13805 (2010). 
20. Zhou, W. et al. An initial characterization of the serum phosphoproteome. J. 
Proteome Res. 8, 5523–5531 (2009). 
21. Dunn, J. D., Reid, G. E. & Bruening, M. L. Techniques for phosphopeptide 
enrichment prior to analysis by mass spectrometry. Mass Spectrom. Rev. 29, 
29–54 (2010). 
22. Adam, G. C., Cravatt, B. F. & Sorensen, E. J. Profiling the specific reactivity of 
the proteome with non-directed activity-based probes. Chem. Biol. 8, 81–95 
(2001). 
23. Van den Bergh, G. & Arckens, L. Fluorescent two-dimensional difference gel 
electrophoresis unveils the potential of gel-based proteomics. Curr. Opin. 
Biotechnol. 15, 38–43 (2004). 
170 
 
24. Wolters, D. A., Washburn, M. P. & Yates, J. R. An automated multidimensional 
protein identification technology for shotgun proteomics. Anal. Chem. 73, 
5683–5690 (2001). 
25. Washburn, M. P., Wolters, D. & Yates, J. R. Large-scale analysis of the yeast 
proteome by multidimensional protein identification technology. Nat. 
Biotechnol. 19, 242–247 (2001). 
26. Mann, M., Hendrickson, R. C. & Pandey, A. Analysis of proteins and 
proteomes by mass spectrometry. Annu. Rev. Biochem. 70, 437–473 (2001). 
27. Aebersold, R. & Mann, M. Mass spectrometry-based proteomics. Nature 422, 
198–207 (2003). 
28. Poste, G. Bring on the biomarkers. Nature 469, 156–157 (2011). 
29. Tamburro, D. et al. Multifunctional core-shell nanoparticles: discovery of 
previously invisible biomarkers. J. Am. Chem. Soc. 133, 19178–19188 (2011). 
30. Merrell, K. et al. Analysis of low-abundance, low-molecular-weight serum 
proteins using mass spectrometry. J. Biomol. Tech. JBT 15, 238–248 (2004). 
31. Marshall, J. et al. Processing of serum proteins underlies the mass spectral 
fingerprinting of myocardial infarction. J. Proteome Res. 2, 361–372 (2003). 
32. Longo, C. et al. A novel biomarker harvesting nanotechnology identifies Bak 
as a candidate melanoma biomarker in serum. Exp. Dermatol. 20, 29–34 
(2011). 
33. Luchini, A., Longo, C., Espina, V., Petricoin, E. F. & Liotta, L. A. Nanoparticle 
technology: Addressing the fundamental roadblocks to protein biomarker 
discovery. J. Mater. Chem. 19, 5071–5077 (2009). 
34. Magni, R. et al. Application of Nanotrap technology for high sensitivity 
measurement of urinary outer surface protein A carboxyl-terminus domain in 
early stage Lyme borreliosis. J. Transl. Med. 13, 346 (2015). 
35. Lv, S., Liu, L. & Yang, W. Preparation of soft hydrogel nanoparticles with 
PNIPAm hair and characterization of their temperature-induced aggregation. 
Langmuir ACS J. Surf. Colloids 26, 2076–2082 (2010). 
36. Hu, Y. et al. Cytosolic delivery mediated via electrostatic surface binding of 
protein, virus, or siRNA cargos to pH-responsive core-shell gel particles. 
Biomacromolecules 10, 756–765 (2009). 
171 
 
37. Petros, R. A. & DeSimone, J. M. Strategies in the design of nanoparticles for 
therapeutic applications. Nat. Rev. Drug Discov. 9, 615–627 (2010). 
38. Choudhury, R. P., Fuster, V. & Fayad, Z. A. Molecular, cellular and functional 
imaging of atherothrombosis. Nat. Rev. Drug Discov. 3, 913–925 (2004). 
39. Castro-Sesquen, Y. E. et al. Use of a novel chagas urine nanoparticle test 
(chunap) for diagnosis of congenital chagas disease. PLoS Negl. Trop. Dis. 8, 
e3211 (2014). 
40. Luchini, A. et al. Application of Analyte Harvesting Nanoparticle Technology to 
the Measurement of Urinary HGH in Healthy Individuals. J. Sports Med. 
Doping Stud. 2, (2012). 
41. Shafagati, N. et al. The use of NanoTrap particles as a sample enrichment 
method to enhance the detection of Rift Valley Fever Virus. PLoS Negl. Trop. 
Dis. 7, e2296 (2013). 
42. Fredolini, C. et al. Investigation of the ovarian and prostate cancer peptidome 
for candidate early detection markers using a novel nanoparticle biomarker 
capture technology. AAPS J. 12, 504–518 (2010). 
43. Hu, Z. Nanostructured polymer gels. Macromol. Symp. 207, 47–56 (2004). 
44. Sahoo, S. K., De, T. K., Ghosh, P. K. & Maitra, A. pH- and Thermo-sensitive 
Hydrogel Nanoparticles. J. Colloid Interface Sci. 206, 361–368 (1998). 
45. Buchwald, P., Margolles-Clark, E., Kenyon, N. S. & Ricordi, C. Organic dyes as 
small molecule protein-protein interaction inhibitors for the CD40-CD154 
costimulatory interaction. J. Mol. Recognit. JMR 23, 65–73 (2010). 
46. Böhme, H.-J., Kopperschläger, G., Schulz, J. & Hofmann, E. Affinity 
chromatography of phosphofructokinase using Cibacron blue F3G-A. J. 
Chromatogr. A 69, 209–214 (1972). 
47. Röschlau, P. & Hess, B. Affinity chromatography of yeast pyruvate kinase with 
Cibacronblau bound to Sephadex G-200. Hoppe-Seylers Z. Für Physiol. Chem. 
353, 441–443 (1972). 
48. Gianazza, E. & Arnaud, P. Chromatography of plasma proteins on immobilized 
Cibacron Blue F3-GA. Mechanism of the molecular interaction. Biochem. J. 
203, 637–641 (1982). 
172 
 
49. Thompson, S. T. & Stellwagen, E. Binding of Cibacron blue F3GA to proteins 
containing the dinucleotide fold. Proc. Natl. Acad. Sci. U. S. A. 73, 361–365 
(1976). 
50. Luchini, A. et al. Smart hydrogel particles: biomarker harvesting: one-step 
affinity purification, size exclusion, and protection against degradation. Nano 
Lett. 8, 350–361 (2008). 
51. Denizli, A. & Pişkin, E. Dye-ligand affinity systems. J. Biochem. Biophys. 
Methods 49, 391–416 (2001). 
52. Thompson, S. T., Cass, K. H. & Stellwagen, E. Blue dextran-sepharose: an 
affinity column for the dinucleotide fold in proteins. Proc. Natl. Acad. Sci. U. S. 
A. 72, 669–672 (1975). 
53. Subramanian, S. & Kaufman, B. T. Dihydrofolate reductases from chicken liver 
and Lactobacillus casei bind Cibacron blue F3GA in different modes and at 
different sites. J. Biol. Chem. 255, 10587–10590 (1980). 
54. Fredolini, C. et al. Concentration and Preservation of Very Low Abundance 
Biomarkers in Urine, such as Human Growth Hormone (hGH), by Cibacron 
Blue F3G-A Loaded Hydrogel Particles. Nano Res. 1, 502–518 (2008). 
55. Nayak, S. & Lyon, L. A. Soft nanotechnology with soft nanoparticles. Angew. 
Chem. Int. Ed Engl. 44, 7686–7708 (2005). 
56. Lee, J. H., Oh, S. H. & Kim, W. G. MMA/MPEOMA/VSA copolymer as a novel 
blood-compatible material: ex vivo platelet adhesion study. J. Mater. Sci. 
Mater. Med. 15, 155–159 (2004). 
57. Gaulding, J. C., Smith, M. H., Hyatt, J. S., Fernandez-Nieves, A. & Lyon, L. A. 
Reversible Inter- and Intra-Microgel Cross-Linking using Disulfides. 
Macromolecules 45, 39–45 (2012). 
58. Aliyar, H. A., Hamilton, P. D. & Ravi, N. Refilling of ocular lens capsule with 
copolymeric hydrogel containing reversible disulfide. Biomacromolecules 6, 
204–211 (2005). 
59. Hiratani, H. et al. Effect of Reversible Cross-linker, N,N‘-
Bis(acryloyl)cystamine, on Calcium Ion Adsorption by Imprinted Gels. 
Langmuir 17, 4431–4436 (2001). 
173 
 
60. Conti, A. et al. Identification of novel candidate circulating biomarkers for 
malignant soft tissue sarcomas: Correlation with metastatic progression. 
Proteomics 16, 689–697 (2016). 
61. Nageswara Rao, A. A., Scafidi, J., Wells, E. M. & Packer, R. J. Biologically 
targeted therapeutics in pediatric brain tumors. Pediatr. Neurol. 46, 203–211 
(2012). 
62. Khatua, S., Sadighi, Z. S., Pearlman, M. L., Bochare, S. & Vats, T. S. Brain 
tumors in children--current therapies and newer directions. Indian J. Pediatr. 
79, 922–927 (2012). 
63. Pisitkun, T., Johnstone, R. & Knepper, M. A. Discovery of urinary biomarkers. 
Mol. Cell. Proteomics MCP 5, 1760–1771 (2006). 
64. Lakshmanachetty, S. & Koster, M. I. Emerging roles for collagen XV and XVIII 
in cancer progression. Exp. Dermatol. 25, 346–347 (2016). 
65. Newman, A. C., Nakatsu, M. N., Chou, W., Gershon, P. D. & Hughes, C. C. W. 
The requirement for fibroblasts in angiogenesis: fibroblast-derived matrix 
proteins are essential for endothelial cell lumen formation. Mol. Biol. Cell 22, 
3791–3800 (2011). 
66. Wu, Z.-S. et al. Prognostic significance of the expression of GFRα1, GFRα3 and 
syndecan-3, proteins binding ARTEMIN, in mammary carcinoma. BMC Cancer 
13, 34 (2013). 
67. Das, D. S. et al. Dickkopf homolog 3 (DKK3) plays a crucial role upstream of 
WNT/β-CATENIN signaling for Sertoli cell mediated regulation of 
spermatogenesis. PloS One 8, e63603 (2013). 
68. Wu, Y. et al. Prosaposin, a regulator of estrogen receptor alpha, promotes 
breast cancer growth. Cancer Sci. 103, 1820–1825 (2012). 
69. Barratt, J. & Topham, P. Urine proteomics: the present and future of 
measuring urinary protein components in disease. CMAJ Can. Med. Assoc. J. J. 
Assoc. Medicale Can. 177, 361–368 (2007). 
70. Chomel, B. Lyme disease. Rev. Sci. Tech. Int. Off. Epizoot. 34, 569–576 (2015). 
71. Rizzoli, A. et al. Lyme borreliosis in Europe. Euro Surveill. Bull. Eur. Sur Mal. 
Transm. Eur. Commun. Dis. Bull. 16, (2011). 
72. Strle, F. & Stanek, G. Clinical manifestations and diagnosis of lyme borreliosis. 
Curr. Probl. Dermatol. 37, 51–110 (2009). 
174 
 
73. Fraser, C. M. et al. Genomic sequence of a Lyme disease spirochaete, Borrelia 
burgdorferi. Nature 390, 580–586 (1997). 
74. Preac-Mursic, V., Wilske, B. & Schierz, G. European Borrelia burgdorferi 
isolated from humans and ticks culture conditions and antibiotic 
susceptibility. Zentralbl. Bakteriol. Mikrobiol. Hyg. [A] 263, 112–118 (1986). 
75. Barbour, A. G. Isolation and cultivation of Lyme disease spirochetes. Yale J. 
Biol. Med. 57, 521–525 (1984). 
76. Gray, J. S. Review The ecology of ticks transmitting Lyme borreliosis. Exp. 
Appl. Acarol. 22, 249–258 
77. Piesman, J., Mather, T. N., Sinsky, R. J. & Spielman, A. Duration of tick 
attachment and Borrelia burgdorferi transmission. J. Clin. Microbiol. 25, 557–
558 (1987). 
78. des Vignes, F. et al. Effect of tick removal on transmission of Borrelia 
burgdorferi and Ehrlichia phagocytophila by Ixodes scapularis nymphs. J. 
Infect. Dis. 183, 773–778 (2001). 
79. Peavey, C. A. & Lane, R. S. Transmission of Borrelia burgdorferi by Ixodes 
pacificus nymphs and reservoir competence of deer mice (Peromyscus 
maniculatus) infected by tick-bite. J. Parasitol. 81, 175–178 (1995). 
80. Piesman, J. in Lyme borreliosis: biology, epidemiology and control (eds. Gray, 
J., Kahl, O., Lane, R. S. & Stanek, G.) 223–249 (CABI, 2002). 
81. Hubálek, Z. Epidemiology of lyme borreliosis. Curr. Probl. Dermatol. 37, 31–50 
(2009). 
82. Jasik, K. P. et al. Congenital Tick Borne Diseases: Is This An Alternative Route 
of Transmission of Tick-Borne Pathogens In Mammals? Vector Borne Zoonotic 
Dis. Larchmt. N 15, 637–644 (2015). 
83. Lyme disease transmission. Available at: 
https://www.cdc.gov/lyme/transmission/. (Accessed: 10th January 2017) 
84. Moore, A., Nelson, C., Molins, C., Mead, P. & Schriefer, M. Current Guidelines, 
Common Clinical Pitfalls, and Future Directions for Laboratory Diagnosis of 
Lyme Disease, United States. Emerg. Infect. Dis. 22, (2016). 
85. WPRO | Climate change and vectorborne diseases. WPRO Available at: 
http://www.wpro.who.int/mvp/climate_change/en/. (Accessed: 7th October 
2016) 
175 
 
86. Kugeler, K. J., Farley, G. M., Forrester, J. D. & Mead, P. S. Geographic 
Distribution and Expansion of Human Lyme Disease, United States. Emerg. 
Infect. Dis. 21, 1455–1457 (2015). 
87. Pepin, K. M. et al. Geographic variation in the relationship between human 
Lyme disease incidence and density of infected host-seeking Ixodes scapularis 
nymphs in the Eastern United States. Am. J. Trop. Med. Hyg. 86, 1062–1071 
(2012). 
88. Surveillance for Lyme Disease --- United States, 1992--2006</FONT>. 
Available at: 
https://www.cdc.gov/mmwr/preview/mmwrhtml/ss5710a1.htm. (Accessed: 
16th June 2016) 
89. Government of Canada, H. C. and the P. H. A. of C. National Lyme Disease 
Surveillance in Canada 2009-2012. (2015). Available at: 
http://healthycanadians.gc.ca/publications/diseases-conditions-maladies-
affections/2009-2012-lyme/index-eng.php. (Accessed: 7th October 2016) 
90. Lyme borreliosis in Europe. Influences of climate and climate change, 
epidemiology, ecology and adaptation measures. (2014). Available at: 
http://www.euro.who.int/en/publications/abstracts/lyme-borreliosis-in-
europe.-influences-of-climate-and-climate-change,-epidemiology,-ecology-
and-adaptation-measures. (Accessed: 22nd October 2016) 
91. Wilking, H. & Stark, K. Trends in surveillance data of human Lyme borreliosis 
from six federal states in eastern Germany, 2009-2012. Ticks Tick-Borne Dis. 
5, 219–224 (2014). 
92. Steere, A. C. & Angelis, S. M. Therapy for Lyme arthritis: strategies for the 
treatment of antibiotic-refractory arthritis. Arthritis Rheum. 54, 3079–3086 
(2006). 
93. Lyme Disease | Lyme Disease | CDC. Available at: http://www.cdc.gov/lyme/. 
(Accessed: 7th October 2016) 
94. Pistone, D. et al. Lyme borreliosis, Po River Valley, Italy. Emerg. Infect. Dis. 16, 
1289–1291 (2010). 
95. Steere, A. C., Coburn, J. & Glickstein, L. The emergence of Lyme disease. J. 
Clin. Invest. 113, 1093–1101 (2004). 
176 
 
96. Rosa, P. Lyme disease agent borrows a practical coat. Nat. Med. 11, 831–832 
(2005). 
97. Baranton, G. & De Martino, S. J. Borrelia burgdorferi sensu lato diversity and 
its influence on pathogenicity in humans. Curr. Probl. Dermatol. 37, 1–17 
(2009). 
98. Steere, A. C. et al. Antibiotic-refractory Lyme arthritis is associated with HLA-
DR molecules that bind a Borrelia burgdorferi peptide. J. Exp. Med. 203, 961–
971 (2006). 
99. Cabello, F. C., Godfrey, H. P. & Newman, S. A. Hidden in plain sight: Borrelia 
burgdorferi and the extracellular matrix. Trends Microbiol. 15, 350–354 
(2007). 
100. Strle, K. et al. Borrelia burgdorferi stimulates macrophages to secrete 
higher levels of cytokines and chemokines than Borrelia afzelii or Borrelia 
garinii. J. Infect. Dis. 200, 1936–1943 (2009). 
101. Diterich, I., Rauter, C., Kirschning, C. J. & Hartung, T. Borrelia burgdorferi-
Induced Tolerance as a Model of Persistence via Immunosuppression. Infect. 
Immun. 71, 3979–3987 (2003). 
102. Battisti, J. M. et al. Outer surface protein A protects Lyme disease 
spirochetes from acquired host immunity in the tick vector. Infect. Immun. 76, 
5228–5237 (2008). 
103. Schutzer, S. E., Coyle, P. K., Dunn, J. J., Luft, B. J. & Brunner, M. Early and 
specific antibody response to OspA in Lyme Disease. J. Clin. Invest. 94, 454–
457 (1994). 
104. Cameron, D. J. An appraisal of ‘chronic Lyme disease’. N. Engl. J. Med. 
358, 429-430-431 (2008). 
105. Fallon, B. A. et al. Regional cerebral blood flow and metabolic rate in 
persistent Lyme encephalopathy. Arch. Gen. Psychiatry 66, 554–563 (2009). 
106. Heckler, A. K. & Shmorhun, D. Asymptomatic, transient complete heart 
block in a pediatric patient with Lyme disease. Clin. Pediatr. (Phila.) 49, 82–85 
(2010). 
107. Barr, W. B., Rastogi, R., Ravdin, L. & Hilton, E. Relations among indexes of 
memory disturbance and depression in patients with Lyme borreliosis. Appl. 
Neuropsychol. 6, 12–18 (1999). 
177 
 
108. Steere, A. C. Lyme disease. N. Engl. J. Med. 345, 115–125 (2001). 
109. Halperin, J. J. Nervous system Lyme disease. Infect. Dis. Clin. North Am. 
29, 241–253 (2015). 
110. Forrester, J. D. et al. Notes from the field: update on Lyme carditis, groups 
at high risk, and frequency of associated sudden cardiac death--United States. 
MMWR Morb. Mortal. Wkly. Rep. 63, 982–983 (2014). 
111. Sanchez E, Vannier E, Wormser GP & Hu LT. Diagnosis, treatment, and 
prevention of lyme disease, human granulocytic anaplasmosis, and 
babesiosis: A review. JAMA 315, 1767–1777 (2016). 
112. Arvikar, S. L. & Steere, A. C. Diagnosis and treatment of Lyme arthritis. 
Infect. Dis. Clin. North Am. 29, 269–280 (2015). 
113. Wormser, G. P. et al. The clinical assessment, treatment, and prevention 
of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical 
practice guidelines by the Infectious Diseases Society of America. Clin. Infect. 
Dis. Off. Publ. Infect. Dis. Soc. Am. 43, 1089–1134 (2006). 
114. Hunfeld, K.-P., Ruzic-Sabljic, E., Norris, D. E., Kraiczy, P. & Strle, F. In vitro 
susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from 
patients with erythema migrans before and after antimicrobial 
chemotherapy. Antimicrob. Agents Chemother. 49, 1294–1301 (2005). 
115. Morgenstern, K. et al. In vitro susceptibility of Borrelia spielmanii to 
antimicrobial agents commonly used for treatment of Lyme disease. 
Antimicrob. Agents Chemother. 53, 1281–1284 (2009). 
116. Wormser, G. P. et al. Duration of antibiotic therapy for early Lyme 
disease. A randomized, double-blind, placebo-controlled trial. Ann. Intern. 
Med. 138, 697–704 (2003). 
117. Ljøstad, U. et al. Oral doxycycline versus intravenous ceftriaxone for 
European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, 
randomised trial. Lancet Neurol. 7, 690–695 (2008). 
118. Mygland, A. et al. EFNS guidelines on the diagnosis and management of 
European Lyme neuroborreliosis. Eur. J. Neurol. 17, 8–16, e1-4 (2010). 
119. Steere, A. C., Schoen, R. T. & Taylor, E. The clinical evolution of Lyme 
arthritis. Ann. Intern. Med. 107, 725–731 (1987). 
178 
 
120. Singh, S. K. & Girschick, H. J. Molecular survival strategies of the Lyme 
disease spirochete Borrelia burgdorferi. Lancet Infect. Dis. 4, 575–583 (2004). 
121. Livengood, J. A. & Gilmore, R. D. Invasion of human neuronal and glial 
cells by an infectious strain of Borrelia burgdorferi. Microbes Infect. 8, 2832–
2840 (2006). 
122. Ma, Y., Sturrock, A. & Weis, J. J. Intracellular localization of Borrelia 
burgdorferi within human endothelial cells. Infect. Immun. 59, 671–678 
(1991). 
123. Aguero-Rosenfeld, M. E., Wang, G., Schwartz, I. & Wormser, G. P. 
Diagnosis of Lyme Borreliosis. Clin. Microbiol. Rev. 18, 484–509 (2005). 
124. Rauter, C. et al. Critical Evaluation of Urine-Based PCR Assay for Diagnosis 
of Lyme Borreliosis. Clin. Diagn. Lab. Immunol. 12, 910–917 (2005). 
125. Wormser, G. P. et al. The Clinical Assessment, Treatment, and Prevention 
of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical 
Practice Guidelines by the Infectious Diseases Society of America. Clin. Infect. 
Dis. 43, 1089–1134 (2006). 
126. Centers for Disease Control and Prevention (CDC). Recommendations for 
test performance and interpretation from the Second National Conference on 
Serologic Diagnosis of Lyme Disease. MMWR Morb. Mortal. Wkly. Rep. 44, 
590–591 (1995). 
127. Bacon, R. M. et al. Serodiagnosis of Lyme disease by kinetic enzyme-linked 
immunosorbent assay using recombinant VlsE1 or peptide antigens of 
Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. 
J. Infect. Dis. 187, 1187–1199 (2003). 
128. Wormser, G. P. et al. Single-tier testing with the C6 peptide ELISA kit 
compared with two-tier testing for Lyme disease. Diagn. Microbiol. Infect. Dis. 
75, 9–15 (2013). 
129. Branda, J. A. et al. Performance of United States serologic assays in the 
diagnosis of Lyme borreliosis acquired in Europe. Clin. Infect. Dis. Off. Publ. 
Infect. Dis. Soc. Am. 57, 333–340 (2013). 
130. Wormser, G. P. et al. Utility of serodiagnostics designed for use in the 
United States for detection of Lyme borreliosis acquired in Europe and vice 
versa. Med. Microbiol. Immunol. (Berl.) 203, 65–71 (2014). 
179 
 
131. Mathiesen, M. J. et al. Peptide-based OspC enzyme-linked 
immunosorbent assay for serodiagnosis of Lyme borreliosis. J. Clin. Microbiol. 
36, 3474–3479 (1998). 
132. Alby, K. & Capraro, G. A. Alternatives to Serologic Testing for Diagnosis of 
Lyme Disease. Clin. Lab. Med. 35, 815–825 (2015). 
133. Coulter, P. et al. Two-Year Evaluation of Borrelia burgdorferi Culture and 
Supplemental Tests for Definitive Diagnosis of Lyme Disease. J. Clin. Microbiol. 
43, 5080–5084 (2005). 
134. Avery, R. A., Frank, G. & Eppes, S. C. Diagnostic utility of Borrelia 
burgdorferi cerebrospinal fluid polymerase chain reaction in children with 
Lyme meningitis. Pediatr. Infect. Dis. J. 24, 705–708 (2005). 
135. Steere, A. C., Berardi, V. P., Weeks, K. E., Logigian, E. L. & Ackermann, R. 
Evaluation of the intrathecal antibody response to Borrelia burgdorferi as a 
diagnostic test for Lyme neuroborreliosis. J. Infect. Dis. 161, 1203–1209 
(1990). 
136. Hytönen, J. et al. CXCL13 and neopterin concentrations in cerebrospinal 
fluid of patients with Lyme neuroborreliosis and other diseases that cause 
neuroinflammation. J. Neuroinflammation 11, 103 (2014). 
137. Sillanpää, H., Skogman, B. H., Sarvas, H., Seppälä, I. J. T. & Lahdenne, P. 
Cerebrospinal fluid chemokine CXCL13 in the diagnosis of neuroborreliosis in 
children. Scand. J. Infect. Dis. 45, 526–530 (2013). 
138. Tjernberg, I., Henningsson, A. J., Eliasson, I., Forsberg, P. & Ernerudh, J. 
Diagnostic performance of cerebrospinal fluid chemokine CXCL13 and 
antibodies to the C6-peptide in Lyme neuroborreliosis. J. Infect. 62, 149–158 
(2011). 
139. Stanek, G., Wormser, G. P., Gray, J. & Strle, F. Lyme borreliosis. Lancet 
Lond. Engl. 379, 461–473 (2012). 
140. Nelson, C., Elmendorf, S. & Mead, P. Neoplasms misdiagnosed as ‘chronic 
lyme disease’. JAMA Intern. Med. 175, 132–133 (2015). 
141. Halpern, M. D., Molins, C. R., Schriefer, M. & Jewett, M. W. Simple 
Objective Detection of Human Lyme Disease Infection Using Immuno-PCR and 
a Single Recombinant Hybrid Antigen. Clin. Vaccine Immunol. CVI 21, 1094–
1105 (2014). 
180 
 
142. Babady, N. E., Sloan, L. M., Vetter, E. A., Patel, R. & Binnicker, M. J. 
Percent positive rate of Lyme real-time polymerase chain reaction in blood, 
cerebrospinal fluid, synovial fluid, and tissue. Diagn. Microbiol. Infect. Dis. 62, 
464–466 (2008). 
143. Molins, C. R. et al. Development of a metabolic biosignature for detection 
of early Lyme disease. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 60, 
1767–1775 (2015). 
144. Schnell, G. et al. Discovery and targeted proteomics on cutaneous 
biopsies infected by borrelia to investigate lyme disease. Mol. Cell. Proteomics 
MCP 14, 1254–1264 (2015). 
145. Magnarelli, L. A., Anderson, J. F. & Stafford, K. C. Detection of Borrelia 
burgdorferi in urine of Peromyscus leucopus by inhibition enzyme-linked 
immunosorbent assay. J. Clin. Microbiol. 32, 777–782 (1994). 
146. Zumstein, G. et al. Genetic polymorphism of the gene encoding the outer 
surface protein A (OspA) of Borrelia burgdorferi. Med. Microbiol. Immunol. 
(Berl.) 181, 57–70 (1992). 
147. Luft, B. J., Dunn, J. J. & Lawson, C. L. Approaches toward the Directed 
Design of a Vaccine against Borrelia burgdorferi. J. Infect. Dis. 185, S46–S51 
(2002). 
148. Dorward, D. W., Schwan, T. G. & Garon, C. F. Immune capture and 
detection of Borrelia burgdorferi antigens in urine, blood, or tissues from 
infected ticks, mice, dogs, and humans. J. Clin. Microbiol. 29, 1162–1170 
(1991). 
149. Brettschneider, S., Bruckbauer, H., Klugbauer, N. & Hofmann, H. 
Diagnostic value of PCR for detection of Borrelia burgdorferi in skin biopsy 
and urine samples from patients with skin borreliosis. J. Clin. Microbiol. 36, 
2658–2665 (1998). 
150. Bockenstedt, L. K., Gonzalez, D. G., Haberman, A. M. & Belperron, A. A. 
Spirochete antigens persist near cartilage after murine Lyme borreliosis 
therapy. J. Clin. Invest. 122, 2652–2660 (2012). 
151. Jones, C. D. & Lyon, L. A. Synthesis and Characterization of 
Multiresponsive Core−Shell Microgels. Macromolecules 33, 8301–8306 
(2000). 
181 
 
152. Dorfmüller, T. R. Pecora (Ed.): Dynamic light scattering — applications of 
photon correlation spectroscopy, Plenum Press, New York and London 1985. 
420 Seiten, Preis: $ 59.90. Berichte Bunsenges. Für Phys. Chem. 91, 498–499 
(1987). 
153. Altschul, S. F. et al. Gapped BLAST and PSI-BLAST: a new generation of 
protein database search programs. Nucleic Acids Res. 25, 3389–3402 (1997). 
154. Dimeski, G. Interference Testing. Clin. Biochem. Rev. 29, S43–S48 (2008). 
155. De Silva, A. M. & Fikrig, E. Growth and migration of Borrelia burgdorferi in 
Ixodes ticks during blood feeding. Am. J. Trop. Med. Hyg. 53, 397–404 (1995). 
156. Douglas, T. A. et al. The use of hydrogel microparticles to sequester and 
concentrate bacterial antigens in a urine test for Lyme disease. Biomaterials 
32, 1157–1166 (2011). 
157. halperin_2012_chap4_johnsonb.pdf. 
158. IDSALymeDiseaseFinalReport.pdf. 
159. Cameron, D. J., Johnson, L. B. & Maloney, E. L. Evidence assessments and 
guideline recommendations in Lyme disease: the clinical management of 
known tick bites, erythema migrans rashes and persistent disease. Expert Rev. 
Anti Infect. Ther. 12, 1103–1135 (2014). 
160. Donta, S. T. Issues in the diagnosis and treatment of lyme disease. Open 
Neurol. J. 6, 140–145 (2012). 
161. Halperin, J. J., Little, B. W., Coyle, P. K. & Dattwyler, R. J. Lyme disease: 
cause of a treatable peripheral neuropathy. Neurology 37, 1700–1706 (1987). 
162. Halperin, J. J., Volkman, D. J. & Wu, P. Central nervous system 
abnormalities in Lyme neuroborreliosis. Neurology 41, 1571–1582 (1991). 
163. Oksi, J., Marjamäki, M., Nikoskelainen, J. & Viljanen, M. K. Borrelia 
burgdorferi detected by culture and PCR in clinical relapse of disseminated 
Lyme borreliosis. Ann. Med. 31, 225–232 (1999). 
164. Shadick, N. A. et al. The long-term clinical outcomes of Lyme disease. A 
population-based retrospective cohort study. Ann. Intern. Med. 121, 560–567 
(1994). 
165. lymes.pdf. 
182 
 
166. Sigal, L. H. Summary of the first 100 patients seen at a Lyme disease 
referral center. Am. J. Med. 88, 577–581 (1990). 
167. Steere, A. C., Taylor, E., McHugh, G. L. & Logigian, E. L. The overdiagnosis 
of Lyme disease. JAMA 269, 1812–1816 (1993). 
168. Hassett, A. L., Radvanski, D. C., Buyske, S., Savage, S. V. & Sigal, L. H. 
Psychiatric comorbidity and other psychological factors in patients with 
‘chronic Lyme disease’. Am. J. Med. 122, 843–850 (2009). 
169. McCabe, J. P., Fletcher, S. M. & Jones, M. N. The effects of detergent on 
the enzyme-linked immunosorbent assay (ELISA) of blood group substances. J. 
Immunol. Methods 108, 129–135 (1988). 
170. Liebler, D. C. & Zimmerman, L. J. Targeted quantitation of proteins by 
mass spectrometry. Biochemistry (Mosc.) 52, 3797–3806 (2013). 
171. Gillette, M. A. & Carr, S. A. Quantitative analysis of peptides and proteins 
in biomedicine by targeted mass spectrometry. Nat. Methods 10, 28–34 
(2013). 
172. Cheung, C. S. F. et al. Quantification of Borrelia burgdorferi Membrane 
Proteins in Human Serum: A New Concept for Detection of Bacterial Infection. 
Anal. Chem. 87, 11383–11388 (2015). 
173. Kuhn, E. et al. Developing multiplexed assays for troponin I and 
interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted 
mass spectrometry. Clin. Chem. 55, 1108–1117 (2009). 
174. Gross, D. M. et al. Identification of LFA-1 as a candidate autoantigen in 
treatment-resistant Lyme arthritis. Science 281, 703–706 (1998). 
175. Klempner, M. S. et al. Intralaboratory reliability of serologic and urine 
testing for Lyme disease. Am. J. Med. 110, 217–219 (2001). 
176. Akin, E., McHugh, G. L., Flavell, R. A., Fikrig, E. & Steere, A. C. The 
immunoglobulin (IgG) antibody response to OspA and OspB correlates with 
severe and prolonged Lyme arthritis and the IgG response to P35 correlates 
with mild and brief arthritis. Infect. Immun. 67, 173–181 (1999). 
177. Brandt, F. C., Ertas, B., Falk, T. M., Metze, D. & Böer-Auer, A. Genotyping 
of Borrelia from formalin-fixed paraffin-embedded skin biopsies of cutaneous 
borreliosis and tick bite reactions by assays targeting the intergenic spacer 
region, ospA and ospC genes. Br. J. Dermatol. 171, 528–543 (2014). 
183 
 
178. Weis, J. J., Ma, Y. & Erdile, L. F. Biological activities of native and 
recombinant Borrelia burgdorferi outer surface protein A: dependence on 
lipid modification. Infect. Immun. 62, 4632–4636 (1994). 
179. Gross, D. M. & Huber, B. T. Cellular and molecular aspects of Lyme 
arthritis. Cell. Mol. Life Sci. CMLS 57, 1562–1569 (2000). 
180. Yang, X. F., Pal, U., Alani, S. M., Fikrig, E. & Norgard, M. V. Essential role 
for OspA/B in the life cycle of the Lyme disease spirochete. J. Exp. Med. 199, 
641–648 (2004). 
181. Oosting, M., Buffen, K., van der Meer, J. W. M., Netea, M. G. & Joosten, L. 
A. B. Innate immunity networks during infection with Borrelia burgdorferi. 
Crit. Rev. Microbiol. 42, 233–244 (2016). 
182. de Silva, A. M., Telford, S. R., Brunet, L. R., Barthold, S. W. & Fikrig, E. 
Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme 
disease vaccine. J. Exp. Med. 183, 271–275 (1996). 
183. Schwan, T. G. & Piesman, J. Temporal changes in outer surface proteins A 
and C of the lyme disease-associated spirochete, Borrelia burgdorferi, during 
the chain of infection in ticks and mice. J. Clin. Microbiol. 38, 382–388 (2000). 
184. Crowley, H. & Huber, B. T. Host-adapted Borrelia burgdorferi in mice 
expresses OspA during inflammation. Infect. Immun. 71, 4003–4010 (2003). 
185. Feder, H. M., Gerber, M. A., Krause, P. J., Ryan, R. & Shapiro, E. D. Early 
Lyme disease: a flu-like illness without erythema migrans. Pediatrics 91, 456–
459 (1993). 
186. Nadelman, R. B. et al. The clinical spectrum of early lyme borreliosis in 
patients with culture-confirmed erythema migrans. Am. J. Med. 100, 502–508 
(1996). 
187. Aucott, J. N., Crowder, L. A. & Kortte, K. B. Development of a foundation 
for a case definition of post-treatment Lyme disease syndrome. Int. J. Infect. 
Dis. IJID Off. Publ. Int. Soc. Infect. Dis. 17, e443-449 (2013). 
188. Barthold, S. W. et al. Ineffectiveness of Tigecycline against Persistent 
Borrelia burgdorferi. Antimicrob. Agents Chemother. 54, 643–651 (2010). 
189. Embers, M. E. et al. Persistence of Borrelia burgdorferi in Rhesus 
Macaques following Antibiotic Treatment of Disseminated Infection. PLoS 
ONE 7, (2012). 
184 
 
190. Embers, M. E., Ramamoorthy, R. & Philipp, M. T. Survival strategies of 
Borrelia burgdorferi, the etiologic agent of Lyme disease. Microbes Infect. 
Inst. Pasteur 6, 312–318 (2004). 
191. Hodzic, E., Feng, S., Holden, K., Freet, K. J. & Barthold, S. W. Persistence of 
Borrelia burgdorferi following antibiotic treatment in mice. Antimicrob. 
Agents Chemother. 52, 1728–1736 (2008). 
192. Szczepanski, A. & Benach, J. L. Lyme borreliosis: host responses to Borrelia 
burgdorferi. Microbiol. Rev. 55, 21–34 (1991). 
193. Mahmoud, A. A. The challenge of intracellular pathogens. N. Engl. J. Med. 
326, 761–762 (1992). 
194. Sapi, E. et al. Characterization of biofilm formation by Borrelia burgdorferi 
in vitro. PloS One 7, e48277 (2012). 
195. Zhang, J. R., Hardham, J. M., Barbour, A. G. & Norris, S. J. Antigenic 
variation in Lyme disease borreliae by promiscuous recombination of VMP-
like sequence cassettes. Cell 89, 275–285 (1997). 
196. Coutte, L., Botkin, D. J., Gao, L. & Norris, S. J. Detailed analysis of sequence 
changes occurring during vlsE antigenic variation in the mouse model of 
Borrelia burgdorferi infection. PLoS Pathog. 5, e1000293 (2009). 
197. Liang, F. T., Jacobs, M. B., Bowers, L. C. & Philipp, M. T. An immune 
evasion mechanism for spirochetal persistence in Lyme borreliosis. J. Exp. 
Med. 195, 415–422 (2002). 
198. Barbour, A. G. & Restrepo, B. I. Antigenic variation in vector-borne 
pathogens. Emerg. Infect. Dis. 6, 449–457 (2000). 
199. Brorson, O. & Brorson, S. H. Transformation of cystic forms of Borrelia 
burgdorferi to normal, mobile spirochetes. Infection 25, 240–246 (1997). 
200. Brorson, O. & Brorson, S. H. In vitro conversion of Borrelia burgdorferi to 
cystic forms in spinal fluid, and transformation to mobile spirochetes by 
incubation in BSK-H medium. Infection 26, 144–150 (1998). 
201. Mursic, V. P. et al. Formation and cultivation of Borrelia burgdorferi 
spheroplast-L-form variants. Infection 24, 218–226 (1996). 
202. Duray, P. H. et al. Invasion of human tissue ex vivo by Borrelia burgdorferi. 
J. Infect. Dis. 191, 1747–1754 (2005). 
185 
 
203. Kersten, A., Poitschek, C., Rauch, S. & Aberer, E. Effects of penicillin, 
ceftriaxone, and doxycycline on morphology of Borrelia burgdorferi. 
Antimicrob. Agents Chemother. 39, 1127–1133 (1995). 
204. Miklossy, J. et al. Persisting atypical and cystic forms of Borrelia 
burgdorferiand local inflammation in Lyme neuroborreliosis. J. 
Neuroinflammation 5, 40 (2008). 
205. Alban, P. S., Johnson, P. W. & Nelson, D. R. Serum-starvation-induced 
changes in protein synthesis and morphology of Borrelia burgdorferi. 
Microbiol. Read. Engl. 146 ( Pt 1), 119–127 (2000). 
206. Kraiczy, P. et al. Complement resistance of Borrelia burgdorferi correlates 
with the expression of BbCRASP-1, a novel linear plasmid-encoded surface 
protein that interacts with human factor H and FHL-1 and is unrelated to Erp 
proteins. J. Biol. Chem. 279, 2421–2429 (2004). 
207. Kraiczy, P., Skerka, C., Kirschfink, M., Zipfel, P. F. & Brade, V. Immune 
evasion of Borrelia burgdorferi: insufficient killing of the pathogens by 
complement and antibody. Int. J. Med. Microbiol. IJMM 291 Suppl 33, 141–
146 (2002). 
208. Pausa, M. et al. Serum-resistant strains of Borrelia burgdorferi evade 
complement-mediated killing by expressing a CD59-like complement 
inhibitory molecule. J. Immunol. Baltim. Md 1950 170, 3214–3222 (2003). 
209. Hartiala, P. et al. Transcriptional response of human dendritic cells to 
Borrelia garinii--defective CD38 and CCR7 expression detected. J. Leukoc. Biol. 
82, 33–43 (2007). 
210. Hartiala, P. et al. Borrelia burgdorferi inhibits human neutrophil functions. 
Microbes Infect. Inst. Pasteur 10, 60–68 (2008). 
211. Fallon, B. A., Levin, E. S., Schweitzer, P. J. & Hardesty, D. Inflammation and 
central nervous system Lyme disease. Neurobiol. Dis. 37, 534–541 (2010). 
212. Lazarus, J. J., Kay, M. A., McCarter, A. L. & Wooten, R. M. Viable Borrelia 
burgdorferi enhances interleukin-10 production and suppresses activation of 
murine macrophages. Infect. Immun. 76, 1153–1162 (2008). 
213. Giambartolomei, G. H., Dennis, V. A. & Philipp, M. T. Borrelia burgdorferi 
stimulates the production of interleukin-10 in peripheral blood mononuclear 
186 
 
cells from uninfected humans and rhesus monkeys. Infect. Immun. 66, 2691–
2697 (1998). 
214. Sartakova, M. L. et al. Novel antibiotic-resistance markers in pGK12-
derived vectors for Borrelia burgdorferi. Gene 303, 131–137 (2003). 
215. Engstrom, S. M., Shoop, E. & Johnson, R. C. Immunoblot interpretation 
criteria for serodiagnosis of early Lyme disease. J. Clin. Microbiol. 33, 419–427 
(1995). 
216. Aguero-Rosenfeld, M. E. et al. Evolution of the serologic response to 
Borrelia burgdorferi in treated patients with culture-confirmed erythema 
migrans. J. Clin. Microbiol. 34, 1–9 (1996). 
217. Nowakowski, J., Nadelman, R. B., Forseter, G., McKenna, D. & Wormser, 
G. P. Doxycycline versus tetracycline therapy for Lyme disease associated with 
erythema migrans. J. Am. Acad. Dermatol. 32, 223–227 (1995). 
218. Wormser, G. P. Clinical practice. Early Lyme disease. N. Engl. J. Med. 354, 
2794–2801 (2006). 
219. Hunfeld, K.-P., Hildebrandt, A. & Gray, J. S. Babesiosis: recent insights into 
an ancient disease. Int. J. Parasitol. 38, 1219–1237 (2008). 
220. dos Santos, C. C. & Kain, K. C. Two tick-borne diseases in one: a case 
report of concurrent babesiosis and Lyme disease in Ontario. CMAJ Can. Med. 
Assoc. J. 160, 1851–1853 (1999). 
221. Coinfecting Deer-Associated Zoonoses: Lyme Disease, Babesiosis, and 
Ehrlichiosis. Available at: 
http://cid.oxfordjournals.org/content/33/5/676.long. (Accessed: 23rd August 
2016) 
222. Aguero-Rosenfeld, M. E. Laboratory aspects of tick-borne diseases: lyme, 
human granulocytic ehrlichiosis and babesiosis. Mt. Sinai J. Med. N. Y. 70, 
197–206 (2003). 
223. Seidel, M. F., Domene, A. B. & Vetter, H. Differential diagnoses of 
suspected Lyme borreliosis or post-Lyme-disease syndrome. Eur. J. Clin. 
Microbiol. Infect. Dis. 26, 611–617 (2007). 
224. Berndtson, K. Review of evidence for immune evasion and persistent 
infection in Lyme disease. Int. J. Gen. Med. 6, 291–306 (2013). 
187 
 
225. Brissette, C. A. et al. The Borrelial Fibronectin-Binding Protein RevA Is an 
Early Antigen of Human Lyme Disease. Clin. Vaccine Immunol. CVI 17, 274–
280 (2010). 
226. Nowalk, A. J., Gilmore, R. D. & Carroll, J. A. Serologic proteome analysis of 
Borrelia burgdorferi membrane-associated proteins. Infect. Immun. 74, 3864–
3873 (2006). 
227. Magnarelli, L. A., Ijdo, J. W., Padula, S. J., Flavell, R. A. & Fikrig, E. Serologic 
Diagnosis of Lyme Borreliosis by Using Enzyme-Linked Immunosorbent Assays 
with Recombinant Antigens. J. Clin. Microbiol. 38, 1735–1739 (2000). 
228. Nowakowski, J. et al. Laboratory diagnostic techniques for patients with 
early Lyme disease associated with erythema migrans: a comparison of 
different techniques. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 33, 2023–
2027 (2001). 
229. Gomes-Solecki, M. J. C. et al. Recombinant assay for serodiagnosis of 
Lyme disease regardless of OspA vaccination status. J. Clin. Microbiol. 40, 
193–197 (2002). 
230. Coleman, A. S. et al. BBK07 Immunodominant Peptides as Serodiagnostic 
Markers of Lyme Disease. Clin. Vaccine Immunol. CVI 18, 406–413 (2011). 
231. Gomes-Solecki, M. J. C., Meirelles, L., Glass, J. & Dattwyler, R. J. Epitope 
Length, Genospecies Dependency, and Serum Panel Effect in the IR6 Enzyme-
Linked Immunosorbent Assay for Detection of Antibodies to Borrelia 
burgdorferi. Clin. Vaccine Immunol. CVI 14, 875–879 (2007). 
232. Wormser, G. P., Aguero-Rosenfeld, M. E. & Nadelman, R. B. Lyme disease 
serology: problems and opportunities. JAMA 282, 79–80 (1999). 
233. Halperin, J. J. Nervous system lyme disease: diagnosis and treatment. Rev. 
Neurol. Dis. 6, 4–12 (2009). 
 
  
188 
 
APPENDICES 
LIST OF ABBREVIATIONS 
AA  Allylamine 
AAc  acrylic acid 
AU  arbitrary units 
BAC  bis(acryloyl)cystamine   
Bb  Borrelia burgdorferi  
BIS   N, N′-methylenebisacrylamide  
CDC  centers for disease control  
CV   coefficient of variation  
DHEA  Dihydroxyethylenebis-acrylamide 
EIA  enzyme immunoassay 
EM  erythema migrans 
IRB  internal review board 
LB  Lyme Borreliosis 
LD  Lyme Disease 
LFA  Lateral Flow Assay 
LLD  lower limit of detection 
LLQ  lower limit of quantification 
mAb  monoclonal antibody 
NIPAm  N-isopropylacrylamide 
OspA  outer surface protein A 
PCR  polymerase chain reaction 
PDB  protein data bank 
SD  standard deviation  
TLR2  toll like receptor 2  
TLR8  toll like receptor 8 
WB  western blot 
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SUPPLEMENTARY FIGURES 
Supplementary table 1. List of 27 candidate relevant proteins statistically significant (raw p-
value) and/or with a biological relevance in at least one of the following comparisons: cases 
vs controls, metastatic vs controls, non-metastatic vs controls, metastatic vs non–metastatic 
cases.  
 
Supplementary table 2. Clinical and diagnostic information of patients suspected of having 
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early stage Lyme disease N=51 (N= 117 healthy volunteers were recruited under informed 
consent and included in the study). Treatment: Dx = doxycycline, Pd = prednisone, RC = 
rocepherin, sv = synovectomy, st = steroids, Am = amoxil, Zm = Zithromax. Urine collection 
timing and presence of symptoms: B = before treatment, PT = during or after treatment, 
symptoms present at the time urine was collected. 
Supplementary table 2. Clinical and diagnostic information of patients suspected of having 
Pt 
ID# 
Clinical manifestation Treatment Serology 
results* (ELISA, 
IgG, IgM) 
Urine 
collection 
timing 
OspA 
urine test 
** 
1 joint pain, malaise, neck pain, 
headache, nausea, dizziness 
Dx N, ND, ND PT N 
3 EM, bell's palsy, myalgia Dx, Pd P, N, N PT P 
8 myalgia, fever, joint pain Dx, Rc, Sv P, P, N PT P 
11 EM, Bell's palsy, joint pain Dx, Rc N, ND, ND PT P 
13 EM, fever, joint pain, neck 
pain, fatigue 
Dx P, N, P PT P 
14 joint pain St, Dx P, P, ND PT P 
15 EM, myalgia, fever, joint pain, 
malaise, fatigue 
Rc, Pc P, N, P PT P 
17 joint pain Dx, Rc P, P, N PT P 
18 EM, fever, joint pain Dx P, P, P PT P 
21 Headaches Dx N, N, N PT P 
23 EM, fever, anthralgiatis Am P, P, P B P 
24 EM, fever, anthralgias Zm P, N, P PT P 
25 EM, fever, neck pain, fatigue Dx P, N, P B P 
26 EM, anthralgiatis Dx, Rc, 
Am 
N, N, N PT P 
27 EM, fatigues, anthralgiatis Dx, Zm ND, ND, ND PT P 
102 EM  N, ND, ND PT P 
103 fatigue, joint pain, pos for 
Lyme on lumber puncture 
Dx P, P, N PT P 
103.
1 
No symptoms Rc P, P, N - N 
105 joint pain, arthritis Dx P, N, N PT P 
108 EM, fever, joint pain Dx P, N, P B P 
108.
1 
no symptoms Dx P, N, P - N 
113 EM, fever, neck pain, fatigue  P, N, P PT P 
116 joint paint, fatigue  N, ND, ND - N 
117 Tick bite  N, NA B P 
118 EM fatigue  P, P, P B P 
119 joint pain, arthritis, fatigue, 
neurologic 
Dx P, N, P PT P 
120 EM, fever, malaise Dx P, N, P B P 
120.
1 
No symptoms Dx P, N, P - N 
121 EM Dx N, NA, NA B P 
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early stage Lyme disease N=51 (N= 117 healthy volunteers were recruited under informed 
consent and included in the study) (continued). 
 
N=negative, P=positive, ND=not done  
**N=negative; P=positive confirmed by competition 
 
 
  
133 joint pain, fever, fatigue  N, N, N - N 
139 joint pain, fatigue Dx P, N, P B P 
139.1 No symptoms  P, N, P - P 
142 rash joint pain  P, N, P B P 
148 joint pain, fatigue  P, P, P B P 
151 fatigue Dx P, N, N PT P 
169 EM, neck stiffness, migraine  Equivocal B P 
180 EM, tick bite Dx N, N, N B P 
180.1 no symptoms Dx P, N, P - N 
601 EM Az Equiv B P 
601.1 no symptoms Az Equiv - N 
602 EM Dx N, ND, ND B P 
603 EM Dx P, P, P B P 
604 EM Dx ND B P 
605 EM Dx ND B P 
606 EM Dx ND B P 
607 EM Dx Equiv B P 
608 EM Dx ND B P 
623 EM Dx N, ND, ND B P 
623.1 EM Dx N, ND, ND - P 
623.2 EM Dx N, ND, ND - N 
623.3 EM Dx N, ND, ND - N 
623.4 EM Dx N, ND, ND - N 
623.5 EM Dx N, ND, ND - N 
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Supplementary Table 3. Sequences of peptides tested for antibody binding. 
 
  
Peptide 
ID 
Sequence Reactivity with mAb 
0551 
OspA 
peptide 1 
KQNVSSLDEKNSASVDLPGE Negative 
OspA 
peptide 2 
VLKNFTLEGKVANDKTLEV Negative 
OspA 
peptide 3 
EVKEGTVTLSKEIAKSGEVT Negative 
OspA 
peptide 4 
VALNDTNTTQATKKTGAWDS Negative 
OspA 
peptide 5 
KTSTLTISVNSKKTTQLVFTK Positive 
OspA 
peptide 6 
QLVFTKQDTITVQKYDSAGT Positive 
OspA 
peptide 7 
NLEGTAVEIKTLDELKNALK Negative 
OspA219-
253 
KTSTLTISVNSKKTTQLVFTKQDTITVQKYDSAGT Positive 
OspA219-
235 
KTSTLTISVNSKKTTQL Negative 
OspA240-
253 
QDTITVQKYDSAGT Negative 
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Supplementary Table 4. The mAb epitope used herein (red rectangle) is conserved in 
common pathogenic species of Borrelia. BAA22342.1 in Borrelia garinii Taxonomy ID 29519, 
ADD14639.1 in Borrelia burgdorferi taxonomy ID 139, WP_012665647.1 in Borrelia valaisiana 
taxonomy ID 62088, WP_012665647.1 in Borrelia sp. SV1 taxonomy ID 498741[114], 
YP_003110622.1 in Borrelia burgdorferi 297 taxonomy ID 521009, NP_045688.1 in Borrelia 
burgdorferi B31 taxonomy ID 224326, WP_014023199.1 in Borrelia bissettii taxonomy ID 
64897, ADG02035.1 in Borrelia afzelii taxonomy ID 29518, AAN65460.1 in Borrelia spielmanii 
taxonomy ID 88916 [115]. BLAST analysis was performed on the sequence 
KTSTLTISVNSKTTQLVFTKQDTITVQKYDSAGT (combination of peptide 5 and 6) with the 
following organisms: Treponema pertenue (taxonomy ID 168), Leptospiraceae (taxonomy ID 
170), Treponema (taxonomy ID 157), Spirochaetes (taxonomy ID 203691) excluding Borrelia 
(taxonomy ID 138), Homo sapiens (taxonomy ID 9606), Epstein-Barr virus EBV (taxid:10376), 
Human cytomegalovirus (taxid:10359), herpes simplex virus 1 HSV-1 (taxid:10298), hepatitis 
C virus HCV (taxid:11103), Babesia txid5864, Anaplasma txid768, Ehrlichieae 
txid942,Bartonella  txid773, Rickettsias txid766.  No significant similarity found.  No homology 
was identified. 
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Supplementary table 5: Post treatment patients being evaluated for recurrent or persistent 
disseminated Lyme disease derived from a Lyme endemic geographic region. **(N=negative; 
P=positive confirmed by competition) 
PtID# Clinical Manifestation Serology results 
(IgG, IgM) 
OspA urine test**  
300 Neurocognitive  ND N 
306 Neurologic  ND N 
309 Neurologic  ND N 
310 Joint pain ND N 
315 Joint pain ND P 
318 Joint pain  ND N 
319 Bladder pain ND N 
320 Neurologic ND N 
323  ND P 
324 asymptomatic ND N 
327 Bladder pain  ND N 
328 Bladder pain ND P 
329 Joint pain ND N 
331 neurologic  ND N 
333 Bladder pain ND N 
334 Joint pain ND P 
336 Fatigue ND N 
337 Joint pain ND P 
339 neurologic ND P 
340 Neurologic ND P 
341 Joint pain ND P 
343 Myalgia ND N 
344 Neurolocognitive ND N 
346 EM N,P P 
347 Neurologic ND P 
348 Neurologic  ND N 
349 Neurocognitive ND P 
350 Neurologic ND P 
353 Neurologic ND N 
355 Neurologic ND N 
356 Neurologic ND P 
360 Joint pain ND P 
361 fatigue ND N 
363 Joint pain ND N 
364 Joint pain ND N 
377 Joint pain ND N 
378 Neurologic ND N 
379 Neurologic ND P 
380 Fatigue ND P 
381 Joint pain ND P 
382 Joint pain ND P 
383 Neurologic ND P 
384 Joint pain N,N P 
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Supplementary table 5: Post treatment patients being evaluated for recurrent or persistent 
disseminated Lyme disease derived from a Lyme endemic geographic region. **(N=negative; 
P=positive confirmed by competition) (continued). 
386 Joint pain ND N 
388 Joint pain, fatigue ND P 
389 Joint pain ND P 
390 Joint pain N,N P 
391 Joint pain N, P N 
392 Joint pain N, N N 
393 Joint pain ND P 
394 Joint pain N, N N 
397  ND N 
400 EM N, N N 
401  ND N 
402  ND N 
403  ND N 
404  ND N 
406 Neurocognitive ND N 
407 Joint pain N,N P 
410  N,N P 
413  ND N 
414 Joint pain ND N 
416  ND N 
417  ND N 
419  ND P 
421  ND N 
424 Neurologic N,N N 
425  N,N P 
426  ND N 
427 EM, joint pain N,N P 
429 Neurologic ND N 
430 Neurocognitive ND N 
431 Neurologic ND N 
433 Joint pain ND N 
435 Neurocognitive ND N 
437  ND P 
438 Joint pain ND P 
439 Joint pain ND P 
443 Myocarditis ND P 
446 Neurocognitive ND N 
452 Myalgia ND N 
458 Joint pain ND N 
459  ND N 
465  ND N 
466 Joint pain ND N 
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Supplementary table 5: Post treatment patients being evaluated for recurrent or persistent 
disseminated Lyme disease derived from a Lyme endemic geographic region. **(N=negative; 
P=positive confirmed by competition) (continued). 
469   P 
470   N 
478  ND N 
487 Neurocognitive, Fatigue ND N 
488 Neurocognitive, 
Neurological 
ND P 
489 Joint pain, Fatigue ND P 
490  ND P 
491  ND N 
492 Fatigue ND P 
493 Neurocognitive ND N 
495 Neurocognitive ND P 
497  ND P 
498 Neurocognitive ND N 
499  ND N 
500  ND N 
501 Joint pain ND P 
 
Supplementary table 6. Quantification of the amount of remazol brilliant blue (RBB) dye 
covalently bound to the Nanotrap particles and percentage of reacted acrylic acid (AAc) 
moles. This information is obtained and recorded for every batch of produced Nanotrap 
particles (example batch # RM37B4 is reported here). 
Parameter  Numerical value Unit of Measure 
Weight of 20 mL of freezed 
dried poly(NIPAm-co-AAc) 
Nanotrap* 
110 Mg 
Weight of 20 mL of freeze 
dried poly(NIPAm/RBB) 
Nanotrap 
153 Mg 
 weight 43 Mg 
Molar quantity of RBB 
covalently bound to the 
Nanotrap 
0.0686 Mmol 
Molar quantity of AAc in the 
poly(NIPAm-co-AAc) 
Nanotrap 
0.2430 Mmol 
Percentage of mol RBB 
bound to AAc / tot mol AAc 
28 % 
*Note: The weight is relative to the poly(NIPAm-co-AAc) Nanotrap before RBB covalently 
binding. 
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Supplementary table 7. List of proteins identified by Mass-spec analysis performed on Lyme 
antigen Grade 2. 
Proteins P (pro) MW Peptide 
Hits  
outer surface protein A  2.22E-15 29421.7 47 
60 kDa heat shock protein  2.66E-14 58915.0 29 
elongation factor Tu  6.66E-15 43371.5 29 
glyceraldehyde 3-phosphate 
dehydrogenase, partial  
1.00E-30 34582.3 29 
integral outer membrane protein p66  2.22E-16 68129.8 28 
outer surface protein B (plasmid)  1.00E-30 31713.6 25 
heat-shock protein  8.88E-15 69232.8 24 
chaperonin GroS  8.16E-11 9899.5 23 
PTS system transporter subunit IIBC 
(plasmid)  
1.00E-30 58899.2 22 
DNA-directed RNA polymerase subunit 
beta'  
2.66E-14 154560.7 21 
enolase  1.00E-30 47260.4 19 
A Chain A, The Crystal Structure Of 
Aminopeptidase I From Borrelia 
Burgdorferi B31 
1.41E-13 51341.9 17 
DNA gyrase subunit A  1.34E-13 91322.5 17 
oligopeptide permease periplasmic 
binding protein  
3.33E-16 62315.8 17 
phosphoglycerate kinase  1.00E-30 42319.2 15 
borrelia P83/P100 antigen  3.37E-11 79910.6 14 
membrane lipoprotein BmpA  8.22E-13 36885.3 14 
ospB  2.06E-05 31755.7 12 
aminoacyl-histidine dipeptidase  3.92E-11 53542.7 10 
DNA-directed RNA polymerase subunit 
beta  
6.66E-15 129543.5 10 
hypothetical protein BB_0238  1.13E-11 29643.5 10 
L-lactate dehydrogenase  1.92E-09 34879.3 10 
periplasmic serine protease DO  9.87E-09 52039.5 10 
B Chain B, X-Ray Crystal Structure Of A 
Periplasmic Oligopeptide-Binding 
ProteinOLIGOPEPTIDE ABC 
TRANSPORTER(OPPAIV) FROM BORRELIA 
Burgdorferi 
7.92E-12 60505.8 9 
flagellar filament outer layer protein  3.60E-12 38416.8 9 
glycerol kinase  1.00E-30 55570.8 9 
oligopeptide permease periplasmic 
binding protein  
5.55E-15 59876.1 9 
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Supplementary table 7. List of proteins identified by Mass-spec analysis performed on Lyme 
antigen Grade 2 (continued). 
phosphoglycerate kinase  1.00E-30 42319.2 15 
borrelia P83/P100 antigen  3.37E-11 79910.6 14 
membrane lipoprotein BmpA  8.22E-13 36885.3 14 
ospB  2.06E-05 31755.7 12 
aminoacyl-histidine dipeptidase  3.92E-11 53542.7 10 
DNA-directed RNA polymerase subunit 
beta  
6.66E-15 129543.5 10 
hypothetical protein BB_0238  1.13E-11 29643.5 10 
L-lactate dehydrogenase  1.92E-09 34879.3 10 
periplasmic serine protease DO  9.87E-09 52039.5 10 
B Chain B, X-Ray Crystal Structure Of A 
Periplasmic Oligopeptide-Binding 
ProteinOLIGOPEPTIDE ABC 
TRANSPORTER(OPPAIV) FROM 
BORRELIA Burgdorferi 
7.92E-12 60505.8 9 
flagellar filament outer layer protein  3.60E-12 38416.8 9 
glycerol kinase  1.00E-30 55570.8 9 
oligopeptide permease periplasmic 
binding protein  
5.55E-15 59876.1 9 
P22  1.83E-09 21809.0 9 
fructose-bisphosphate aldolase  2.55E-14 39955.3 8 
glycerol-3-phosphate dehydrogenase, 
partial  
6.77E-14 54933.2 8 
hypothetical protein BB_0323  1.45E-12 44123.4 8 
hypothetical protein (plasmid)  1.33E-14 34535.2 7 
phosphoenolpyruvate-protein 
phosphatase  
5.39E-12 64554.9 7 
elongation factor G  4.03E-10 77523.8 6 
Fla, partial  1.16E-05 15751.8 6 
long-chain-fatty-acid CoA ligase  2.92E-12 72841.3 6 
outer membrane protein (plasmid)  2.78E-14 19210.1 6 
outer surface protein A  1.73E-07 29375.7 6 
phosphotransferase enzyme II  5.78E-12 20768.0 6 
protein GrpE  1.24E-10 21925.3 6 
30S ribosomal protein S1  4.00E-11 63209.0 5 
30S ribosomal protein S4  2.41E-13 23938.3 5 
AF288609_1 BmpD  1.83E-09 37068.1 5 
B Chain B, Structure Of A 
Pyrophosphate-dependent 
Phosphofructokinase From The Lyme 
Disease Spirochete Borrelia Burgdorferi 
8.88E-15 62437.5 5 
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Supplementary table 7. List of proteins identified by Mass-spec analysis performed on Lyme 
antigen Grade 2 (continued). 
D Chain D, Crystal Structure Of A 
Phosphoglycerate Mutase Gpma From 
Borrelia Burgdorferi B31 
2.72E-10 31099.4 5 
DNA-directed RNA polymerase subunit 
alpha  
4.69E-09 38530.1 5 
hypothetical protein BB_0752  1.60E-08 57398.6 5 
peptidase  1.77E-11 67584.6 5 
polyribonucleotide 
nucleotidyltransferase  
4.81E-09 79261.1 5 
ribosomal protein L25, partial  4.00E-07 21177.4 5 
transcription elongation factor GreA  6.25E-09 105248.4 5 
triosephosphate isomerase  3.86E-08 27741.5 5 
30S ribosomal protein S2  4.04E-07 29657.8 4 
30S ribosomal protein S6  1.49E-10 16426.8 4 
30S ribosomal protein S7  1.65E-13 18240.6 4 
30S ribosomal protein S9  2.05E-10 15407.2 4 
50S ribosomal protein L13  9.21E-08 16683.2 4 
50S ribosomal protein L15  3.97E-13 16029.0 4 
50S ribosomal protein L4  1.08E-09 23477.9 4 
A Chain A, Crystal Structure Of A Putative 
5'-methylthioadenosine/s- 
Adenosylhomocysteine Nucleosidase 
From Borrelia Burgdorferi B31 Bound To 
Adenine (target Nysgrc-029268) 
2.45E-06 29030.7 4 
arginine--tRNA ligase  1.96E-08 66809.9 4 
ATP-dependent zinc metalloprotease 
FtsH  
2.22E-15 70758.3 4 
bifunctional methylenetetrahydrofolate 
dehydrogenase/methenyltetrahydrofolat
e cyclohydrolase  
1.21E-11 34010.5 4 
D Chain D, Napa Protein From Borrelia 
Burgdorferi 
3.69E-07 17740.0 4 
DNA polymerase III subunit beta  1.87E-09 44586.0 4 
elongation factor Ts  2.95E-13 31284.7 4 
F Chain F, Transition State Mimic Of 
Nucleoside-Diphosphate Kinase From 
Borrelia Burgdorferi With Bound 
Vanadate And Adp 
1.56E-04 21646.9 4 
flagellin  2.13E-13 35742.9 4 
 
 
200 
 
 
Supplementary table 7. List of proteins identified by Mass-spec analysis performed on Lyme 
antigen Grade 2 (continued). 
hypothetical protein BB_K13 (plasmid)  4.50E-10 26517.8 4 
peptidase S41  6.07E-11 53508.1 4 
superoxide dismutase  2.89E-14 23507.9 4 
transcription 
termination/antitermination protein 
NusA  
3.76E-08 54782.5 4 
50S ribosomal protein L18  7.34E-06 13713.7 3 
50S ribosomal protein L7/L12  1.77E-07 12895.9 3 
50S ribosomal protein L9  4.93E-10 19946.8 3 
aminopeptidase  3.39E-10 47354.8 3 
basic membrane protein  1.52E-07 37972.0 3 
chaperone protein DnaJ  5.49E-09 40472.8 3 
flagellar hook protein FlgE  6.06E-10 47359.9 3 
hypothetical protein BB_0713  9.40E-06 29688.6 3 
hypothetical protein BB_0751  4.28E-06 39518.5 3 
methionine aminopeptidase  3.23E-08 27693.7 3 
protein HflC  4.57E-05 33282.1 3 
UDP-N-acetylglucosamine 1-
carboxyvinyltransferase  
8.28E-11 46579.9 3 
unknown, partial  1.35E-09 8117.2 3 
30S ribosomal protein S11  7.46E-09 13870.4 2 
30S ribosomal protein S13  1.16E-07 14068.8 2 
30S ribosomal protein S3  4.11E-05 33122.2 2 
30S ribosomal protein S5  2.63E-07 17767.7 2 
30S ribosomal protein S8  6.08E-09 14805.0 2 
3-hydroxy-3-methylglutaryl-CoA 
synthase  
2.01E-04 46000.3 2 
50S ribosomal protein L1  2.23E-06 25651.6 2 
50S ribosomal protein L11  3.62E-07 15158.3 2 
50S ribosomal protein L2  6.19E-07 30572.6 2 
50S ribosomal protein L20  1.32E-08 13460.7 2 
50S ribosomal protein L22  3.84E-05 13657.4 2 
50S ribosomal protein L5  8.13E-08 20403.1 2 
50S ribosomal protein L6  2.55E-06 19926.0 2 
acetyl-CoA C-acetyltransferase  4.87E-06 42913.6 2 
AF305611_1 LMP1  1.26E-07 97373.1 2 
aminopeptidase II  1.18E-07 46769.2 2 
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Supplementary table 7. List of proteins identified by Mass-spec analysis performed on Lyme 
antigen Grade 2 (continued). 
ATP synthase subunit A  5.07E-06 63992.9 2 
ATP-dependent Clp protease 
proteolytic subunit  
7.24E-08 22201.9 2 
ATP-dependent protease La  3.55E-08 90653.2 2 
ATP-dependent protease subunit HslV  1.43E-06 19624.5 2 
B Chain B, 2.4 A Resolution Crystal 
Structure Of Borrelia Burgdorferi 
Inosine 5'- Monphosphate 
Dehydrogenase In Complex With A 
Sulfate Ion 
8.71E-06 43740.0 2 
B Chain B, Erpc, A Member Of The 
Complement Regulator Acquiring 
Family Of Surface Proteins From 
Borrelia Burgdorfei, Possesses An 
Architecture Previously Unseen In This 
Protein Family. 
9.36E-12 18287.3 2 
cell division protein FtsZ  7.77E-15 42371.8 2 
cysteine desulfurase  1.49E-11 48094.4 2 
family 5 extracellular solute-binding 
protein  
2.25E-08 59864.0 2 
flagellar assembly protein FliH  5.61E-10 35168.8 2 
flagellar basal body-associated protein 
FliL  
4.44E-14 20047.7 2 
GroEL, partial  3.42E-08 9830.2 2 
hypothetical protein BB_0195  2.06E-10 44095.8 2 
hypothetical protein BB_0405  2.23E-09 22237.7 2 
hypothetical protein BB_0749  1.00E+00 48642.2 2 
hypothetical protein BBA69, partial 
(plasmid)  
3.20E-07 30402.3 2 
lipoprotein  5.55E-06 21852.1 2 
long-chain-fatty-acid CoA ligase  6.55E-09 70717.7 2 
lysine--tRNA ligase  4.05E-11 60900.4 2 
membrane fusion protein  7.03E-09 35021.2 2 
methionine--tRNA ligase  8.21E-11 85160.6 2 
methyl-accepting chemotaxis protein  2.66E-10 84517.5 2 
outer membrane protein  7.62E-09 94508.4 2 
P34 protein  1.25E-13 34114.0 2 
PF-49 protein (plasmid)  2.74E-10 21934.0 2 
protein RepU (plasmid)  4.56E-12 25824.0 2 
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Supplementary table 7. List of proteins identified by Mass-spec analysis performed on Lyme 
antigen Grade 2 (continued). 
RepU (plasmid)  2.76E-08 18734.8 2 
spermidine/putrescine ABC transporter 
substrate-binding protein  
2.05E-08 40655.1 2 
1-phosphofructokinase  3.55E-04 33573.5 1 
30S ribosomal protein S10  1.00E+00 11758.6 1 
30S ribosomal protein S15  5.19E-05 10210.8 1 
30S ribosomal protein S16  4.05E-06 10030.4 1 
30S ribosomal protein S17  1.15E-04 9845.6 1 
30S ribosomal protein S19  9.47E-09 10403.7 1 
30S ribosomal protein S20  1.42E-04 9940.9 1 
4-methyl-5(b-hydroxyethyl)-thiazole 
monophosphate biosynthesis protein  
1.00E+00 19871.4 1 
50S ribosomal protein L10  6.57E-05 18047.9 1 
50S ribosomal protein L14  1.39E-05 13435.3 1 
50S ribosomal protein L16  4.85E-05 15558.4 1 
50S ribosomal protein L19  3.10E-07 14001.9 1 
50S ribosomal protein L23  2.50E-05 11136.1 1 
50S ribosomal protein L25/general 
stress protein Ctc  
5.32E-07 20437.0 1 
50S ribosomal protein L3  2.09E-10 22198.0 1 
A Chain A, Crystal Structure Of 
Complement Factors H And Fhl-1 
Binding Protein Bbh06 Or Crasp-2 From 
Borrelia Burgdorferi (native) 
4.82E-09 25001.9 1 
A Chain A, Crystal Structure Of Psts 
(bb_0215) From Borrelia Burgdorferi 
9.65E-07 29292.2 1 
ABC transporter ATP-binding protein  8.71E-09 35161.4 1 
acetate kinase, partial  1.11E-15 45307.3 1 
acylphosphatase (plasmid)  2.26E-11 11035.7 1 
AF410891_1 putative partitioning 
protein (plasmid)  
1.80E-07 29505.7 1 
aminopeptidaseI-like  1.73E-05 51467.6 1 
arginine deiminase  4.03E-06 46814.2 1 
asparagine--tRNA ligase  9.65E-04 53080.5 1 
aspartyl/glutamyl-tRNA(Asn/Gln) 
amidotransferase subunit B  
2.29E-13 54486.5 1 
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Supplementary table 7. List of proteins identified by Mass-spec analysis performed on Lyme 
antigen Grade 2 (continued). 
ATP-dependent DNA helicase RecG  7.44E-06 78993.6 1 
ATP-dependent protease ATP-binding 
subunit ClpX  
3.62E-04 47571.5 1 
B Chain B, Bbcrasp-1 From Borrelia 
Burgdorferi 
1.00E+00 21433.4 1 
B Chain B, Crystal Structure Of A 
Glutamyl-Trna Synthetase Glurs From 
Borrelia Burgdorferi Bound To 
Glutamic Acid And Zinc 
3.85E-08 59110.8 1 
B Chain B, Crystal Structure Of Borrelia 
Burgdorferi Pur-alpha 
9.02E-08 11299.7 1 
B Chain B, Crystal Structure Of The 
Chex-Chey-Bef3-Mg+2 Complex From 
Borrelia Burgdorferi 
1.66E-05 18762.0 1 
Borrelia burgdorferi REV protein 
(plasmid)  
4.19E-04 17879.4 1 
carboxypeptidase  4.22E-08 30656.4 1 
cell division protein FtsA  1.97E-06 38216.4 1 
chemoreceptor glutamine deamidase 
CheD  
6.60E-06 18129.5 1 
D Chain D, Crystal Structure Of Glycine 
Betaine, L-Proline Abc Transporter, 
GlycineBETAINEL-Proline-Binding 
Protein (Prox) From Borrelia 
Burgdorferi 
4.79E-06 31730.0 1 
D Chain D, Outer Surface Protein C 
(ospc) Of Borrelia Burgdorferi Strain 
B31 
6.82E-07 18555.0 1 
deoxyguanosine/deoxyadenosine 
kinase  
5.24E-05 23645.3 1 
DNA gyrase subunit B  9.02E-09 71406.4 1 
DNA polymerase III subunit alpha  2.79E-04 132283.7 1 
DNA-directed RNA polymerase subunit 
omega  
5.05E-09 7573.9 1 
dnaK suppressor  1.19E-07 14537.6 1 
elongation factor P  7.64E-04 21399.6 1 
ErpA8 protein (plasmid)  1.54E-09 19557.9 1 
excinuclease ABC subunit A  4.13E-04 105729.7 1 
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F Chain F, Crystal Structure Of 
Glucosamine-6-phosphate Deaminase 
From Borrelia Burgdorferi 
1.30E-08 32620.6 1 
flagellar distal rod protein  4.87E-08 39950.2 1 
flagellar motor switch protein FliG  1.92E-11 38982.7 1 
Supplementary table 7. List of proteins identified by Mass-spec analysis performed on Lyme 
antigen Grade 2 (continued). 
flagellar MS-ring protein FliF  8.84E-04 65093.2 1 
flagellin  6.23E-05 35767.0 1 
flagellin, partial  2.61E-05 17275.5 1 
glucose-6-phosphate isomerase  3.87E-06 60083.2 1 
glucose-6-phosphate isomerase  5.94E-06 60153.3 1 
glycerol uptake facilitator  3.13E-05 27177.4 1 
glycerol-3-phosphate dehydrogenase  9.26E-10 39442.8 1 
glycine--tRNA ligase  1.91E-05 52176.2 1 
glycosyl transferase  9.65E-07 42078.8 1 
haloacid dehalogenase-like hydrolase  3.63E-09 33257.8 1 
hypothetical protein BB_0227  1.47E-04 27473.4 1 
hypothetical protein BB_0267  2.88E-06 70708.5 1 
hypothetical protein BB_0345  6.57E-04 46427.4 1 
hypothetical protein BB_0351  3.50E-07 60696.8 1 
hypothetical protein BB_0429  3.54E-10 14687.0 1 
hypothetical protein BB_0449  4.21E-10 11583.4 1 
hypothetical protein BB_0458  3.52E-12 58175.1 1 
hypothetical protein BB_0543  1.98E-09 24078.5 1 
hypothetical protein BB_0563  1.46E-07 18806.0 1 
hypothetical protein BB_0646  3.06E-06 37572.1 1 
hypothetical protein BB_0650  9.80E-07 11434.8 1 
hypothetical protein BB_0696  1.61E-05 9247.1 1 
hypothetical protein BB_0739  1.02E-04 23087.2 1 
hypothetical protein BB_A40 (plasmid)  5.24E-05 22348.6 1 
hypothetical protein BB_A46 (plasmid)  1.43E-07 40334.1 1 
hypothetical protein BB_A59 (plasmid)  1.19E-06 8989.4 1 
hypothetical protein BB_B28 (plasmid)  7.99E-05 49348.9 1 
hypothetical protein BB_D21 (plasmid)  2.70E-05 28750.1 1 
hypothetical protein BBA69, partial 
(plasmid)  
3.04E-06 30293.3 1 
hypothetical protein L144_02645  2.88E-13 7775.1 1 
immunogenic protein P37 (plasmid)  2.86E-04 34269.5 1 
leucine--tRNA ligase  3.70E-10 98096.6 1 
lipoprotein (plasmid)  1.06E-09 22690.8 1 
lipoprotein (plasmid)  1.40E-08 22690.8 1 
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mannose-6-phosphate isomerase  5.54E-13 42812.3 1 
membrane fusion protein  1.17E-04 35021.2 1 
 
 
Supplementary table 7. List of proteins identified by Mass-spec analysis performed on Lyme 
antigen Grade 2 (continued). 
membrane lipoprotein BmpB  1.00E+00 37525.5 1 
membrane protein insertase YidC  4.52E-04 63961.2 1 
methionyl-tRNA formyltransferase  7.78E-10 35084.8 1 
N-acetylglucosamine-6-phosphate 
deacetylase  
4.99E-05 44174.7 1 
nucleotide sugar epimerase  9.80E-10 40157.2 1 
oligoendopeptidase F  5.44E-10 69678.9 1 
outer membrane efflux protein  8.28E-04 49307.9 1 
outer membrane porin OMS28 
(plasmid)  
2.35E-06 27930.6 1 
outer membrane protein P13  4.29E-06 19081.0 1 
p41, partial  1.56E-12 35729.9 1 
peptide ABC transporter ATP-binding 
protein  
7.64E-05 37076.8 1 
PF-32 protein (plasmid)  4.00E-14 29341.5 1 
phenylalanine--tRNA ligase subunit 
alpha  
2.91E-04 59915.0 1 
phosphocarrier protein HPr  3.91E-07 9380.0 1 
phosphoribosylpyrophosphate 
synthetase  
9.41E-06 45720.2 1 
proline--tRNA ligase  1.28E-06 56275.2 1 
protein HflK  4.57E-05 35803.3 1 
protein-export membrane protein 
SecG  
2.15E-05 13363.0 1 
RIP metalloprotease RseP  3.28E-12 49206.8 1 
S-adenosylmethionine synthetase  8.80E-04 43043.7 1 
septation protein SpoVG  1.35E-04 11189.0 1 
serine--tRNA ligase  4.89E-04 48756.4 1 
sugar ABC transporter ATP-binding 
protein  
1.78E-06 60352.0 1 
telomere resolvase ResT (plasmid)  1.12E-04 54260.2 1 
transcriptional regulator  2.62E-07 27017.2 1 
transglycosylase SLT domain-
containing protein  
1.42E-08 83813.3 1 
translation initiation factor IF-3  3.72E-05 21520.7 1 
xylose operon regulatory protein  1.05E-10 46051.9 1 
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Supplementary table 8. Protein candidates for an expanded panel of Borrelia antigen. 
Peptides and respective transitions are listed. 
Precursor Product 
M/Z 
Collision 
Energy 
Peptide Subunits Fragme
nt Ion 
718.854437 1106.584 24.5 GADSNFLSEVLER 
 
aminopeptidase 
 
y9 
718.854437 992.5411 24.5 y8 
718.854437 845.4727 24.5 y7 
718.854437 732.3886 24.5 y6 
718.854437 645.3566 24.5 y5 
1027.538245 1533.852 33.7 YEDLINPIEPIIPSESPK 
 
P34 
 
y14 
1027.538245 1420.768 33.7 y13 
1027.538245 1306.725 33.7 y12 
1027.538245 1209.673 33.7 y11 
1027.538245 1096.588 33.7 y10 
1027.538245 967.5459 33.7 y9 
1027.538245 644.325 33.7 y6 
816.920643 1115.544 27.4 LALGYAENNVNELGR 
 
FLiL 
 
y10 
816.920643 1044.507 27.4 y9 
816.920643 915.4643 27.4 y8 
798.412454 1152.641 26.9 NTNNAAIGSAFLQFK 
 
p66 
 
y11 
798.412454 1081.604 26.9 y10 
798.412454 1010.567 26.9 y9 
798.412454 897.4829 26.9 y8 
798.412454 840.4614 26.9 y7 
798.412454 753.4294 26.9 y6 
798.412454 682.3923 26.9 y5 
964.481065 1211.642 31.8 SWNISEDGIIYTFNLR 
 
OppA 
 
y10 
964.481065 1096.615 31.8 y9 
964.481065 1039.593 31.8 y8 
846.951412 1375.722 28.3 IGFLGGIEGEIVDAFR 
 
BmpA 
 
y13 
846.951412 1262.638 28.3 y12 
846.951412 1205.616 28.3 y11 
846.951412 1148.595 28.3 y10 
846.951412 1035.511 28.3 y9 
846.951412 906.468 28.3 y8 
846.951412 849.4465 28.3 y7 
 
207 
 
Supplementary table 8. Protein candidates for an expanded panel of Borrelia antigen. 
Peptides and respective transitions are listed. 
1150.076255 1485.72
2 
37.
4 
LTVSADLNTVYLEAFDASNQ
K 
 
OspB 
 
y13 
1150.076255 1384.67
4 
37.
4 
y12 
1150.076255 1285.60
6 
37.
4 
y11 
641.319699 1080.55
7 
22.
1 
NSTEYAIENLK 
 
Flagellin 
 
y9 
641.319699 979.509
5 
22.
1 
y8 
641.319699 850.466
9 
22.
1 
y7 
641.319699 687.403
6 
22.
1 
y6 
641.319699 503.282
4 
23.
1 
y5 
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Virginia Biosciences Health Research Corporation (N/A)  $466,494 
Role: Faculty Associate  
Nanotrap Tick‐Panel Test Development 
Goals: Mason will identify and validate reagents for the detection of Lyme disease 
co-infection pathogens in human urine. In order to achieve this goal, Mason will 
perform the following tasks: 1) procure lysates of Bartonella henselae and Babesia 
microti, 2) perform mass spectrometry analysiis in order to identify major protein 
components, 3) source antibodies against Babesia and Bartonella, 4) test antibody 
specificity, 5) map the antibody binding domain with pepsin digestion and mass 
spectrometry analysis, 6) custom order new antibodies against Bartonella and 
Babesia antigens identified in point 1). 
 
Istituto Superiore di Sanita’    10/1/2005 – 5/31/2015 
Role: Faculty Associate      $2,496,295 
MOU between GMU and Istituto Superiore Di Sanita 
This project applies mass spectrometry and protein array technologies to serum and 
tissue samples supplied by collaborators from Italy. The goal is to discover protein 
biomarkers which correlate with cancer stage for several types of cancer. 
 
Italian Health Ministry PE-2011-02346849  05/30/2014-05/29/2017 
Role: Faculty Associate      € 369,109.16 
Nanotechnology for the multiplex diagnosis of infectious diseases 
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Role: Faculty Associate      $ 173,933 
Development of Urine Lyme Disease Assay Using Nanotrap Capture 
This project applies hydrogel nanoparticles to the capture and concentration of Lyme 
disease antigens in urine of patients. Quantitative immunoassays are developed 
against bacterial antigens. Nanoparticle-enhanced immunoassay results are 
correlated to standard of care predicate devices. 
 
GMU Grant # 222836 (Petricoin, Emanuel F)  7/1/2015 - 1/31/2017   
Medstar Research Institute (N/A)    $25,987 
Role: Faculty Associate  
Proteomics, Genomics, and MicroRNA Analysis of Pancreatic Cancer 
Goals: CAPMM will perform the Laser Capture Microdissection on 28 frozen 
pancreatic tissue specimens and perform RPPA pathway analysis on ~150 analytes 
and share all data with MedStar Health Research Institute. CAPMM will perform 
nanoparticle capture and high resolution mass spectrometry analysis of 54 serum 
blood samples (including 13 healthy controls). CAPMM will share data with MedStar 
Health Research Institute and jointly analyze the data. Specimens shall be provided 
by MedStar Health Research Institute. 
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Role: Faculty Associate      $1,386,472 
Nanotrap Technology for One Step Preservation and Amplification of Cancer 
Biomarkers 
This project is advanced development and validation of capturing nanoparticles that 
will maximize the quality and utility of biologic fluid specimens, and permit the 
measurement of previously invisible low abundance biomarkers emanating from 
small (<2 mm) early stage cancers with high precision and accuracy. 
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